Business Wire

Pfizer Receives FDA Approval to Extend Use of Prevnar 13® for Prevention of Pneumococcal Pneumonia and Invasive Disease in Adults 50 Years and Older

Fri, 30 Dec 2011 20:47:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the Company’s pneumococcal conjugate vaccine Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults. Prevnar 13 is indicated for adults 50 years of age and older for active immunization for the prevention of pneumonia and invasive disease caused by the 13 Streptococcus pneumoniae (S. pneumoniae)

Pfizer Reports Results From Three Phase 4 Studies Demonstrating EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII Impact On Drug Liking And Withdrawal Symptoms

Thu, 22 Dec 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today results from three Phase 4 studies of EMBEDA® (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules CII designed to assess the effect of the drug when crushed and taken either orally or intranasally. Studies ALO-01-10-4005 and ALO-01-10-4004 were double-blind cross-over designed studies in non-dependent, recreational opioid users that compared subjective measures relating to abuse potential of crushed EMBEDA t

Pfizer Invites Public To View And Listen To Webcast Of January 31 Conference Call With Analysts

Tue, 20 Dec 2011 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 31, 2012. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qu

Pfizer Announces FDA Acceptance For Review Of New Drug Application For Tofacitinib For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis

Tue, 20 Dec 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in August 2012 for the NDA. Pfizer has

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabalin) Capsules CV In Restless Legs Syndrome

Fri, 16 Dec 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study for Lyrica (pregabalin) in patients with Restless Legs Syndrome (RLS) met each of its three co-primary endpoints, showing significant benefit as compared with placebo and pramipexole. Pfizer will continue to further analyze these top-line results. The study, A0081186, was a randomized, double-blind, 12-month trial. It enrolled more than 700 patients, who received either a placebo, Lyrica at 300 mg/day, pramip

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (pregabaline) Capsules CV In Restless Legs Syndrome

Fri, 16 Dec 2011 13:00:00 UT

Pfizer Reports Positive Results From Phase 3 Trial Of Lyrica (prebabalin) Capsules CV In Restless Legs Syndrome

Fri, 16 Dec 2011 13:00:00 UT

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries

Fri, 16 Dec 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company’s commitment to help protect millions of infants and young children in the developing world from pneumococcal disease – the leading cause of vaccine-preventable death in young children. Pfizer is now committed to supply up to a total of 480 million doses of Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent,

Pfizer Broadens and Extends Commitment to Help Prevent Pneumococcal Disease in Infants and Young Children in the World’s Poorest Countries

Fri, 16 Dec 2011 12:00:00 UT

New Survey Reveals Top Misperceptions Parents Have When Treating Their Child’s Fever

Tue, 13 Dec 2011 13:00:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Tis’ the season for sneezing, coughing and fevers. As the temperature drops and cold and flu season gets under way, parental anxiety is expected to rise. According to two new surveys of parents and pediatricians from Pfizer Consumer Healthcare, makers of Children’s Advil®, more than half of all parents report feeling anxious, fearful or helpless when their child comes down with a fever. In addition, many parents are not managing the fever correctly. This is nothin

Pfizer Elects CEO Ian Read As Chairman Of The Board

Mon, 12 Dec 2011 20:16:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected current President and Chief Executive Officer, Ian Read, as Chairman of the Board and Chief Executive Officer, effective immediately. Mr. Read succeeds George Lorch as Chairman of the Board. The independent members of the board named Mr. Lorch as Lead Independent Director. “Over the past year, Ian has clearly demonstrated the leadership and vision necessary to drive Pfizer’s strategies and

Pfizer Declares A 22-Cent First-Quarter 2012 Dividend

Mon, 12 Dec 2011 16:24:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 22-cent first-quarter 2012 dividend on the company’s common stock, payable March 6, 2012, to shareholders of record at the close of business on February 3, 2012. Pfizer increased the dividend by 10 percent, to 22 cents from 20 cents per share. The first-quarter 2012 cash dividend will be the 293rd consecutive quarterly dividend paid by Pfizer. The board of directors also authorized a new share repurchas

Jon Bon Jovi Reveals His True Advil® Story

Fri, 9 Dec 2011 13:01:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Jon Bon Jovi’s schedule is packed - on any given day he’s performing sold-out stadium shows, staying fit with daily runs, spending time with his family and giving back through the Jon Bon Jovi Soul Foundation. One thing that’s not on his schedule is pain. The artist gives a glimpse into his life in a new advertisement for Advil®. The TV ad was shot in Red Bank, New Jersey, at the Jon Bon Jovi Soul Kitchen, a community kitchen that recently opened as an initiative

Jon Bon Jovi Reveals His True Advil® Story

Fri, 9 Dec 2011 01:01:00 UT

The Advil® Congestion Relief Project Tackles Congestion in Chicago, the Country’s #1 City for Traffic Congestion*

Thu, 8 Dec 2011 15:08:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, stopped in Westside Chicago yesterday as part of a nationwide effort to help communities fight congestion. Chicago ranks #1 in the country for traffic congestion*, and to help alleviate congestion on busy roads this winter, Advil® Congestion Relief donated snow removal equipment specifically for the newly-established protected bicycle lanes, an initiative of Mayor Rahm Emanuel. Chicago Bears legen

FDA Advisory Committee Finds The Benefit/Risk Profile Of Axitinib In Previously Treated Advanced Renal Cell Carcinoma (RCC) To Be Favorable

Wed, 7 Dec 2011 16:42:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) voted unanimously 13 to 0 that data for the investigational agent axitinib support a favorable benefit/risk profile for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of a first-line systemic therapy. The ODAC panel’s recommendation will be considered by the FDA when making its decision regarding Pfizer’s New Drug

Pfizer’s Toviaz Shows Positive Top-Line Primary Endpoint Result In Study Of Overactive Bladder In Vulnerable Elderly Patients

Mon, 5 Dec 2011 22:03:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the top-line primary endpoint result for Toviaz (fesoterodine fumarate) Study A0221049 – Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder. The study met its primary endpoint: treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urgency urinary incontinence (UUI) episodes per day at the end of treatment.

Pfizer Completes Acquisition of Excaliard

Fri, 2 Dec 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Excaliard Pharmaceuticals, Inc., a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. “It is imperative at Pfizer that we continue to develop new and innovative treatments to address unmet medical needs, and there is currently no FDA-approved treatment for excessive skin scarring,” said

Pfizer Completes Acquisition of Ferrosan Consumer Health’s Business

Thu, 1 Dec 2011 10:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. “Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, President, Pfizer Consumer Healthcare. “Today, we have taken an important step by adding leading brands to our exis

New Research Initiative Examines Economic Impact of Smoke-free Policies on Restaurants and Bars

Wed, 30 Nov 2011 21:26:00 UT

ATLANTA--(BUSINESS WIRE)--As part of ongoing efforts to reduce disease and death caused by smoking and secondhand smoke exposure, the CDC Foundation and CDC have launched a new initiative to study the economic impact of smoke-free policies on restaurants and bars in nine states. Previous research shows that smoke-free policies that prohibit smoking in workplaces and public places, including restaurants and bars, reduce nonsmokers’ exposure to secondhand smoke and help employees who smoke to quit

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

Tue, 29 Nov 2011 14:14:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for ELIQUIS® (apixaban), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation. The FDA accepted the filing and assigned a priority-review designation. The Prescription Drug User Fee Act (PDUFA) goal date f

Pfizer to Acquire Excaliard Pharmaceuticals

Tue, 22 Nov 2011 12:30:00 UT

NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year. Excaliard’s lead product, EXC 001, an antisense oligonucleotide in p

Pfizer And MIT Break Ground On New Research Units In Kendall Square

Mon, 21 Nov 2011 16:00:00 UT

NEW YORK and CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. and the Massachusetts Institute of Technology (MIT) today held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units at 610 Main Street, Cambridge, MA. In September, Pfizer announced it had entered into a 10-year lease agreement with MIT for more than 180,000 square feet. Taking part in the groundbreaking event were: Pfizer Board Member Dennis

Pfizer Announces European Medicines Agency Acceptance Of Regulatory Submission For Tofacitinib For The Treatment Of Rheumatoid Arthritis

Mon, 21 Nov 2011 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that its Market Authorisation Application for tofacitinib (development code CP-690,550), a novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), has been validated by the European Medicines Agency (EMA). Validation means that the EMA has confirmed that the application is complete and the agency is beginning its review procedure. Pfizer studied tofacitinib for moderate-to-

Pfizer Wins Corporate Citizenship Award For Global Health Partnerships Program

Fri, 18 Nov 2011 14:28:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 Business Civic Leadership Center’s Corporate Citizenship Award in the Best International Ambassador category for Pfizer’s Global Health Partnerships program. The “Citizens” Awards honor excellence in corporate citizenship and civic leadership for initiatives in both the United States and across the world. “The essence of a successful corporate social responsibility program is when it becomes a model that other c

Pfizer’s Vyndaqel® (tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)

Thu, 17 Nov 2011 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the European Commission has approved Vyndaqel® (tafamidis) for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) in adult patients with stage 1 symptomatic polyneuropathy. TTR-FAP is a rare, progressive and fatal neurodegenerative disease that affects approximately 8,000 patients worldwide. 1,2,3 “A diagnosis of TTR-FAP, usually made in patients during their mid-life years, impacts both the physical and emotional well-

The Advil® Congestion Relief Project Hits the Road to Relieve Congestion in Communities

Wed, 16 Nov 2011 17:37:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, the makers of Advil® Congestion Relief, yesterday, kicked off a nationwide effort to make a difference in communities. The cold and flu brand is putting a twist on its tagline – “The Right Relief for the Real Problem,” and providing literal relief in congested places across the US. In its first relief stop, The Advil® Congestion Relief Project unveiled a new library at P.S. 130 in the Bronx. Yankee fan favorite Brett Gardner helped unve

Kathryn Joosten Speaks Out About Lung Cancer Profiles; ‘Desperate’ to Share Her Personal Lung Cancer Story to Help Others

Mon, 14 Nov 2011 18:01:00 UT

NEW YORK--(BUSINESS WIRE)--Kathryn Joosten, two-time Emmy® Award-winning actress and star of Desperate Housewives and The West Wing, is opening up about her 10-year battle with lung cancer as part of a new national campaign, Lung Cancer Profiles. Lung Cancer Profiles aims to reduce the stigma associated with lung cancer by educating about the diversity of the disease inside and out. The campaign, created by Pfizer Oncology in collaboration with the nation’s leading lung cancer advocacy groups, a

New Data Presented On Phase 3 Trial Of ELIQUIS® (apixaban) In The Prevention Of Venous Thromboembolism In Patients With Acute Medical Illness

Sun, 13 Nov 2011 13:01:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis) trial, which evaluated apixaban versus enoxaparin in acutely ill medical patients, did not meet the primary efficacy outcome of superiority to enoxaparin for the endpoint of venous thromboembolism (VTE) and VTE-related death at day 30. The apixaban arm had a 13 percent lower rate

Toviaz Top-Line Primary Endpoint Results Positive In Overactive Bladder Study Of Nocturnal Urinary Urgency

Tue, 8 Nov 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today top-line results for Toviaz (fesoterodine fumarate) Study A0221048 – Effectiveness and Safety of a Flexible Dose Regimen for Patients with Overactive Bladder including Nocturnal Urinary Urgency. The study met its primary endpoint, as treatment with Toviaz was found to be statistically significantly superior to placebo in reducing the mean number of urinary urgency episodes overnight during sleep hours after 12 weeks of treatment.

Pfizer To Present Clinical Data From Its Hematology Portfolio At The 53rd Annual Meeting Of The American Society Of Hematology

Mon, 7 Nov 2011 19:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data on a number of investigational compounds from its hematology portfolio, including new data from bosutinib in chronic myeloid leukemia (CML),1 inotuzumab in non-Hodgkin lymphoma (NHL),2 as well as the first presentation of clinical data for PF-04449913,3 which inhibits Smoothened (SMO), a key component of the Hedgehog pathway.4 In addition, ongoing investigator-initiated research on gemtuzumab ozogamicin (Mylotarg) will be presented in

Treatment with Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients with Moderately Active Disease

Sat, 5 Nov 2011 21:20:00 UT

THOUSAND OAKS, Calif. & NEW YORK--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results of the second and final period of the PRESERVE trial. PRESERVE is a two-period multi-center trial in patients with moderately active rheumatoid arthritis (RA) who achieved Disease Activity Score (DAS) 28 low disease activity (LDA) or clinical remission on combination Enbrel® (etanercept) plus methotrexate (MTX) in Period one and were randomized to continue on ENBREL plus MT

Pfizer Reports Third-Quarter 2011 Results

Tue, 1 Nov 2011 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter(4) Year-to-Date(4) 2011 2010 Change 2011 2010 Change Reported Revenues $ 17,193 $ 15,995 7 % $ 50,679 $ 49,703 2 % Adjusted Income(1) 4,820 4,352 11 % 14,354 14,141 2 % Adjusted Diluted EPS(1) 0.62 0.54 15 % 1.81 1.75 3 % Reported Net Income(2) 3,738 866 * 8,570 5,367 60 % Reported Diluted EPS(2) 0.48 0.11 * 1.08 0.66 64 % See end of te

Pfizer Reports Third-Quarter 2011 Results

Tue, 1 Nov 2011 11:00:00 UT

Pfizer Completes Acquisition Of Icagen

Fri, 28 Oct 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed its acquisition of Icagen, Inc., through the merger of its wholly owned subsidiary, Eclipse Acquisition Corp., with and into Icagen. Icagen is now a wholly-owned subsidiary of Pfizer. Under the terms of the transaction, each issued and outstanding share of Icagen common stock has been converted into the right to receive $6.00 in cash, without interest thereon, and less any applicable withholding and transfer

Pfizer Declares A 20-Cent Fourth-Quarter 2011 Dividend

Thu, 27 Oct 2011 13:37:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent fourth-quarter 2011 dividend on the company’s common stock, payable December 6, 2011, to shareholders of record at the close of business on November 11, 2011. The fourth-quarter 2011 cash dividend will be the 292nd consecutive quarterly dividend paid by Pfizer.

Pfizer Receives European Approval to Extend Use of Prevenar 13 to Adults 50 Years and Older for the Prevention of Invasive Pneumococcal Disease

Thu, 27 Oct 2011 09:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved the Company’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older. “Prevenar 13, the first and only pneumococcal conjugate vaccine approved by the European Commission for use in adul

Pfizer Establishes Precision Medicine Research Collaboration With Medco

Wed, 26 Oct 2011 20:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has established a research collaboration with Medco Health Solutions, Inc. (NYSE: MHS) and its wholly owned subsidiary, United BioSource Corporation (UBC), aimed at more effectively matching patients with treatments that will benefit them the most, thereby improving patient outcomes. The collaboration is intended to enhance Pfizer’s precision medicine approach, which integrates genomic and phenotypic information, to help

Peggy Fleming and the Makers of Robitussin® Provide Relief this Cold and Flu Season with a Simple Question: "Does Your Last Name Sound Contagious?"

Wed, 26 Oct 2011 13:25:00 UT

MADISON, N.J.--(BUSINESS WIRE)--This week, Robitussin® marked the start of another cold and flu season by shaking up the most contagious months of the calendar year for America’s “sick but can’t stop” sufferers with the launch of the Simple Acts of Relief program. To kick-off the launch of the program, Robitussin® has teamed up with iconic Olympic and World ice skating champion and sports commentator, Peggy Fleming. As the “simplest” act of relief, the makers of Robitussin® and Ms. Fleming are m

Leading Pharmaceutical Companies & Research Institutions Offer IP and Expertise for use in Treating Neglected Tropical Diseases as Part of WIPO Re:Search

Wed, 26 Oct 2011 12:00:00 UT

GENEVA--(BUSINESS WIRE)--The World Intellectual Property Organization (WIPO), in an unprecedented collaboration with leading pharmaceutical companies and BIO Ventures for Global Health (BVGH), launched today WIPO Re:Search, a new consortium where public and private sector organizations share valuable intellectual property (IP) and expertise with the global health research community to promote development of new drugs, vaccines, and diagnostics to treat neglected tropical diseases, malaria, and t

Pfizer Invites Public to View and Listen to Webcast of November 6 Pfizer Analyst and Investor Meeting at ACR

Mon, 24 Oct 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s specialty care leadership team at an analyst and investor meeting on Sunday, November 6, 2011 at 6:30 p.m. Central Standard Time, in connection with the annual meeting of the American College of Rheumatology (ACR). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ACR” link in T

Additional Data From Pfizer’s Prevnar 13® Clinical Trials In Adults 50 Years And Older To Be Presented At The 49th Annual Meeting Of The Infectious Diseases Society Of America

Fri, 21 Oct 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that additional data from several clinical studies of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) conducted in adults 50 years and older will be presented during the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA), which is being held Oct. 20-23, 2011, in Boston, Mass. The data from these studies provide support for the pending regulatory applications for the use of

Pfizer Animal Health and the Resource Foundation Expand Initiative to Increase Productivity of Small Family Farms in Latin America and India

Tue, 18 Oct 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health and The Resource Foundation announced today the expansion of a comprehensive education and training program to increase the capacity, productivity and quality of life of rural farmers in eight Latin American countries. Plans call for tailoring the program to the needs of rural communities in India. The agreement was guided by results of a decade-long collaboration also announced today. Pfizer Animal Health and the Pfizer Foundation have committed $

Humana and Pfizer Form Research Partnership to Improve Health Care Delivery for Seniors

Thu, 13 Oct 2011 19:00:00 UT

LOUISVILLE, Ky. & NEW YORK--(BUSINESS WIRE)--Humana Inc. (NYSE: HUM) and Pfizer Inc. (NYSE: PFE) today announced a five-year research partnership to explore new ideas and ways to improve the quality, outcomes and costs of the health care delivery system for senior citizens and other populations. Humana, one of the nation’s largest health care companies, and Pfizer, the world’s largest biopharmaceutical company, will bring together researchers and health care experts from both organizations to st

Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc. For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor

Wed, 5 Oct 2011 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today an agreement with Puma Biotechnology, Inc. for the development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, being studied for the treatment of cancer. Under the terms of the agreement, Puma will assume sole responsibility for global development and commercialization of neratinib. Pfizer will be entitled to receive payments upon Puma’s achieve

Pfizer Invites Public To View And Listen To Webcast Of November 1 Conference Call With Analysts

Mon, 3 Oct 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, November 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qua

Excellence in Scientific Innovation and Humanitarian Efforts Honored at 2011 Prix Galien Award Ceremony

Fri, 30 Sep 2011 21:36:00 UT

NEW YORK--(BUSINESS WIRE)--The Prix Galien USA committee recognized excellence in scientific innovation that improves the state of human health last night during the fifth annual Prix Galien Awards Gala. The Pro Bono Humanum Award and the Prix Galien USA 2011 Awards for best biotechnology product and best pharmaceutical agent were presented at a ceremony held at the Museum of Natural History in New York City. The Prix Galien USA 2011 Award selection committee is an unrivaled network that include

Pfizer Reports Top-Line Results Of A Phase 3 Clinical Trial Comparing The Efficacy And Safety Of VFEND® (voriconazole) And ERAXISTM (anidulafungin) Combination Therapy To VFEND Alone In Invasive Aspergillosis

Fri, 30 Sep 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND® (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis (IA), a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems. The primary analysis of this double-blinded prospective randomized clinical trial was

The National Association Of Boards Of Pharmacy And Pfizer Partner To Educate Patients About The Flood Of Counterfeit Medicines Online

Thu, 29 Sep 2011 13:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the National Association of Boards of Pharmacy® (NABP) are launching a new effort to draw attention to the risks associated with counterfeit prescription medicines and help patients learn how to safely buy medicines online. Prescription medicines are among the most counterfeited consumer goods. Worldwide sales of counterfeit medicines were estimated to exceed $75 billion last year – an increase of 90 percent since 2005. Last year, one in six

Even Famous Faces Have an Advil® Story to Share

Thu, 22 Sep 2011 14:52:00 UT

MADISON, N.J.--(BUSINESS WIRE)--After a day on the tennis court with his doubles partner and wife, Joy, Regis Philbin takes Advil® to relieve the pain that comes from a long match. Just like millions of Americans who rely on Advil® to relieve their tough pain, Regis and Joy have real stories to tell about how Advil® helps them keep doing what they love. The Philbins are the first famous faces to join real Advil® users who share their Advil® stories. The advertisements, which focus on the Philbin

New Phase 3 Safety Data For Bazedoxifene/Conjugated Estrogens, An Investigational Therapy Being Studied For The Treatment Of Menopausal Symptoms, Show Less Than One Percent Incidence Of Endometrial Hyperplasia

Thu, 22 Sep 2011 12:00:00 UT

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September 21-24 in Washington, D.C. BZA/CE is being developed by Pfizer for the treatment of moderate-to-severe hot flashes, v

Pfizer Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Shares of Icagen, Inc.

Tue, 20 Sep 2011 12:00:00 UT

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the expiration of the subsequent offering period of the cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The subsequ

Pfizer Extends Subsequent Offering Period of Tender Offer to Acquire Icagen, Inc.

Tue, 13 Sep 2011 12:00:00 UT

NEW YORK and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of the subsequent offering period of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. T

Pfizer to Present Clinical Data from Oncology Portfolio at the 2011 European Multidisciplinary Cancer Congress

Tue, 13 Sep 2011 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer’s renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT® (sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 – 27, 2011. “As SUTENT changed the treatment landscape for patients wit

Pfizer And Guoyuan Form Joint Venture To Expand Development, Manufacture And Distribution Of Animal Vaccines In China

Thu, 8 Sep 2011 21:01:00 UT

MADISON, N.J. & HUINAN, China--(BUSINESS WIRE)--Pfizer Animal Health, a business unit of Pfizer Inc. (NYSE: PFE), and Jilin Guoyuan Animal Health Company, Ltd., an innovator in animal health vaccines based in Huinan, today announced an agreement to jointly develop, manufacture and distribute animal health vaccines in China. The new joint venture, Jilin Pfizer Guoyuan Animal Health Co., Ltd., will bolster the capabilities of both companies to offer a comprehensive range of vaccine products tailor

Introducing ProNutrients™, A New Line Of Dietary Supplements From The Makers Of Centrum

Thu, 8 Sep 2011 15:09:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Consumer Healthcare, makers of Centrum® multivitamins, announced today the launch of ProNutrients™, a line of supplements from the most trusted multivitamin brand helping to increase confidence in supplementing and make nutrition possible. ProNutrients is a new line of dietary supplements launched by the makers of Centrum multivitamins, and is formulated to naturally work with a multivitamin. The line includes Omega-3, Probiotic, and Fruit & Veggie—thre

Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting

Thu, 8 Sep 2011 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that nine abstracts about tofacitinib (development code CP-690,550), an investigational, novel, oral JAK inhibitor being studied for the treatment of moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) 2011 Annual Scientific Meeting, which is being held November 5-9 in Chicago. Detailed Results Being Presented for ORAL Standard, ORAL Scan and ORAL Step ORAL Standard

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Wed, 7 Sep 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the Morgan Stanley Global Healthcare Conference on Wednesday, September 14, 2011 at 9:10 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global Healthcare Conference” link in the Investor Presentations section located on the lower right-hand corner of that

Pfizer Announces Successful Completion of Initial Cash Tender Offer for Outstanding Shares of Icagen, Inc. and Commencement of Subsequent Offering Period

Tue, 6 Sep 2011 12:00:00 UT

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today the successful completion of the initial cash tender offer by Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), for all of the outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The initial tender offer p

Pfizer Extends Tender Offer To Acquire Icagen, Inc.

Fri, 2 Sep 2011 12:00:00 UT

NEW YORK & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The tender offer is now scheduled to

Pfizer Signs Agreement With MIT For Future Cambridge Research Center

Thu, 1 Sep 2011 19:45:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced it has entered into a 10-year lease agreement with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, Massachusetts. Located at 610 Main Street South in Kendall Square, the new site will be the future location of Pfizer’s Cardiovascular, Metabolic and Endocrine Disease (CVMED) and Neuroscience Research Units. The relocation of the two Research Units will substan

Pfizer Extends Tender Offer to Acquire Icagen, Inc.

Thu, 1 Sep 2011 12:00:00 UT

NEW YORK and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) (“Pfizer”) and Icagen, Inc. (NASDAQ: ICGN) (“Icagen”) announced today that Pfizer’s wholly-owned subsidiary, Eclipse Acquisition Corp. (“Eclipse”), has extended the expiration date of its tender offer for all outstanding shares of common stock of Icagen for $6.00 per share, paid to the seller in cash, without interest thereon, less any applicable withholding and transfer taxes. The tender offer is now scheduled t

FDA Approval of XALKORI (crizotinib) and Invitation to Media Briefing from Pfizer

Mon, 29 Aug 2011 15:38:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. has received FDA approval of XALKORI® (crizotinib) capsules – the first and only therapy specifically for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates and, as XALKORI received accelerated approval from the FDA, Pfizer is conducting post-marketing clinical trials to further

ELIQUIS® (apixaban) was Superior to Warfarin for the Reduction of Stroke or Systemic Embolism with Significantly Less Major Bleeding in Patients with Atrial Fibrillation in Phase 3 ARISTOTLE Trial

Sun, 28 Aug 2011 06:01:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the main results of the Phase 3 clinical trial ARISTOTLE, which evaluated ELIQUIS® (apixaban) compared to warfarin for the prevention of stroke or systemic embolism in 18,201 patients with atrial fibrillation and at least one risk factor for stroke. In the ARISTOTLE trial, ELIQUIS as compared with warfarin significantly reduced the risk of stroke or systemic embolism

U.S. Food And Drug Administration Approves Pfizer’s XALKORI® (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer

Fri, 26 Aug 2011 20:54:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI® (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test. The effectiveness of XALKORI is based on objective response rates (ORR) and, as XALKORI received accelerated approval from th

Bristol-Myers Squibb And Pfizer Announce Data Presentations For Apixaban At European Society of Cardiology Congress 2011

Tue, 23 Aug 2011 11:30:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Multiple data presentations for ELIQUIS® (apixaban), an oral direct Factor Xa inhibitor being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), will be given at the European Society of Cardiology Congress, August 27-31, 2011, in Paris, France. Globally-conducted registrational studies evaluating ELIQUIS for the prevention of stroke in patients with atrial fibrillation will be presented during the congress. Of note is t

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies

Wed, 17 Aug 2011 16:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myel

Pfizer Announces European Medicines Agency Acceptance of Regulatory Submissions For Two Investigational Cancer Therapies

Wed, 17 Aug 2011 16:30:00 UT

Pfizer Wins Viagra Patent Trial

Mon, 15 Aug 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has prevailed in its patent infringement action against Teva Pharmaceuticals USA, Inc. in the United States District Court for the Eastern District of Virginia. "We are pleased that the court recognized the validity and enforceability of our Viagra patent for the treatment of erectile dysfunction," said Amy Schulman, executive vice president and general counsel for Pfizer. "Protecting the intellectual property rights of our innovativ

Dana Delany Partners with Caltrate® to Celebrate Women and How They Move the World Every Day through Their Amazing Strength and Contributions

Wed, 3 Aug 2011 18:46:00 UT

NEW YORK--(BUSINESS WIRE)--For more than 25 years, Caltrate® has helped replenish the calcium and vitamin D women need each day in order to keep their bodies active—so they can move the world physically, emotionally and for the causes in which they believe. This year, Caltrate® is partnering with Dana Delany to celebrate women who move our world by issuing a national call-to-action inviting women everywhere to share their individual stories and everyday accomplishments. As part of this celebrati

NCCN Receives $2M Educational Grant from Pfizer to Support Tailored Quality Improvement Plans at Leading Cancer Centers

Wed, 3 Aug 2011 14:30:00 UT

FORT WASHINGTON, Pa.--(BUSINESS WIRE)--NCCN receives $2M educational grant from Pfizer to support first CME program to measure impact on patient outcomes & clinician performance through data collected in the NCCN Database for Breast Cancer

Pfizer Reports Second-Quarter 2011 Results

Tue, 2 Aug 2011 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2011 2010 Change 2011 2010 Change Reported Revenues $ 16,984 $ 17,132 (1 %) $ 33,486 $ 33,708 (1 %) Adjusted Income(2) 4,726 4,927 (4 %) 9,534 9,789 (3 %) Adjusted Diluted EPS(2) 0.60 0.61 (2 %) 1.19 1.21 (2 %) Reported Net Income(3) 2,610 2,475 5 % 4,832 4,501 7 % Reported Diluted EPS(3) 0.33 0.31 6 % 0.61 0.56 9 % See end of text prior to tables for notes.

Pfizer Completes Sale Of Capsugel Business To KKR

Mon, 1 Aug 2011 21:43:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Capsugel business to an affiliate of Kohlberg Kravis Roberts & Co. L.P. (together with its affiliates, “KKR”), following the receipt of required regulatory clearances, including in the U.S. and the European Union. Under the terms of the previously announced agreement, KKR acquired the Capsugel business for $2.375 billion in cash. Pfizer’s financial advisors for the transaction were Morgan

Pfizer Provides U.S. Regulatory Update on Prevnar 13® for Use in Adults 50 Years and Older

Fri, 29 Jul 2011 18:19:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has issued a 90-day extension to the action date for the Company’s supplemental Biologics License Application (sBLA) for use of Prevnar 13®, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 and older. This extends the review period to January 2012. The extension is due to additional data that Pfizer elected to submit from two studies that were

Pfizer To Acquire Icagen

Wed, 20 Jul 2011 12:30:00 UT

NEW YORK, N.Y., and RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) today announced that they have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen’s fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share. The aggregate transaction value, including the value of the shares currently owned by Pfizer, is approximately $56 million. In 2007, Pfizer and

Pfizer To Explore Strategic Alternatives For Its Animal Health And Nutrition Businesses

Thu, 7 Jul 2011 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it is exploring strategic alternatives for its Animal Health and Nutrition businesses based on its recent business portfolio review to determine the optimal mix of businesses for maximizing shareholder value. The company is considering options that may include, among others, a full or partial separation of each of these businesses from Pfizer through a spin-off, sale or other transaction. Given the separate and distinct natu

Positive Top-Line Results For Pfizer’s Lyrica In Phase 3 Study Of Patients With Fibromyalgia In Japan

Wed, 6 Jul 2011 01:00:00 UT

TOKYO & NEW YORK--(BUSINESS WIRE)--Pfizer Japan announced today the top-line results for Lyrica (pregabalin) Study A0081208 – Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate Efficacy and Safety of Pregabalin (CI-1008) in the Treatment of Fibromyalgia. The results demonstrated a statistically significant reduction in the endpoint mean pain score, the primary efficacy analysis in the study, with pregabalin compared to placebo. Further analyses will be conducted on these

Pfizer Affirms CHANTIX/CHAMPIX as Important Treatment Option for Smokers Wanting to Quit

Mon, 4 Jul 2011 17:44:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that the reliable science on varenicline (CHANTIX/CHAMPIX), involving more than 14 clinical trials with more than 7,000 smokers, and the medicine’s approval by regulatory authorities around the world, demonstrate the importance of the medicine as an effective and appropriate treatment option for adult smokers wanting to quit. Pfizer stands behind the benefit/risk profile of Chantix. The company expressed concerns about the reliability of the meta-anal

Pfizer and ChemRar High Tech Center Announce Plans to Explore Innovative Medical Research and Development Partnership in Russia

Wed, 29 Jun 2011 13:21:00 UT

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and the Russian pharmaceutical investment and R&D group ChemRar High Tech Center (ChemRar) announced today that they have signed a Memorandum of Understanding (MoU) to explore a collaboration focused on research, development and commercialization of innovative drugs in Russia and other countries. The announcement was made during the BIO International Convention. The two companies will explore opportunities for accelerated development and c

Pfizer Nutrition Data Demonstrate that Appropriate Early Child Nutrition May Be Linked to Long-Term Health Outcomes in At-Risk Populations and Picky Eaters

Wed, 29 Jun 2011 12:00:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Results from studies presented by Pfizer Nutrition at the 5th Europaediatrics Congress in Vienna provide further evidence that appropriate feeding practices are critical to support the healthy growth and development of at-risk infants and picky eaters facing nutritional challenges. Data from two studies presented at the Congress demonstrate that many infants and children face nutritional challenges, including those who are preterm and low-birthweight, as well as c

Pfizer Invites Public To View And Listen To Webcast Of August 2 Conference Call With Analysts

Tue, 28 Jun 2011 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 2, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quar

Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

Tue, 28 Jun 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Pfizer’s filing for standard review of axitinib for patients with advanced renal cell carcinoma (RCC). This submission was based on Phase 3 data from the AXIS 1032 trial, comparing axitinib with sorafenib in patients with previously treated advanced RCC, which Pfizer recently presented at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). “This filing rep

Pfizer Files With The FDA For Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

Tue, 28 Jun 2011 12:00:00 UT

Pfizer Announces Data Presentations For Investigational Compounds In Its Lung Cancer Portfolio

Tue, 28 Jun 2011 09:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. will present early and mid-stage data from its lung cancer portfolio, including PF-00299804 (PF-299) an investigational, oral, pan-HER inhibitor;1 and crizotinib, an investigational, oral, first-in-class compound that inhibits the anaplastic lymphoma kinase, or ALK,2 at the International Association for the Study of Lung Cancer’s (IASLC) 14th World Conference on Lung Cancer (WCLC), July 3-7 in Amsterdam, The Netherlands. “While lung cancer remains a difficu

FDA Complete Response Letter Received for REMOXY

Fri, 24 Jun 2011 12:00:00 UT

NEW YORK & AUSTIN, Texas--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Pain Therapeutics, Inc. (NASDAQ: PTIE) announced that a Complete Response Letter was received from the U.S. Food and Drug Administration (FDA) on the resubmission to the new drug application (NDA) for REMOXY® (oxycodone) Extended-Release Capsules CII. Pfizer is working to evaluate the issues described in the Complete Response Letter and plans to have further discussions with FDA around them. REMOXY is an investigational extended-r

Pfizer Declares A 20-Cent Third-Quarter 2011 Dividend

Thu, 23 Jun 2011 20:24:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent third-quarter 2011 dividend on the company’s common stock, payable September 6, 2011, to shareholders of record at the close of business on August 5, 2011. The third-quarter 2011 cash dividend will be the 291st consecutive quarterly dividend paid by Pfizer.

ELIQUIS® (apixaban) Meets Primary and Key Secondary Endpoints in Phase 3 ARISTOTLE Study

Wed, 22 Jun 2011 23:14:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced today topline results of the Phase 3 ARISTOTLE trial of ELIQUIS®. In this study of patients with atrial fibrillation and at least one additional risk factor for stroke, ELIQUIS met the primary efficacy objective of non-inferiority to warfarin on the combined outcome of stroke (ischemic, hemorrhagic or unspecified type) and systemic embolism. In addition, ELIQUIS met the key

Pfizer’s Lyrica Top-Line Results Positive In Global Phase 3 Study Of Central Neuropathic Pain Following Spinal Cord Injury

Tue, 21 Jun 2011 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that top-line results for Lyrica Study A0081107 – Central Neuropathic Pain Following Spinal Cord Injury – demonstrated that the study met its primary endpoint: positive efficacy in reducing Central Neuropathic Pain following Spinal Cord Injury with Lyrica (pregabalin) compared to placebo. Further analysis will be conducted on these initial results. Central Neuropathic Pain is a heterogeneous group of pain conditions initiated or

Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII

Mon, 20 Jun 2011 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Acura Pharmaceuticals Inc. (NASDAQ: ACUR) announce the marketing approval from the U.S. Food and Drug Administration (FDA) of OXECTATM (oxycodone HCl, USP) Tablets CII. OXECTA is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate. OXECTA is the first immediate-release oxycodone HCl medicine that applies technology designed to discourage common methods of tampering ass

Pfizer Injectables Adds Doxorubicin Hydrochloride Injection, USP to Its Portfolio of Off-Patent Oncology Products

Wed, 15 Jun 2011 17:29:00 UT

PEAPACK, N.J.--(BUSINESS WIRE)--Pfizer Injectables, part of Pfizer Inc.’s (NYSE: PFE) Established Products Business Unit, announced today the addition of doxorubicin hydrochloride injection, USP, to Pfizer Injectables’ growing portfolio of off-patent oncology products. In March 2011, the US Food and Drug Administration (FDA) approved the reintroduction of doxorubicin hydrochloride injection, USP, in medical grade Cytosafe® polypropylene vials in the following vial sizes: 5 mL (10 mg), 10 mL (20

Pfizer Recognized By CIO Magazine As One Of The CIO 100 Award Honorees

Thu, 9 Jun 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has received the 2011 CIO 100 award presented by CIO magazine. The 24th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology (IT). "This year's CIO 100 awards draws well-deserved attention to companies that are not only innovating with IT but creating genuine business value as well," said Maryfran Johnson, editor in chief of C

Boston’s Top Academic Medical Centers Join Pfizer’s Centers For Therapeutic Innovation

Wed, 8 Jun 2011 18:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced its network of translational research partnerships, called the Centers for Therapeutic Innovation, has launched in Boston with Beth Israel Deaconess Medical Center, Boston University School of Medicine, Children’s Hospital Boston, Harvard University, Partners HealthCare, Tufts Medical Center, Tufts University, as well as University of Massachusetts Medical School in Worcester. These organizations follow on previously announced partnerships w

Pfizer Launches “Migraines at Work” Web Site to Educate Employers and Workers about the Condition

Wed, 8 Jun 2011 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has announced the launch of a web site, “Migraines at Work” (http://migrainesatwork.com), to educate U.S. employers and the public regarding one of the world’s top 20 most disabling illnesses. According to the Migraine Research Foundation1, American employers lose 113 million workdays due to Migraines per year. The Migraine Research Foundation reported an estimated 30 million Americans suffer from Migraines—which is among the world’s top 20 most

Pfizer Conducts First “Virtual” Clinical Trial Allowing Patients to Participate Regardless Of Geography

Tue, 7 Jun 2011 19:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it is conducting the first-ever randomized clinical trial under an investigational new drug (IND) application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their proximity to clinical sites. The pilot project, initiated following review from the U.S. Food and Drug Administration (FDA), uses mobile phone and web-based technology to collect necessary

Pfizer to Announce New Boston-Area Research Partnerships Wednesday, June 8, 2011 2:00 p.m.

Tue, 7 Jun 2011 11:39:00 UT

--(BUSINESS WIRE)--Pfizer What Major announcement concerning new network for innovative science. News will also concern Pfizer’s real estate footprint in the City of Boston Who Massachusetts Governor Deval Patrick, Boston Mayor Tom Menino, Pfizer senior executives, Boston’s top research and academic leaders When Wednesday, June 8, 2011, 2:00 p.m.Interviews immediately following announcement Where Center for Life Science BostonLongwood Medical Area3 Blackfan Circle,Boston, Mass.Ground flo

Pfizer and Hisun Sign MOU to Increase Access to Quality and Low-Cost Medicines for Patients in China

Thu, 2 Jun 2011 13:22:00 UT

SHANGHAI & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading pharmaceutical company in China, today jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture. This potential partnership would aim to strengthen the ability of both companies to reach more patients with high-quality and low-cost medicines in the branded generics arena. Under the MOU, the two companies wi

Pfizer Files For European Regulatory Review Of Axitinib For Patients With Advanced Renal Cell Carcinoma

Wed, 1 Jun 2011 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer’s filing for regulatory review of axitinib for patients with advanced renal cell carcinoma (RCC) after failure of prior systemic treatment. This submission was based on Phase 3 data from the AXIS 1032 trial. Pfizer will present full results from this trial, as well as additional data on axitinib, at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO), being

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Tue, 31 May 2011 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mace Rothenberg, Senior Vice President, Clinical Development and Medical Affairs, Oncology Business Unit, at the Goldman Sachs 32nd Annual Global Healthcare Conference on Tuesday, June 7, 2011 at 3:30 p.m. Pacific Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 32nd Annual Global Healthcare Conference” lin

Pfizer Invites Public to View and Listen to Webcast of June 6 Pfizer Analyst and Investor Meeting at ASCO

Tue, 31 May 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Pfizer’s oncology leadership team at an analyst and investor meeting on Monday, June 6, 2011 at 6:00 p.m. Central Daylight Saving Time, in connection with the annual meeting of the American Society of Clinical Oncology (ASCO). To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Analyst and Investor Meeting at ASCO” link

Pfizer Announces New Strategic Partnerships With ICON And PAREXEL International Corporation

Thu, 26 May 2011 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011. The new partnerships will be fully implemented over an 18-to-24 month period. The ICON and PAREXEL alliances reflect Pfizer’s recent commitment to strengthen the performance of its innovative core. Pfizer announced in February a co

Data Presented at Two Global Medical Congresses Reinforce Benefit of Enbrel® (etanercept) for Patients with Chronic Inflammatory Conditions

Wed, 25 May 2011 12:03:00 UT

THOUSAND OAKS, Calif. and NEW YORK--(BUSINESS WIRE)--Amgen (Nasdaq: AMGN) and Pfizer Inc. (NYSE: PFE) today announced new results from multiple studies of ENBREL, further expanding the body of evidence supporting the efficacy and safety profile of ENBREL, the most prescribed biologic by rheumatologists in the United States (U.S.). Eighteen abstracts across four indications, including moderate-to-severe rheumatoid arthritis (RA), ankylosing spondylitis (AS), moderate-to-severe plaque psoriasis (P

Pfizer Announces Detailed Results Of ORAL Sync Showing Investigational Compound Tofacitinib Reduces Signs And Symptoms And Improves Physical Function In Patients With Moderate-To-Severe Active Rheumatoid Arthritis, With Results Seen As Early As Two Weeks

Tue, 24 May 2011 23:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced data from ORAL Sync (A3921046) and Study A3921109, two clinical trials of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor, being studied in rheumatoid arthritis (RA). Top-line results of ORAL Sync, a pivotal Phase 3 trial, were announced earlier this year. A separate trial, Study A3921109, evaluated the safety and efficacy of atorvastatin versus placebo in reducing LDL cholesterol (LDL-C)

Adding Inspra® (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows

Sun, 22 May 2011 12:15:00 UT

GOTHENBURG, Sweden--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a pre-specified sub-analysis1 of the EMPHASIS-HF trial2 which showed that Inspra® (eplerenone), added to standard recommended therapy, statistically significantly reduced the incidence of new onset atrial fibrillation or flutter (AF/F) in patients with systolic heart failure and mild symptoms, compared with placebo plus standard therapy. This analysis was a pre-specified secondary endpoint in the EMPHASIS-H

SUTENT® Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors

Fri, 20 May 2011 20:04:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SUTENT® (sunitinib malate) as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors (NET) in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.1,2 “We are delighted that SUTENT has been granted approval by the FDA as an eff

ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement

Fri, 20 May 2011 14:41:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The European Commission has approved ELIQUIS® in the 27 countries of the European Union (EU) for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. This decision marks the first approval for ELIQUIS®, a new oral direct Factor Xa inhibitor being developed by the alliance of Bristol-Myers Squibb Company and Pfizer Inc. “Major orthopedic surgery, such as total knee replaceme

Pfizer Presents New Phase 3 Data Showing Axitinib Significantly Extended Progression-Free Survival Compared With Sorafenib In Patients With Previously-Treated Advanced Renal Cell Carcinoma

Wed, 18 May 2011 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95%CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population. PFS was significantly longer in axitinib-treated

Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare

Tue, 17 May 2011 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that its New Drug Application (NDA) for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA) and has been filed with the Japanese Ministry of Health, Labour and Welfare (MHLW). The proposed indication is for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). “Our abilit

Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting

Mon, 16 May 2011 12:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,1 crizotinib,2 and bosutinib,3 as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,4,5 at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. The Company will also share analyses from early stage compounds focused on the science behind tumor growth.6,7,8 “The research we are presenting

Pfizer Animal Health And American Humane Association Partner To Conduct Research On The Power Of The Human-Animal Bond In Pediatric Cancer Patients

Wed, 11 May 2011 12:30:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Animal Health and American Humane Association today announced a partnership to conduct a study on the impact of animal-assisted therapy on pediatric oncology patients, as well as on their parents, caregivers, siblings, and other close family members. The partnership — which includes a $282,000 grant from Pfizer and the Pfizer Foundation — exemplifies the strategic goal of both organizations to better quantify in clinical terms what many in health care alrea

Alzheimer’s Association Salutes Advocate And Mountaineer Now Climbing Everest As Part Of The 7 Summits Climb For Alzheimer’s

Tue, 10 May 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the Alzheimer’s Association™, the world's leading voluntary health organization in Alzheimer's care, support and research, as a new beneficiary of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. Through this campaign, mountaineer and Alzheimer’s disease advocate Alan Arnette is seeking to climb the 7 Summit

Pfizer’s Prevnar 13® Meets All Study Endpoints In Two Pivotal Phase 3 Trials In Adults Aged 50 And Older Presented Today

Mon, 9 May 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 years and older met all study endpoints. These studies provide the clinical foundation for the regulatory filings that have been submitted in the United States, the European Union and more than a dozen other countries. The results are being presented to

The European Commission Approves Pfizer’s Revatio® (sildenafil) for the Treatment of Pulmonary Arterial Hypertension in Children

Thu, 5 May 2011 12:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. “Pulmonary arterial hypertension is a rare, devastating disease that can

PRISTIQ® (desvenlafaxine) Extended Release Tablets Shown To Significantly Reduce Number And Severity Of Moderate-To-Severe Hot Flashes Associated With Menopause

Tue, 3 May 2011 14:30:00 UT

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ® (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington, D.C.1 PRISTIQ, which is approved by the U.S

Pfizer Reports First-Quarter 2011 Results

Tue, 3 May 2011 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) First-Quarter 2011 2010 Change Reported Revenues $ 16,502 $ 16,576 -- Adjusted Income(1) 4,808 4,862 (1 %) Adjusted Diluted EPS(1) 0.60 0.60 -- Reported Net Income(2) 2,222 2,026 10 % Reported Diluted EPS(2) 0.28 0.25 12 % See end of text prior to tables for notes. Pfizer Inc. (NYSE: PFE) today reported financial results for first-quarter 2011. As a result of Pfizer

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Mon, 2 May 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2011 Healthcare Conference on Tuesday, May 10, 2011 at 11:20 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of America Merrill Lynch 2011 Healthcare Conference” link

Centrum® multivitamins and Celebrity Personal Trainer Harley Pasternak Share Star-Tested Secrets to Shape up for Summer

Mon, 2 May 2011 12:36:00 UT

MADISON, N.J.--(BUSINESS WIRE)--It’s not what celebrities know about getting fit for summer, it’s who they know. And when Hollywood stars want to get in the best shape of their lives, they call Harley Pasternak, creator of the 5 Factor Diet. This spring, the makers of Centrum® multivitamins are teaming up with Pasternak to bring star-worthy tips to Americans. One lucky person will win a trip to Los Angeles and a training session with Harley, a renowned fitness and nutrition expert and best-selli

Pfizer Hosts Annual Meeting of Shareholders

Thu, 28 Apr 2011 15:16:00 UT

DALLAS--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared a 20-cent second-quarter 2011 dividend on the company’s common stock, payable June 7, 2011, to shareholders of record at the close of business on May 13, 2011. The second-quarter 2011 cash dividend will be the 290th consecutive quarterly dividend paid by Pfizer. “Through dividends and share repurchases, we returned approximately $7.1 billion to our shareholders in 2010,” said Ian Read, president and chief executive off

Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

Thu, 28 Apr 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Standard (A3921064) and ORAL Step (A3921032) Phase 3 studies of tofacitinib (development code: CP-690,550), an investigational, novel, oral JAK inhibitor. ORAL Standard is a completed twelve-month study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib 5 or 10 mg BID, adalimumab 40 mg subcutaneousl

Pfizer Launches New Advanced GOLD Range Of Early Child Nutrition Products

Wed, 27 Apr 2011 12:55:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Inc. today announced the global launch of its new advanced GOLD range of child nutrition products, developed to meet the changing nutritional and feeding needs of young children. The GOLD range of infant and follow-on formulas, and growing-up milks provides the right balance of high-quality nutrients needed to support ideal health, growth and development in growing children. Globally, in 2010 around 43 million children under the age of five were overweight.

Pfizer Comments on ORAL Sync Tofacitinib Data in EULAR Abstract LB0005

Thu, 21 Apr 2011 22:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. commented on an abstract concerning the ORAL Sync Phase 3 study of tofacitinib in patients with rheumatoid arthritis (RA) which has been posted for the European League Against Rheumatism (EULAR) conference. In this study, four deaths were reported in the tofacitinib arms, three of which were determined by the investigators not to be study drug related. The cases reported that were determined not to be study drug related involve one case of brain injury foll

Pfizer Invites Public To Listen To Webcast Of April 28 Annual Meeting Of Shareholders

Thu, 21 Apr 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday, April 28. To access the Webcast, visit our Web site at www.pfizer.com/annualmeeting and click on the “Annual Meeting of Shareholders Webcast” link. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com beginning today. Visitors to www.pfizer.com will be able to list

Pfizer and Shanghai Pharmaceutical Sign Memorandum of Understanding for Potential Strategic Partnership

Wed, 20 Apr 2011 15:27:00 UT

SHANGHAI, China and NEW YORK--(BUSINESS WIRE)--Shanghai Pharmaceutical Co. Ltd. (SHSE: 601607) and Pfizer Inc. (NYSE: PFE) today announced the signing of a memorandum of understanding (MOU) for the companies to jointly pursue potential business opportunities in China. The potential partnership is intended to leverage both companies’ strengths, matching Pfizer’s global capabilities in developing innovative medicines with Shanghai Pharmaceutical’s capabilities and reach in the China market. The co

Pfizer Announces Top-Line Results Of Third Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

Fri, 15 Apr 2011 12:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today top-line results from the ORAL Scan Phase 3 study (A3921044) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor. ORAL Scan is an ongoing two-year study in patients with moderate-to-severe active rheumatoid arthritis (RA) who had an inadequate response to methotrexate (MTX) and were randomized to receive tofacitinib 5 or 10 mg BID or placebo added to background MTX. The

Tafamidis, An Oral, Investigational Compound For The Treatment Of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP) Sustained A Slowing Of Disease Progression Over 30 Months

Tue, 12 Apr 2011 23:00:00 UT

HONOLULU--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today data from an open-label extension study (Fx-006) of the pivotal Phase II/III (Fx-005) trial. This extension study evaluated the long-term clinical outcomes of tafamidis, a novel, oral, investigational compound being studied as a treatment for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). TTR-FAP is a rare and fatal neurodegenerative disease affecting approximately 8,000 patients worldwide. These data show

FDA Advisory Committee Finds Data Support The Favorable Benefit-Risk Profile Of SUTENT® In Unresectable Pancreatic Neuroendocrine Tumors (NET)

Tue, 12 Apr 2011 21:54:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 8-2 that SUTENT® (sunitinib malate) provides a favorable benefit-risk profile for the treatment of unresectable pancreatic neuroendocrine tumors (NET). The panel’s advice will be considered by the FDA when finalizing its review of Pfizer’s supplemental New Drug Application (sNDA) for sunitinib for this indication. "We are encouraged by the panel’s favorable review of sunitinib

Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease

Mon, 11 Apr 2011 11:40:00 UT

NEW YORK and SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints, the Mini-Mental State Examination (MMSE), which measures cognition (p=0.39), or the Clinician's Interview-Based Impression of Change, plus caregiver input (CIBIC-p

Pfizer Invites Public To View And Listen To Webcast Of May 3 Conference Call With Analysts

Tue, 5 Apr 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 3, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2011 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quarterl

Pfizer to Sell Capsugel to KKR

Mon, 4 Apr 2011 11:30:00 UT

PEAPACK, N.J.--(BUSINESS WIRE)--Pfizer and Kohlberg Kravis Roberts & Co L.P. (together with its affiliates, “KKR”) today announced they have entered into an agreement whereby an affiliate of KKR will acquire Pfizer’s Capsugel business for $2.375 billion in cash. Capsugel, the world leader in hard capsules and an innovator in drug-delivery systems, generated approximately $750 million in revenue and manufactured more than 180 billion hard capsules in 2010. “The transaction is an endorsement o

Pfizer Receives Refusal To File Letter From U.S. FDA On Tafamidis New Drug Application

Mon, 4 Apr 2011 11:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) for tafamidis, the company’s novel, oral investigational compound for patients with Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). Upon preliminary review, the FDA determined that the application, which was submitted in February 2011, was not sufficiently complete to permit a substantive review. The company believes t

Pfizer Oncology To Present Broad Array Of New Pre-Clinical And Clinical Data From Early And Late Stage Compounds

Fri, 1 Apr 2011 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present nearly 30 abstracts highlighting research in new and established pathways, including inhibition of Hedgehog signaling (PF-04449913);1 dual inhibition of PI3K/mTOR (phosphatidylinositol 3-kinase/mammalian target of rapamycin)(PF-04691502);2 and cancer stem cell-based targets.3 Data from this research as well as data from studies involving investigational compounds, including crizotinib,4 an oral first-in-class compound that inhibits the anap

Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010

Thu, 31 Mar 2011 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today released a report detailing the company’s financial interactions with health care professionals and researchers in 2010. Specifically, the report, posted today on www.pfizer.com/WorkingWithHCP, presents 2010 data on payments -- including compensation for clinical research activities, professional consulting, and speaking at expert-led forums –- and the value of other items, such as meals, educational items and reimbursed travel expenses, provided to U

Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling

Sat, 26 Mar 2011 17:41:00 UT

PEAPACK, N.J.--(BUSINESS WIRE)--Greenstone LLC announced today that it is voluntarily conducting a recall, to the patient level, of medicines with lot number FI0510058-A on the label. This includes Citalopram 10mg Tablets (100-count bottle) and Finasteride 5mg Tablets (90-count bottle), both distributed in the U.S. market. The recall is due to the possibility that incorrect labels have been placed on the bottles by a third-party manufacturer. This is the only lot number being recalled and no oth

Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling

Sat, 26 Mar 2011 17:41:00 UT

Pfizer Animal Health Continues to Invest in the Future of Veterinarians with Announcement of 2011 Veterinary Scholarship Recipients

Fri, 25 Mar 2011 13:00:00 UT

MADISON, N.J.--(BUSINESS WIRE)--As part of its ongoing commitment to invest in the future of the veterinary profession, Pfizer Animal Health today announced the recipients of its second annual student scholarship program. Pfizer awarded $2,500 each to 300 second- and third-year veterinary students at accredited universities throughout the United States and the Caribbean, for a total of $750,000. A total of 1,562 students applied for the scholarship. Students were chosen based on several criteria

SPIRIVA HandiHaler Prolonged Time To First COPD Exacerbation, New Study In NEJM Shows

Wed, 23 Mar 2011 21:01:00 UT

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--A new study, published today in The New England Journal of Medicine (NEJM), showed that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder), a long-acting anticholinergic, was significantly more effective at preventing Chronic Obstructive Pulmonary Disease (COPD) exacerbations than salmeterol HFA-MDI (hydrofluororalkane-metered dose inhaler). While salmeterol HFA-MDI, a beta-agonist is widely used as a COPD maintenance treatment worldwide, i

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Thu, 10 Mar 2011 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 11:15 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Barclays Capital 2011 Global Healthcare Conference” link in the Investor Presentations sect

Pfizer Announces Primary Endpoints Met In Second Phase 3 Clinical Trial Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis

Fri, 4 Mar 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the ORAL Sync Phase 3 study (A3921046) of tofacitinib (development code: CP-690,550), formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis (RA), met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical funct

World-Class Professional Golfer Phil Mickelson Launches “On Course with Phil” for People with Certain Inflammatory Joint and Skin Conditions

Wed, 2 Mar 2011 13:40:00 UT

THOUSAND OAKS, Calif., & COLLEGEVILLE, Pa.--(BUSINESS WIRE)--World-class professional golfer and psoriatic arthritis patient Phil Mickelson today launches “On Course with Phil,” a disease education program for people with certain chronic inflammatory joint and skin conditions, in partnership with Amgen (NASDAQ: AMGN) and Pfizer, Inc. (NYSE:PFE). This program seeks to inspire patients with psoriatic arthritis, rheumatoid arthritis or plaque psoriasis to take action, educate themselves and work wi

King Pharmaceuticals, Inc. Announces Final Results of Its Offer to Purchase Convertible Notes

Tue, 1 Mar 2011 17:16:00 UT

BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (the “Company”), a wholly owned subsidiary of Pfizer Inc., announced today the final results of its tender offer to purchase (the “Fundamental Change Put Option”) any and all of its outstanding 1 1/4% Convertible Senior Notes Due 2026 (the “Securities”). The Fundamental Change Put Option expired on February 28, 2011, at 11:59 p.m., New York City time (the “Expiration Date”). The Paying Agent has advised the Company that prior to the Exp

Pfizer Completes Acquisition Of King Pharmaceuticals, Inc.

Tue, 1 Mar 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has combined operations with King Pharmaceuticals, Inc. On February 28, 2011, Pfizer completed its acquisition of King through the merger of its wholly owned subsidiary, Parker Tennessee Corp., with and into King. King is now a wholly owned subsidiary of Pfizer. Under the terms of the transaction, each outstanding share of King common stock has been converted into the right to receive $14.25, net in cash (without interest

Pfizer Announces Updated, Interactive Development Pipeline

Mon, 28 Feb 2011 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its development pipeline, available at www.pfizer.com/pipeline. The updated pipeline includes an overview of the company’s research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action. The company has redesigned the format of the development pipeline, providing interactive capabilities that will allow interested parties to search for assets by dev

XIAPEX® (Collagenase Clostridium Histolyticum) Authorized in the European Union (EU) For Dupuytren’s Contracture

Mon, 28 Feb 2011 18:37:00 UT

NEW YORK & MALVERN, Pa.--(BUSINESS WIRE)--XIAPEX® (collagenase clostridium histolyticum), a new non-surgical treatment option for Dupuytren’s contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and is expected to be available for use in some European markets later this year.1 Collagenase clostridium histolyticum is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture. Pfizer (NYSE:

NH Citizens Health Initiative to Premiere Mini-Documentaries on NH Multi-Stakeholder Patient Centered Medical Home Pilot

Wed, 23 Feb 2011 16:27:00 UT

CONCORD, N.H.--(BUSINESS WIRE)--NH Citizens Health Initiative, in collaboration with Pfizer, Inc. and the New Hampshire Medical Society, is premiering two mini-documentaries detailing what it means to be a patient and a provider in a patient-centered medical home. The videos were created by The Initiative and Pfizer in an effort to describe the value and benefits of medical homes. Patient-centered medical homes put a patient’s needs at the fore and provide primary, preventive, and chronic condit

U.S. Supreme Court Decision In Bruesewitz V. Wyeth A Win For Public Health

Tue, 22 Feb 2011 18:49:00 UT

WASHINGTON--(BUSINESS WIRE)--Today, in a 6-2 decision, the U.S. Supreme Court affirmed the ruling of the U.S. Court of Appeals for the Third Circuit in favor of Pfizer’s subsidiary Wyeth, in Bruesewitz v. Wyeth. The Third Circuit determined that the National Childhood Vaccine Injury Act prevents civil suits against manufacturers of FDA-approved childhood vaccines based on a claim that a particular vaccine should have been designed differently. “Vaccines are one of modern medicine's greatest succ

New AVERROES Data Demonstrate Investigational Apixaban Superior to Aspirin in Reducing Stroke and Systemic Embolism in Patients with Atrial Fibrillation Unsuitable for Warfarin Therapy

Fri, 11 Feb 2011 03:28:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY - News) and Pfizer Inc. (NYSE:PFE - News) today announced the publication of the full results of the AVERROES study of apixaban in The New England Journal of Medicine. Conducted in 36 countries, the study was coordinated by the Population Health Research Institute (PHRI) at McMaster University and at Hamilton Health Sciences in Canada. The study demonstrated that, for patients with atrial fibrillation (AF) who we

Apixaban Superior To Aspirin In Reducing Stroke And Systemic Embolism In Patients With Atrial Fibrillation Unsuitable For Warfarin Therapy

Thu, 10 Feb 2011 18:41:00 UT

Pfizer To Acquire Ferrosan’s Consumer Healthcare Business

Mon, 7 Feb 2011 08:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into a definitive agreement to purchase Ferrosan’s consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. Based in Copenhagen, Ferrosan is an innovative and long-established consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to serve a broader market including Russia, the Ukraine,

Enbrel® (etanercept) Significantly Improved Scalp Involvement in Patients with Moderate to Severe Plaque Psoriasis

Fri, 4 Feb 2011 14:00:00 UT

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La. “At least half of people with plaque psoriasis have involvement on

New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan

Fri, 4 Feb 2011 02:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Japan Inc. (“Pfizer,” headquarters: Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited (“Takeda,” headquarters: Chuo-ku, Tokyo) announced today an agreement to extend the period for co-promotion in Japan for the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept). The companies also signed a new co-promotion agreement in Japan for the investigational drug tofacitinib (development code: CP-690,550), formerly known as tasocitinib, which is

National Family Caregivers Association Supports Advocate in His Mission to Raise Awareness of the Burden of Alzheimer’s Disease

Thu, 3 Feb 2011 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the addition of the National Family Caregivers Association (NFCA), an organization that empowers family caregivers to act on behalf of themselves and their loved ones, as a supporter of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. NFCA joins the campaign just as alpine mountaineer and Alzheimer’s disease

Pfizer Announces New $5 Billion Share Repurchase Program

Tue, 1 Feb 2011 13:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company’s total repurchase authorization to $9 billion. Pfizer currently expects to repurchase approximately $5 billion of its common stock during 2011 with the remaining authorized amount ava

Pfizer Reports Fourth-Quarter and Full-Year 2010 Results; Provides 2011 Financial Guidance and Updates 2012 Financial Targets

Tue, 1 Feb 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Fourth-Quarter Full-Year 2010 2009 Change 2010 2009 Change Reported Revenues $ 17,561 $ 16,537 6 % $ 67,809 $ 50,009 36 % Reported Net Income(2) 2,890 767 277 % 8,257 8,635 (4 %) Reported Diluted EPS(2) 0.36 0.10 260 % 1.02 1.23 (17 %) Adjusted Income(1) 3,770 3,825 (1 %) 17,983 14,202 27 % Adjusted Diluted EPS(1) 0.47 0.49 (4 %) 2.23 2.02 10 %

Dr. Yvonne Greenstreet Joins Pfizer As Senior Vice President And Head Of Medicines Development, Specialty Care Business Unit

Mon, 31 Jan 2011 14:10:00 UT

COLLEGEVILLE, Pa.--(BUSINESS WIRE)--Pfizer Inc. today announced that Dr. Yvonne Greenstreet has been appointed Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit, effective February 1 2011. Upon her arrival, she will assume global responsibility for leading the advancement of the development portfolio, ensuring its alignment with Specialty Care’s strategic objectives. “Yvonne has a strong track record of leadership and outstanding results during her care

Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.

Mon, 31 Jan 2011 13:22:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The offering period and withdrawal

Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman Of The Year

Fri, 28 Jan 2011 14:48:00 UT

NEW YORK--(BUSINESS WIRE)--The Healthcare Businesswomen’s Association (HBA) announced that its 2011 “Woman of the Year” is Freda Lewis-Hall, MD, chief medical officer of Pfizer. In her distinguished 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, pharmaceuticals and biotechnology. “I am deeply honored to be named Woman of the Year by the Healthcare Businesswomen’s Association,” said Dr. Lewis-Hall. “HBA has been an agent of positive

Pfizer Announces HSR Clearance for the Acquisition of King Pharmaceuticals

Thu, 27 Jan 2011 23:50:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. Termination

Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. RELISTOR Kit Packaging

Tue, 25 Jan 2011 19:06:00 UT

NEW YORK & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Pfizer Inc and Progenics Pharmaceuticals, Inc. have learned of a United States market recall of alcohol prep pads and swabs manufactured by the Triad Group. In the interest of patient safety, Pfizer and Progenics are alerting U.S. patients and physicians to Triad’s recall. Triad® Alcohol Prep Pads are packaged for use with the kit presentation of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection in the U.S. The RELISTOR vial and other compon

Pfizer Announces Seven Of New York City’s Top Research Hospitals Join Global Centers For Therapeutic Innovation

Tue, 25 Jan 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that seven major research-based medical centers in New York City, including Rockefeller University, NYU Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College, have joined Pfizer’s Centers for Therapeutic Innovation, a network of partnerships that aims to speed the translatio

Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc. to January 28, 2011

Fri, 21 Jan 2011 13:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 5:00 p.m., New York City time on Friday, January 28, 2011, un

Pfizer Initiates Rolling Submission For A New Drug Application In The U.S. For Its Fast-Tracked Investigational Compound Crizotinib (PF-02341066) For Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer

Wed, 12 Jan 2011 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011. “This action represents a significant step in

Pfizer Invites Public to View and Listen to Webcast of February 1 Conference Call with Analysts

Tue, 4 Jan 2011 17:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 1, 2011. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Qu

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Tue, 4 Jan 2011 16:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care and Oncology, at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011 at 3:00 p.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “29th Annual J.P. Morgan Healthcare Conference” link in the Investor Presentations sec

Pfizer Animal Health Completes Acquisition of Synbiotics Corporation

Mon, 3 Jan 2011 21:47:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Animal Health today announced the completion of its acquisition of Synbiotics Corporation (Pinksheets SYNB.PK) on December 30, 2010, resulting in the cessation of trading of Synbiotics common stock. Shareholders of record of Synbiotics’ common stock will receive written instructions, including a letter of transmittal, for exchanging their Synbiotics common stock for the merger consideration. Holders in "street" name should contact their broker to receive th

Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.

Wed, 15 Dec 2010 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 12:00 midnight, New York City time on Friday, January 21, 2011 (which

Pfizer Declares A 20-Cent First-Quarter 2011 Dividend

Mon, 13 Dec 2010 21:32:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 20-cent first-quarter 2011 dividend on the company's common stock, payable March 1, 2011, to shareholders of record at the close of business on February 4, 2011. Pfizer increased the dividend by approximately 11 percent, to 20 cents from 18 cents per share. "This dividend increase is a testament to our commitment to enhance shareholder value and reflects continued confidence in our business," said Ian R

Pfizer Board of Directors Elects George A. Lorch Non-Executive Chairman

Mon, 13 Dec 2010 21:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Company's Board of Directors has elected George A. Lorch, 68, who has served as an independent director since 2000, as non-executive Chairman of the Board, effective immediately. The Board's Lead Independent Director, Constance J. Horner, said, "George Lorch has been a valuable, independent voice on the Pfizer Board for over 10 years, and he is ideally suited to lead the Board as non-executive Chairman. George has been a

Young Children In Developing World Receive Accelerated Access to Pfizer's Prevenar 13 Vaccine

Sun, 12 Dec 2010 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) was introduced into the first childhood immunization program for pneumococcal disease (PD) in the developing world under the auspices of the Advance Market Commitment (AMC) when Nicaragua launched its program today. The AMC is an innovative program which involves private-public partnerships to help make newer vaccines available on a sustainable, aff

Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety

Fri, 10 Dec 2010 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that, in the interest of patient safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the treatment of pulmonary arterial hypertension (PAH) in regions where it is approved (the European Union, Canada and Australia). In addition, Pfizer is discontinuing clinical studies of Thelin worldwide. Pfizer's decision was based on a review of emerging safety information from clinical trials and post-marketing reports. While liver

Angie Harmon and Children's Advil® Invite Families to Sing Away the Cold and Flu Season Blues

Tue, 7 Dec 2010 15:06:00 UT

MADISON, N.J.--(BUSINESS WIRE)--At the height of this year's cold and flu season, Angie Harmon, mom of three, is teaming up with the makers of Children's Advil® to launch "Relieve My Fever" -- a contest that invites parents and their kids to sing the Children's Advil® rendition of the classic song "Fever" for a chance to win $15,000. The kid-friendly version of the song tells the story of mommy fighting her little one's fever and making her child feel better. Additionally, for every entry and vo

National Initiative Urges 10 Million At-Risk Boomers to 'Face Alzheimer's'

Mon, 6 Dec 2010 17:00:00 UT

CHICAGO and NEW YORK--(BUSINESS WIRE)--With as many as 10 million U.S. baby boomers at risk for developing Alzheimer's,(1) the Alzheimer's Association and Pfizer (NYSE: PFE) are collaborating to help raise awareness of Alzheimer's disease by emphasizing to all Americans, "It's Time to Face Alzheimer's." The effort encourages people to share photos and stories related to their personal experience with the disease in an effort to show the real and varied "faces" of Alzheimer's. The initiative will

Pfizer Announces Phase 3 Results of Investigational Compound Bosutinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia

Mon, 6 Dec 2010 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that a significantly higher proportion of patients with newly diagnosed chronic myeloid leukemia who were treated with bosutinib (39 percent) experienced a major molecular response (MMR), a secondary endpoint, compared with patients treated with imatinib (26 percent) in the intent-to-treat (ITT) population (p=0.002). However, the study did not meet its primary endpoint of superior complete cytogenetic response (CCyR) rate at one

Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer

Mon, 6 Dec 2010 01:09:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its Board of Directors has elected Ian C. Read, 57, currently head of the Company's global biopharmaceutical operations, as President, Chief Executive Officer and Director. Mr. Read succeeds Jeffrey B. Kindler, who has retired from the Company. The Board's Lead Independent Director, Constance J. Horner, said, "In 2006, Jeff Kindler took on the challenge of transforming Pfizer in the face of enormous changes in the global hea

Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia

Fri, 3 Dec 2010 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today it is planning regulatory submissions of bosutinib in patients with chronic myeloid leukemia (CML) based on data from a clinical program evaluating the compound in newly diagnosed and previously treated patients. These regulatory submissions are planned for 2011. Pfizer has begun the process of preparing a Marketing Authorization Application (MAA) for submission to the European Medicine Agency (EMA) for bosutinib as a treatment o

AVERROES Study of Investigational Agent Apixaban Closes Early Due to Clear Evidence of Efficacy

Thu, 2 Dec 2010 15:06:00 UT

PRINCETON, N.J. and NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today announced that the companies have agreed to stop the Phase 3 AVERROES clinical trial of apixaban in patients with atrial fibrillation. The study will be stopped early because a predefined interim analysis by the independent Data Monitoring Committee (DMC) revealed clear evidence of a clinically important reduction in stroke and systemic embolism in patients with atrial fibrillatio

Centrum® and Molly Shannon Search for 'America's Most Amazingly Energized Woman' This Holiday Season

Thu, 2 Dec 2010 14:00:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Getting it all done while enjoying life takes the right attitude and energy. A new contest from the makers of Centrum® multivitamins seeks to find out how some women manage to stay energized to enjoy life and love to the max this holiday season. Despite a calendar full of parties to plan and gifts to wrap, there are always those special women who manage to get everything done with a smile on their face, and the makers of Centrum® multivitamins want to celebrate th

SUTENT® Receives European Approval for a New Indication in Progressive Pancreatic Neuroendocrine Tumors (NET)

Thu, 2 Dec 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.(1,2) Sutent is the first treatment to be approved for

Caltrate® Soft Chews Offer A New and Delicious Way to Help Americans Reach Their Recommended Daily Calcium and Vitamin D Intake

Tue, 30 Nov 2010 05:02:00 UT

MADISON, N.J.--(BUSINESS WIRE)--On the heels of the Institute of Medicine increasing the daily recommended intake of vitamin D to maintain bone health, Americans may be left wondering how to meet the new guidelines. Pfizer Consumer Healthcare, the makers of the #1 selling brand of calcium and vitamin D supplements, announces the launch of new Caltrate® Soft Chews, a great-tasting and convenient way to help reach the new, higher daily vitamin D goals.* Specifically the new guidelines issued by th

Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology

Mon, 29 Nov 2010 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase 3 study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia

Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease

Mon, 29 Nov 2010 07:00:00 UT

NEW YORK and CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX, TASE: PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment of Gaucher disease on March 23, 2010. On November

Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc.

Mon, 22 Nov 2010 13:15:00 UT

Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)

Fri, 19 Nov 2010 12:55:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a generally manageable safety profile in t

APPRAISE-2 Study with Investigational Compound Apixaban in Acute Coronary Syndrome Discontinued

Thu, 18 Nov 2010 23:17:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) today reported that the companies have discontinued the Phase 3 APPRAISE-2 clinical trial in patients with recent Acute Coronary Syndrome (ACS) treated with apixaban or placebo in addition to mono or dual antiplatelet therapy. The study was stopped early based on the recommendation of an independent Data Monitoring Committee (DMC). There was clear evidence of a clinically important increa

Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco

Wed, 17 Nov 2010 01:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. The University of California, San Francisco is the first collaboration in the network. "The Centers for Therapeutic Innovation represents a truly novel open innovation paradigm, combining the unique

Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds

Tue, 16 Nov 2010 03:00:00 UT

MADISON, N.J.--(BUSINESS WIRE)--From crowded malls to stuffy noses, consumers are in need of relief, especially during the hectic holiday season. In fact, a recent poll shows that about 70 percent of people avoid crowded or congested areas during the holidays.(1) To help holiday shoppers breathe easier this season, Pfizer Consumer Healthcare, maker of Advil® pain-relief products, is celebrating the launch of Advil® Congestion Relief by offering "literal congestion relief" in the form of a person

Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows

Sun, 14 Nov 2010 14:00:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy. The results were presented to physicians attending the American Heart Association Scientific Sessions in Chicago and we

Lower Protein in Infant Formula Supports Growth Rate Similar to Breast Milk, New Study Shows

Wed, 10 Nov 2010 09:30:00 UT

MADISON, N.J.--(BUSINESS WIRE)--Newly published findings indicate that infants fed a lower protein infant formula developed by Pfizer Nutrition gained weight at a similar rate to those who were breastfed,(1) according to a study published online today in the European Journal of Clinical Nutrition. Pfizer Nutrition has always recognized that breast milk is the best source of infant nutrition. The study established that infants fed a new, lower-protein infant formula attained the same growth rate

Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent to Raise Awareness of Growing Prevalence and Burden of Alzheimer's Disease

Tue, 9 Nov 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Alpine mountaineer and Alzheimer's disease advocate Alan Arnette will embark later this month to climb the 7 Summits, the highest peak on each continent. This ambitious year-long climbing campaign – The 7 Summits Climb for Alzheimer's: Memories are Everything – aims to raise awareness of the growing Alzheimer's prevalence in our aging population and the enormous financial and personal burden it places on people with the disease, their caregivers and society. "The menta

In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function

Sun, 7 Nov 2010 22:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, v

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Wed, 3 Nov 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, President and General Manager, Primary Care, at the 2010 Annual Credit Suisse Healthcare Conference on Wednesday, November 10, 2010 at 8:00 a.m. Mountain Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the "2010 Annual Credit Suisse Healthcare Conference" link in the Investor Prese

Pfizer Reports Third-Quarter 2010 Results

Tue, 2 Nov 2010 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): Third-Quarter 2010 Revenues of $16.2 Billion Third-Quarter 2010 Adjusted Diluted EPS(1) of $0.54; Reported Diluted EPS(2) of $0.11 Tightens Ranges for 2010 Financial Guidance Components, Increases Range for Adjusted Diluted EPS(1) and Reduces Range for Reported Diluted EPS(2); Reaffirms 2012 Financial Targets Advances Strategic Priorities with Agreement to Acquire King Pharmaceuticals, Inc., Acquisition of FoldRx, Alliance with Biocon and Pendi

Pfizer's Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan

Thu, 28 Oct 2010 21:37:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd. "Neuropathic pain remains an under-diagnosed c

Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend

Thu, 28 Oct 2010 21:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent fourth-quarter 2010 dividend on the company's common stock, payable December 1, 2010, to shareholders of record at the close of business on November 8, 2010. The fourth-quarter 2010 cash dividend will be the 288th consecutive quarterly dividend paid by Pfizer.

Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)

Wed, 27 Oct 2010 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were published in the October 28 issue of the New

Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.

Fri, 22 Oct 2010 12:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the commencement of a tender offer by its wholly owned subsidiary, Parker Tennessee Corp., for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated October 22, 2010, and in connection with the previously announced

New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

Thu, 21 Oct 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to methicillin-resistant Staphylococcus aureus) study was th

Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil

Wed, 20 Oct 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines. Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements. The partnership will enhance Pfizer's position in Brazil, a key emerging market, by providing access to Teuto's broad portfolio of

Biocon and Pfizer Enter Into Global Commercialization Agreement

Mon, 18 Oct 2010 11:00:00 UT

BANGALORE, India and NEW YORK--(BUSINESS WIRE)--Biocon, Asia's premier biotechnology company, and Pfizer Inc. (NYSE: PFE), the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products: Recombinant Human Insulin, Glargine, Aspart and Lispro. Pfizer will have exclusive rights to commercialize these products globally, with certain exce

Alzheimer's Disease Caregivers Identify Memory Loss, Personal Safety and Confusion as Top Three Concerns Related to Progression of Their Loved One's Disease

Thu, 14 Oct 2010 12:00:00 UT

WOODCLIFF LAKE, N.J., and NEW YORK--(BUSINESS WIRE)--Results announced today from a national survey of Alzheimer's disease (AD) caregivers found that memory loss and confusion, which are cognitive symptoms, in addition to personal safety, are the greatest concerns related to the progression of their loved one's AD. In fact, 67 percent of AD caregivers surveyed said changes in cognitive symptoms were among their main concerns. The survey of 524 non-professional caregivers, which was conducted by

Pfizer to Acquire King Pharmaceuticals, Inc.

Tue, 12 Oct 2010 12:00:00 UT

NEW YORK and BRISTOL, Tenn.--(BUSINESS WIRE)--Pfizer Inc.(NYSE: PFE) and King Pharmaceuticals, Inc. (NYSE: KG) today announced that they have entered into a definitive merger agreement. Under the terms of the agreement, Pfizer will acquire King, a diversified specialty pharmaceutical discovery and clinical development company, for $3.6 billion in cash, or $14.25 per share, which represents a premium of approximately 40% to King's closing price as of October 11, 2010, and 46% percent to the one-m

Oral Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People With Moderate to Severe Plaque Psoriasis

Thu, 7 Oct 2010 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that data from a Phase 2 efficacy and safety study of tasocitinib (proposed INN name for CP-690,550), the company's investigational oral JAK inhibitor, met its primary endpoint of a statistically significant greater proportion of patients achieving at least a 75 percent reduction from baseline in PASI (Psoriasis Area and Severity Index) at week 12 in individuals with chronic moderate to severe plaque psoriasis. At week 12, PASI 7

Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets

Thu, 7 Oct 2010 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present new data across its portfolio representing novel approaches to researching treatments for patients with rare and difficult-to-treat cancers. These results will be presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy from October 8-12. "Pfizer (NYSE: PFE) has focused its oncology research on targeting molecular drivers and pathways in various cancers, such as EGFR, ALK and IGF-1R," said Dr. Mace Rothenb

Pfizer Receives FDA Approval for Prefilled Dual-Chamber Syringe for Use in the Treatment of Hemophilia A

Mon, 9 Aug 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of the use of a Prefilled Dual-Chamber Syringe for administration of XYNTHA® Antihemophilic Factor (Recombinant) Plasma/Albumin-Free to hemophilia A patients. XYNTHA is a recombinant factor VIII product indicated for both the control and prevention of bleeding episodes in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia) and f

Pfizer Reports Second-Quarter 2010 Results

Tue, 3 Aug 2010 10:00:00 UT

NEW YORK--(BUSINESS WIRE)-- ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2010 2009 Change 2010 2009 Change Reported Revenues $ 17,327 $ 10,984 58 % $ 34,077 $ 21,851 56 % Reported Net Income(1) 2,475 2,261 9 % 4,501 4,990 (10 %) Reported Diluted EPS(1) 0.31 0.34 (9 %) 0.56 0.74 (24 %) Adjusted Income(2) 4,959 3,249 53 % 9,841 6,916 42 % Adjusted Diluted EPS(2) 0.62 0.48 29 % 1.22 1.03 18 % See end of text prior

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Thu, 29 Jul 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Established Products, at the BMO Capital Markets 10th Annual Focus On Healthcare Conference on Thursday, August 5, 2010 at 11:15 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the "BMO Capital Markets Healthcare Conference" link in the Investo

Eisai Inc. and Pfizer Inc Announce U.S. FDA Approval for New Higher-Dose Aricept® (donepezil HCl) 23 mg Tablet for the Treatment of Moderate-to-Severe Alzheimer’s Disease

Fri, 23 Jul 2010 10:36:00 UT

WOODCLIFF LAKE, N.J. & NEW YORK--(BUSINESS WIRE)--Eisai Inc. and Pfizer Inc [NYSE: PFE] announced today that the U.S. Food and Drug Administration (FDA) approved a new once-daily, higher-dose Aricept (donepezil HCl) 23 mg tablet for the treatment of moderate-to-severe Alzheimer’s disease (AD). Aricept 23 mg tablet offers another dosing option for patients with moderate-to-severe AD, for whom few treatments are available. According to the Alzheimer’s Association, approximately 3.6 million America

Pfizer To Offer Free Public Access To Mental Health Assessment Tools To Improve Diagnosis And Patient Care

Thu, 22 Jul 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--As part of its commitment to improving the quality of patient care, Pfizer today announced that it will make available assessment scales used by physicians and others in the healthcare community to support the evaluation and diagnosis of patients suffering from certain mental disorders. For the first time, these users can directly access and download the Patient Health Questionnaire (PHQ) and the General Anxiety Disorder questionnaire (GAD-7) without copyright restrict

Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program; Some Studies Continue In Areas Of Unmet Medical Need

Mon, 19 Jul 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain. The FDA’s request follows further consideration of reports of adverse events in osteoarthritis patient

Pfizer And SMC Collaborate On Liver Cancer

Wed, 14 Jul 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Samsung Medical Center and the world’s leading bio-pharmaceutical company Pfizer Inc. announced that they have formed a research partnership to jointly analyze tumors from Korean patients to generate gene expression profiles and that may ultimately direct therapies and enhance clinical outcomes in the patients with liver cancer. The two organizations held a signing ceremony at the main conference hall located on the fifth floor of Samsung Medical Center in Seoul on Jun

New Research Presented At Alzheimer’s Association International Conference On Alzheimer's Disease Indicates Alzheimer’s Disease May Lead To Increased Comorbid Conditions And Economic Burden

Tue, 13 Jul 2010 11:00:00 UT

HONOLULU, Hawaii--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE), together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, presented new research this week at the Alzheimer’s Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) from two podium and four poster presentations. This research indicates there may be potential for an increased risk of comorbid conditions, such as seizures, stroke and type 2 diabetes, with Alzheimer’s di

Pfizer To Present More Than 40 Abstracts On Pre-Clinical, Clinical And Outcomes Research At Alzheimer's Association International Conference On Alzheimer’s Disease

Thu, 8 Jul 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present new data on its investigational compounds targeting various aspects of Alzheimer’s disease (AD), a complex degenerative brain disorder. New findings on the role of comorbidities, the burden of care and costs associated with AD, also will be discussed. These data, some in collaboration with our partners, will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease 2010 (ICAD 2010) in Honolulu, July

Pfizer Strengthens Manufacturing Capabilities In Asia With Expansion Of Singapore Nutrition Plant

Wed, 7 Jul 2010 11:00:00 UT

SINGAPORE--(BUSINESS WIRE)--Pfizer Inc. today announced a $100 million (U.S.) investment into the expansion of its Singapore Nutrition Plant, helping it continue to set the standard for the manufacture of high-quality, safe and environmentally sustainable nutritional products for infants and children. This expansion, which brings the total investment in the plant to $372 million (U.S.), makes it one of the largest nutritional plants worldwide. The expansion of the plant to 91,963 square meters (

Pfizer Announces European Union Approval Of A New Form Of Lipitor (atorvastatin) For Use In Children

Tue, 6 Jul 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL (“bad”) cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently avail

Pfizer Invites Public To View And Listen To Webcast Of August 3 Conference Call With Analysts

Tue, 29 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, August 3, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quar

Pfizer Declares An 18-Cent Third-Quarter 2010 Dividend

Thu, 24 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent third-quarter 2010 dividend on the company’s common stock, payable September 1, 2010, to shareholders of record at the close of business on August 6, 2010. The third-quarter 2010 cash dividend will be the 287th consecutive quarterly dividend paid by Pfizer.

Pfizer Suspends Tanezumab Osteoarthritis Clinical Trial Program

Wed, 23 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the suspension of the osteoarthritis clinical program for the investigational compound tanezumab following a request by the U.S. Food and Drug Administration (FDA). The worldwide suspension – which is effective immediately – follows a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. To date, this adverse event has not been observed in non-osteoarthritis patien

Pfizer Enters Into Agreement With Ergonex Pharma To Acquire Investigational Treatment For Pulmonary Arterial Hypertension

Mon, 21 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Ergonex Pharma GmbH announced today that they have entered into an agreement under which Pfizer will acquire terguride, which is in development as a potential treatment for Pulmonary Arterial Hypertension (PAH). Under the terms of the agreement, Pfizer will support the completion of the ongoing Phase 2 trial for terguride and will have exclusive worldwide rights excluding Japan to commercialize terguride for the treatment of PAH. Ergonex wil

Caduet Reduces 10-Year Calculated Risk Of Coronary Heart Disease, Fatal Cardiovascular Disease

Mon, 21 Jun 2010 11:00:00 UT

OSLO, Norway--(BUSINESS WIRE)--Caduet® (amlodipine besylate/atorvastatin calcium) was associated with a significantly reduced calculated 10-year risk of coronary heart disease (CHD) based on a Framingham risk assessment model. In addition, Caduet was shown to reduce calculated fatal cardiovascular disease (CVD) risk, as a secondary trial endpoint based on the SCORE risk assessment model. The Framingham and SCORE risk assessment models are widely used in the U.S. and EU, respectively. These data

New CELEBREX® (celecoxib) Study Using Novel Endpoint, Published By The Lancet, Contributes to Knowledge Of NSAID-Associated Gastrointestinal Adverse Events

Thu, 17 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin and/or hematocrit of defined or presumed GI o

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Tue, 8 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Geno Germano, President and General Manager, Specialty Care & Vaccines, at the Goldman Sachs 31st Annual Global Healthcare Conference on Tuesday, June 15, 2010 at 8:35 a.m. Pacific Daylight Saving Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs 31st Annual Global Healthcare Conference” link on our ho

Phase 3 Study Showed MACUGEN® Improved Vision Over Standard Of Care In Patients With Diabetic Macular Edema

Sat, 5 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Results from a Phase 3 study demonstrate MACUGEN® (pegaptanib sodium) significantly improved vision in patients with diabetic macular edema (DME), a complication of diabetes that is a leading cause of blindness in people of working age.(1) In the study, 37 percent of patients treated with MACUGEN gained two lines, or 10 letters, of vision on the ETDRS eye chart at 54 weeks, compared to 20 percent of patients who received a sham (placebo-like) procedure which consists o

Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions

Wed, 2 Jun 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Epocrates, Inc., today announced a collaboration to give healthcare providers (HCPs) mobile access to the Pfizer Medical Information Group to obtain scientific answers to their product questions or to report an adverse event. For the first time, clinicians can make direct contact through the Epocrates drug reference app on their iPhone® device to pharmaceutical manufacturers and immediately apply findings to patient care. Pfizer is enabling e

Pfizer Announces EMPHASIS-HF Trial To Halt Recruitment Due To Significant Benefit Observed In Patients Treated With Inspra® (Eplerenone)

Thu, 27 May 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that it plans to halt recruitment to the EMPHASIS-HF trial early on the recommendations of the trial’s independent Executive Steering Committee (ESC). The recommendations follow a second interim analysis by the independent Data Safety Monitoring Committee (DSMC) of the EMPHASIS-HF trial confirming the study has reached its primary efficacy endpoint early according to the protocol pre-defined stopping rules. The interim analysis showed

Pfizer Appoints Mikael Dolsten President Of Worldwide Research And Development

Wed, 26 May 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Today, Pfizer Inc. named Mikael Dolsten, M.D., PhD, President of Pfizer Worldwide Research and Development, as the Company completes its integration of these functions following the Wyeth acquisition. Dr. Dolsten previously led Wyeth’s Research and Development organization from May 2008, and after the close of the Wyeth acquisition was named President of Pfizer’s BioTherapeutics Research & Development. Prior to his appointment at Wyeth, Dr. Dolsten held key leaders

Pfizer Animal Health Expands Global Commitment To A Safe Food Supply With A New Focus On Healthy Fish

Tue, 25 May 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health today announced its acquisition of Microtek International, Inc., a recognized innovator in aquaculture vaccines, R&D and healthcare diagnostic services. The acquisition further expands Pfizer’s commitment to a safe food supply from healthy beef and dairy cattle, swine, poultry and, now, fish. Total global fish production – largely for human consumption – now exceeds that of pork, poultry, beef or dairy. Farmed fish production is becoming increa

Pfizer Oncology To Present New Clinical Data From Ten Molecules Across Multiple Tumor Types

Thu, 20 May 2010 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present new data highlighting the company’s focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology (ASCO) meeting in Chicago from June 4-8. “Pfizer Oncology is committed to applying discoveries from cancer biology and genetics to the development of new drugs in a focused and rational way. This approach is bei

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Wed, 19 May 2010 23:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010, at 10:30 a.m. Eastern Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Citi 2010 Global HealthcarConference” link on our homepage. Information on accessing and pre-regi

Pfizer Global Manufacturing Announces Plans To Reconfigure Its Global Plant Network

Tue, 18 May 2010 23:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Global Manufacturing announced today plans to reconfigure its worldwide plant network to create a fully aligned manufacturing and supply organization from the combined networks of Pfizer and Wyeth. This implementation of the first phase of Pfizer’s previously announced Plant Network Strategy includes recommendations to cease operations at eight manufacturing sites in Ireland, Puerto Rico, and the United States by the end of 2015, as well as to reduce operations

Pfizer, Washington University Announce Groundbreaking Collaboration

Mon, 17 May 2010 23:00:00 UT

NEW YORK--(BUSINESS WIRE)--In a first-of-a-kind collaboration between academia and industry, Pfizer Inc. will give scientists at Washington University School of Medicine in St. Louis unprecedented access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates in a partnership that focuses on discovering new uses for existing compounds. Under the five-year agreement announced today, Pfizer will provide $22.5 million to Washington University and give its scientists acc

Pfizer Animal Health Announces First Recipients of New $2 Million Veterinary Scholarship Program

Wed, 5 May 2010 23:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health announced today the first recipients of a new $2 million scholarship program for U.S. veterinary students. The initiative, designed to support the future of the veterinary profession, will provide up to $2 million in scholarships over its first three years. Administered in partnership with the American Veterinary Medical Foundation (AVMF), the program is an opportunity for Pfizer Animal Health to further demonstrate its support of veterinary educat

Pfizer Reports First-Quarter 2010 Results; Reaffirms 2010 Financial Guidance

Tue, 4 May 2010 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE): First-Quarter 2010 Revenues of $16.8 Billion First-Quarter 2010 Reported Diluted EPS(1) of $0.25, Adjusted Diluted EPS(2) of $0.60 Reaffirms 2010 Financial Guidance and 2012 Diluted EPS Target Ranges Continues to Make Solid Progress on the Wyeth Integration ($ in millions, except per share amounts) First-Quarter 2010 2009 Change Reported Revenues $ 16,750 $ 10,867 54 % Reported Net Income(1) 2,026 2,729 (26 %) Reported Diluted EPS(1)

World Bank And Pfizer Announce Initiative To Help Improve Healthcare Delivery In Developing Countries

Fri, 23 Apr 2010 16:00:00 UT

NEW YORK & WASHINGTON--(BUSINESS WIRE)--The World Bank and Pfizer Inc. today announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. The novel public-private collaboration will focus on enhanced use of Information and Communication Technologies’ (ICT) transformative power to improve healthcare delivery. The project demonstrates both Pfizer’s and the World Bank’s commitment to improving healthcare deli

Pfizer And Medicines For Malaria Venture Seek To Expand Fight Against Malaria With Intermittent Preventive Treatment Option For Pregnant Women

Fri, 23 Apr 2010 04:00:00 UT

NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women a

Pfizer Discontinues Phase 3 Trial of Sutent® in Advanced Hepatocellular Carcinoma

Thu, 22 Apr 2010 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma (HCC), or liver cancer. Following a review by the independent Data Monitoring Committee (DMC), the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either

Pfizer Hosts Annual Meeting Of Shareholders; Declares 18-Cent Second-Quarter 2010 Dividend

Thu, 22 Apr 2010 14:10:00 UT

CLEVELAND--(BUSINESS WIRE)--The board of directors of Pfizer Inc. today declared an 18-cent second-quarter 2010 dividend on the company’s common stock, payable June 1, 2010, to shareholders of record at the close of business on May 7, 2010. The second-quarter 2010 cash dividend will be the 286th consecutive quarterly dividend paid by Pfizer. At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive Officer Jeffrey B. Kindler said the legacy of advancing health continues stron

Pfizer Invites Public To Listen To Webcast Of April 22 Annual Meeting Of Shareholders

Thu, 15 Apr 2010 20:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. Eastern Daylight Time on Thursday, April 22, 2010. To access the Webcast, visit the Website at www.pfizer.com and click on the “Annual Meeting of Shareholders” Webcast link on the homepage. Information on accessing and pre-registering for the Webcast will be available at www.pfizer.com beginning April 19. Visitors to www.pfizer.com will be able

Stemgent and Pfizer Announce Collaboration

Thu, 15 Apr 2010 19:57:00 UT

BOSTON & NEW YORK--(BUSINESS WIRE)--Stemgent, Inc. and Pfizer Inc. (NYSE: PFE) today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research. According to the agreement, scientists involved in c

Pfizer Oncology To Present Over 30 Abstracts On Pre-Clinical And Clinical Research At The American Association For Cancer Research Annual Meeting

Wed, 14 Apr 2010 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that it will present new data from the company’s pipeline, including two novel, dual PI3K/mTOR (phosphatidylinositol 3-kinase / mammalian target of rapamycin) inhibitors (PF-046915021 and PKI-587, also known as PF-05212384);2 crizotinib (PF-02341066), an ALK (anaplastic lymphoma kinase) inhibitor that also inhibits c-MET (c-mesenchymal-epithelial transition factor);3 and PF-04605412, an anti-α5β1 inhibitor.4 Data from these, and other in

Pfizer And Acacia Living Partner To Support Seniors In Living Independently

Thu, 1 Apr 2010 20:19:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. and Acacia Living, Inc. (Acacia) announced today they have entered into a strategic alliance to develop an innovative holistic technology solution dedicated to helping seniors age positively and independently. Acacia Living is developing an at-home assisted living connectivity platform to support the ability of a growing aging population to live independently, by improving what Acacia calls access to C.A.R.E.: Community, Activities, Resources, and Education

Pfizer Posts Details About Interactions With U.S. Physicians, Other Healthcare Professionals And Clinical Research Partners

Wed, 31 Mar 2010 18:12:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today released detailed information about how and why the company works with a range of healthcare professionals and researchers to advance patient care and develop lifesaving medicines. The information reflects payments or exchanges of value received by licensed U.S. healthcare professionals who consulted with Pfizer about the development and marketing of new medicines and helped to educate other healthcare professionals about the safe and appropriate use

Pfizer Invites Public to View and Listen to Webcast of May 4 Conference Call with Analysts

Mon, 29 Mar 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, May 4, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2010 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the “Pfizer Quarterl

Pfizer Signs Long-Term Agreement To Supply Prevenar 13* To The World’s Poorest Countries

Tue, 23 Mar 2010 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced it has signed a 10-year Provisional Supply Agreement to supply Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]), the company’s 13-valent pneumococcal conjugate vaccine, for infants and young children in the world’s poorest countries under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease. The AMC is a novel public-private approach to public hea

Pfizer Animal Health Encourages Pet Owners to Consult Their Veterinarian for Safe, Effective Flea-and-Tick Control Recommendations

Tue, 23 Mar 2010 13:15:00 UT

NEW YORK--(BUSINESS WIRE)--Because pet owners may be even more confused this spring about how to safely use topical flea-and-tick control treatments, Pfizer Animal Health is encouraging pet owners to consult with their veterinarian, instead of attempting to manage flea-and-tick control on their own. This month, the U.S. Environmental Protection Agency (EPA) announced new actions to increase the safety of dozens of spot-on pesticide products that the EPA regulates for pet flea-and-tick control. P

Study Shows Prevenar 13* Is Immunogenic In Young Children Previously Vaccinated With Prevenar*

Wed, 17 Mar 2010 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--According to results from a Phase III safety and immunogenicity study presented today, Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine, [13-valent, adsorbed]) was shown to be immunogenic and generally well tolerated in healthy young children who had received at least three prior doses of Prevenar* (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed). These data were presented today at the 7th International Symposium on Pneumococci and Pneumococcal Disease

Intensive Lipitor Therapy Was Associated With Reduced Risk Of Cardiovascular Events In Two High-Risk Patient Groups

Mon, 15 Mar 2010 19:30:00 UT

ATLANTA--(BUSINESS WIRE)--Lipitor® (atorvastatin calcium) 80 mg was associated with a significantly reduced risk of major cardiovascular events compared with Lipitor 10 mg among patients with both coronary heart disease (CHD) and chronic kidney disease (CKD) who were obese or had metabolic syndrome. These data, from two sub-analyses of the Treating to New Targets (TNT) trial that were designed and completed following the completion of TNT, were presented today at the 59th Annual Scientific

Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Thu, 11 Mar 2010 22:02:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). An independent Data Safety Monitoring Committee (DSMC) recommended A4021018 be stopped after concluding that the addition of figit

Two Phase 3 Trials Of Sunitinib With Commonly Used Chemotherapies In Advanced Breast Cancer Did Not Meet The Primary Endpoint

Thu, 11 Mar 2010 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that two Phase 3 studies of Sutent® (sunitinib malate) in advanced breast cancer did not meet their primary endpoints. The SUN 1064 Phase 3 study of sunitinib in combination with docetaxel for the first-line treatment of patients with advanced HER-2 negative breast cancer did not show a statistically significant improvement in progression-free survival compared with docetaxel alone. In addition, the SUN 1099 Phase 3 study of sunitinib p

ADVANCE-2 Study Results Demonstrate Investigational Anticoagulant Apixaban Was Statistically Superior To Enoxaparin In The Prevention Of Venous Thromboembolism Following Knee Replacement Surgery

Thu, 4 Mar 2010 23:30:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Apixaban, an oral anticoagulant being developed by Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE), was statistically superior to 40 mg once daily enoxaparin in reducing the incidence of venous thromboembolism in patients undergoing elective total knee replacement surgery, according to the ADVANCE-2 study results published today in The Lancet. The study results also showed numerically lower rates of major and clinically relevant n

“Project Runway’s” Tim Gunn Returns to Address Psoriasis™ and Empower Patients to be Confident in Their Personal Style

Wed, 3 Mar 2010 15:45:00 UT

NEW YORK--(BUSINESS WIRE)--Amgen and Pfizer have once again partnered with Tim Gunn, television host, fashion consultant and chief creative officer of Liz Claiborne, Inc., to launch the second year of Addressing Psoriasis™, the disease awareness program designed to help people with psoriasis get more information about their condition and feel more confident in their everyday style. Dermatologist Susan C. Taylor, M.D., and Gunn are working together, again in 2010, to encourage people with p

Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer’s Disease Clinical Development Program

Wed, 3 Mar 2010 12:30:00 UT

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced results from two Phase 3 trials of the investigational drug dimebon (latrepirdine*) in patients with Alzheimer’s disease (AD). In the CONNECTION trial, dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo. Co-primary endpoints were measures of cognition and global function. “The results from the CONNECTION study are unexpected, and

Pfizer Invites Public To View And Listen To Webcast Of Investor Breakfast At Healthcare Conference

Tue, 2 Mar 2010 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and Company 30th Annual Healthcare Conference on Tuesday, March 9, 2010 at 7:00 a.m. Eastern Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Pfizer Investor Breakfast at the Cowen and Company 30th Annual Healthcare Conferenc

William Ringo, Pfizer’s Senior Vice President, Worldwide Business Development, Strategy And Innovation, To Retire

Thu, 25 Feb 2010 20:47:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that William Ringo will retire from the company. Mr. Ringo made many important contributions to advance the company’s innovative business development activities. “Bill has accomplished a great deal in positioning Pfizer for future success,” said Jeff Kindler, chairman and chief executive officer, Pfizer. “He has helped diversify Pfizer’s portfolio through our acquisition of Wyeth; worked to create a new world-le

CDC’s Advisory Committee On Immunization Practices Recommends Pfizer’s Prevnar 13™ Vaccine For The Prevention Of Invasive Pneumococcal Disease In Infants And Young Children In The U.S.

Wed, 24 Feb 2010 18:33:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the United States Centers for Disease Control and Prevention's (CDC’s) Advisory Committee on Immunization Practices (ACIP) has recommended the use of Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) for healthy children aged 2 months through 59 months for the prevention of invasive pneumococcal disease caused by the 13 pneumococcal serotypes included in the vaccine. The ACIP's reco

Pfizer Receives FDA Approval for Prevnar 13™ for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children

Wed, 24 Feb 2010 16:22:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that the United States Food and Drug Administration (FDA) has granted approval for Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s 13-valent pneumococcal conjugate vaccine. Prevnar 13 is indicated for active immunization of children 6 weeks through 5 years of age for the prevention of invasive disease caused by 13 Streptococcus pneumoniae (S. pneumoniae) serotypes 1, 3,

Lilly, Merck, And Pfizer Join Forces To Accelerate Research And Improve Treatment Of Lung And Gastric Cancers In Asia

Tue, 23 Feb 2010 15:57:00 UT

INDIANAPOLIS, WHITEHOUSE STATION, N.J. & NEW YORK--(BUSINESS WIRE)--Eli Lilly and Company, Merck (also known as Merck Sharp & Dohme (MSD) outside the USA and Canada), and Pfizer Inc. today announced the formation of the Asian Cancer Research Group, Inc., (ACRG), an independent, not-for-profit company established to accelerate research and ultimately improve treatment for patients affected with the most commonly-diagnosed cancers in Asia. The ACRG’s formation represents a prime example

Pfizer and Keas Partner to Help Consumers Take a More Active Role in Their Health and Wellness

Mon, 8 Feb 2010 12:28:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer and Keas announced today they have entered into an alliance to collaborate on the Keas platform to enable Health and Wellness experts to author, sell and distribute personalized online Care Plans directly to patients. Pfizer and Keas will collaborate to develop care plans and related capabilities that seek to provide consumers, patients and their providers an intuitive, engaging, easy-to-use, and low-cost way to manage their health & wellness, prevention and

QIAGEN Unit And Pfizer Enter Into An Agreement To Develop A Companion Diagnostic For Brain Tumor Patients

Thu, 4 Feb 2010 21:00:00 UT

MANCHESTER, England & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM). Financial terms of the diagnostic agreement have not been disclosed. On April 16, 2008, Pfizer and Celldex The

Pfizer Reports Fourth-Quarter and Full-Year 2009 Results; Provides 2010 Financial Guidance and 2012 Financial Targets

Wed, 3 Feb 2010 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Fourth-Quarter Full-Year 2009 2008 Change 2009 2008 Change Reported Revenues $ 16,537 $ 12,346 34% $ 50,009 $ 48,296 4% Reported Net Income(1) 767 266 188% 8,635 8,104 7% Reported Diluted EPS(1) 0.10 0.04 150% 1.23 1.20 3% Adjusted Income(2) 3,825 4,389 (13%) 14,202 16,366 (13%)

New Pfizer Pipeline Shows Progress And Growth In Vaccines, Biologics And High-Priority Disease Areas

Wed, 27 Jan 2010 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the company invests in research and development. “This pipeline of investigational medicines represents the strong future of Pfizer

Data Show Progression-Free Survival Advantage With Sutent® In Patients With Pancreatic Neuroendocrine Tumors

Fri, 22 Jan 2010 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced final results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic neuroendocrine tumors, a type of cancer which originates in the hormone-producing area of the pancreas. Sunitinib more than doubled the time patients with pancreatic neuroendocrine tumors lived without disease progression compared with patients treated with placebo, according to study findings that will be presented tomorrow at the

Pfizer and Auxilium Announce Commencement of European Regulatory Review of XIAFLEXTM for the Treatment of Dupuytren’s Contracture

Thu, 21 Jan 2010 12:00:00 UT

COLLEGEVILLE, Pa. & MALVERN, Pa.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that Pfizer received notification from the European Medicines Agency that the Marketing Authorization Application (MAA) for XIAFLEX™ (collagenase clostridium histolyticum), a novel, first-in-class, biologic for the treatment of Dupuytren’s contracture (a condition resulting in the contracture of the fingers into the palm), has completed the vali

Pfizer And Debiopharm Collaborate To Co-Develop Investigational Compound Tremelimumab (CP-675,206) In Advanced Melanoma

Thu, 7 Jan 2010 13:00:00 UT

LAUSANNE, Switzerland & NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma. A biomarker will be used to select patients considered likely to respond to tremelimumab. Under the terms of the agreement, Debiopharm will assume

Pfizer and Strides Arcolab to Collaborate on Generic Products

Wed, 6 Jan 2010 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Strides Arcolab (BSE: 532531, NSE: STAR) today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit. These finished dosage form products will be licensed and supplied by Strides and Onco Laboratories Limited and Onco Therapies Limited, two joint ventures between Strides and Aspen, South Africa, in which each has a 50% ow

Pfizer Invites Public To View And Listen To Webcast Of Pfizer Presentation At Healthcare Conference

Tue, 5 Jan 2010 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, PharmaTherapeutics Research & Development, at the 28th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2010 at 8:30 a.m. Pacific Standard Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “28th Annual J.P. Morgan Healthcare Conference” link in the Investor Presen

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Mon, 4 Jan 2010 17:11:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Jeff Kindler, Chairman & CEO, at the Goldman Sachs Healthcare CEOs Unscripted: A View from the Top on Wednesday, January 6, 2010 at 8:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Goldman Sachs Healthcare CEOs Unscripted: A View from the Top” link in the Investor Presentations tab on our homep

European Commission Approves New Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Mon, 4 Jan 2010 17:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the European Commission has approved Revatio® (sildenafil) solution for injection for patients who are currently prescribed oral Revatio and who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Revatio is the only phosphodiesterase 5 (PDE5) inhibitor with both oral and I.V. formulations approved in the European Union for the treatment of PAH. Pulmonary arterial hypertension is

Pfizer Provides U.S. Regulatory Update On Prevnar 13™ Vaccine

Wed, 30 Dec 2009 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine. As a result, the review will continue beyond the prescription drug user fee (PDUFA) action date of December 30, 2009. “We remain confident that the

Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For Futility

Tue, 29 Dec 2009 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today the discontinuation of A4021016 (also known as ADVIGO 1016), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC) due to the study meeting predefined boundaries for early termination. An analysis by an independent Data Safety Monitoring Committee (DSMC) showed that the addition of figitumumab to paclit

Pfizer’s Lyrica Receives Complete Response Letter From FDA For Generalized Anxiety Disorder Monotherapy Treatment

Thu, 24 Dec 2009 00:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Food and Drug Administration (FDA) issued a Complete Response letter regarding the company’s New Drug Application (NDA) for Lyrica® (pregabalin) capsules CV as a monotherapy treatment for generalized anxiety disorder (GAD). The FDA determined that the data contained in the NDA were insufficient to support approval. The application was a resubmission in response to a “not-approvable” letter issued b

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Wed, 23 Dec 2009 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, February 3, 2010. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2009 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on

Despite Stresses of Today, Survey Finds Women and Men Set Health and Wellness Goals – But Sex Often Influences Success

Fri, 18 Dec 2009 18:13:00 UT

MADISON, N.J.--(BUSINESS WIRE)--How will you achieve the “healthy” part of your New Year's resolutions? Your approach probably depends on whether you’re a woman or a man. According to a new national survey sponsored by Centrum® Ultra multivitamins, a line of scientifically-advanced, gender-and age-specific adult multivitamins, nearly all Americans (93 percent) surveyed have established at least one new health and wellness goal in the past year, but the survey shows that me

FDA Approves SPIRIVA® HandiHaler® for the Reduction of COPD Exacerbations

Thu, 17 Dec 2009 23:03:00 UT

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) for the reduction of exacerbations in patients with chronic obstructive pulmonary disease (COPD). SPIRIVA HandiHaler is already FDA-approved as a once-daily maintenance treatment for breathing problems associated with COPD, which includes chronic

Toviaz 8 Mg Was More Effective Than Detrol LA In Treating Urge Urinary Incontinence In Patients With Overactive Bladder

Wed, 16 Dec 2009 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Patients treated with Toviaz® (fesoterodine fumarate) 8 mg extended release tablets had greater and statistically significant reductions in urge urinary incontinence episodes at week 12 (P=0.017) compared with Detrol® LA (tolterodine tartrate extended release capsules) in a placebo-controlled randomized clinical trial. The primary endpoint of the study was reductions in urge urinary incontinence episodes. This new study, published today in the January issue o

Takeda and Pfizer to Co-Promote Takeda’s Actos® (Pioglitazone HCl) for the Treatment of Type 2 Diabetes in China

Tue, 15 Dec 2009 14:28:00 UT

OSAKA, Japan & NEW YORK--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (“Takeda”) and Pfizer Inc. (“Pfizer”) announced that they have entered into an agreement under which Pfizer in China will co-promote Takeda’s Actos® (pioglitazone HCl) with Tianjin Takeda Pharmaceuticals in China. The exclusive co-promotion agreement will build on the current sales capability for Actos in China by increasing the number of medical representatives supporting the sales

Pfizer Declares an 18-Cent First-Quarter 2010 Dividend

Mon, 14 Dec 2009 20:08:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent first-quarter 2010 dividend on the company’s common stock, payable March 2, 2010, to shareholders of record at the close of business on February 5, 2010. Pfizer increased the dividend by 12.5 percent, to 18 cents from 16 cents per share. “The board has determined that a measured dividend increase can be supported at this time,” said Jeffrey Kindler, Pfizer Chairman and Chief E

New pH1N1 Vaccine Available for Swine

Mon, 14 Dec 2009 19:34:00 UT

NEW YORK--(BUSINESS WIRE)--Swine producers have a new conditionally-licensed vaccine from Pfizer Animal Health to help protect their herds from the pandemic H1N1 (pH1N1) strain of Swine Influenza Virus (SIV).1 Pfizer Animal Health today announced that its Swine Influenza Vaccine, pH1N1 – Killed Virus, has been approved by the U.S. Department of Agriculture (USDA) for vaccination of healthy swine, including pregnant sows and gilts, three weeks of age or older against SIV subtype H1N1. Pfize

Pfizer Inc. Affirms Confidence In Its Hormone Therapy Medicines As Important Treatment Options

Sun, 13 Dec 2009 02:49:00 UT

NEW YORK--(BUSINESS WIRE)--In connection with the New York Times’ recent coverage of hormone therapy1, Pfizer Inc. today released important facts and context to respond to the newspaper’s account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT) medicines. Premarin (conjugated estrogens tablets USP) and Prempro (conjugated estrogens/medroxyprogesterone acetate tablets), which are approved by the Food a

Pfizer Announces Neratinib Data In HER2 Positive Breast Cancer

Sat, 12 Dec 2009 23:30:00 UT

SAN ANTONIO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Neratinib is now part of Pfizer’s expanded oncology portfolio, following the recent acquisition of Wyeth. “Data gathered from on

Pfizer Receives European Authorization For Prevenar 13* For The Prevention Of Pneumococcal Disease In Infants And Young Children

Fri, 11 Dec 2009 10:52:00 UT

NEW YORK--(BUSINESS WIRE)--The European Commission has granted Pfizer Inc. (NYSE: PFE) a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disea

Adele Gulfo joins Pfizer as U.S. President, Primary Care

Thu, 10 Dec 2009 19:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today the appointment of Adele Gulfo, U.S. President, Primary Care. In this new position, Ms. Gulfo is responsible for the company’s U.S. Primary Care business, including its five Regional Business Units, commercial operations, marketing, and corporate and government customer relationships. She reports to Olivier Brandicourt, President and General Manager of Pfizer’s Worldwide Primary Care business. “This is a pivotal

Pfizer Extends Commitment to Help Unemployed Americans

Thu, 10 Dec 2009 18:41:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced it will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines. Pfizer launched MAINTAIN in May to help unemployed and uninsured Americans stay on their Pfizer medicines. The p

Pfizer Announces Updated Trial Results for AROMASIN® (exemestane tablets) In Switch And Upfront Settings

Thu, 10 Dec 2009 16:42:00 UT

SAN ANTONIO--(BUSINESS WIRE)--Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse. These data showed that women who switched to Aromasin® (exemestane tablets) after 2.5 years of tamoxifen experienced a 19 percent

Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System

Wed, 9 Dec 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods. Nearly 60 percent of physicians who responded to the survey also agreed that adverse event reporting through an EHR system would improve patient care. “Patient safety continues to be a top priority at Pfizer,” said Freda Lewis-Hall,

CORRECTING and REPLACING Pfizer And Crown Bioscience Announce A Collaboration To Research And Develop New Treatments For Asian Cancers

Wed, 9 Dec 2009 01:03:00 UT

SANTA CLARA, Calif. & NEW YORK--(BUSINESS WIRE)--In the PFIZER DISCLOSURE NOTICE section, the date should read December 8, 2009 (sted December 4, 2009). The corrected release reads: PFIZER AND CROWN BIOSCIENCE ANNOUNCE A COLLABORATION TO RESEARCH AND DEVELOP NEW TREATMENTS FOR ASIAN CANCERS Pfizer (PFE) and Crown Bioscience, Inc. (Crown) announced today that they have entered into a collaboration to research and develop novel therapeutics for Asian cancers. Specific treatments for Asian cancers

Pfizer To Present Clinical Data From Expanded Breast Cancer Portfolio At The San Antonio Breast Cancer Symposium

Fri, 4 Dec 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13. Presentations will highlight results from long-term follow-up of Aromasin® (exemestane tablets)

Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher’s Disease Treatment

Tue, 1 Dec 2009 11:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Protalix (NYSE-Amex: PLX) today announced that they have entered into an agreement to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Gaucher’s disease. Under the terms of the agreement, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercial

Pfizer Receives FDA Approval For Geodon® (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults

Fri, 20 Nov 2009 18:18:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the U.S. Food and Drug Administration (FDA) has approved Geodon® (ziprasidone HCI) Capsules for maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults. The approval is based on clinical data demonstrating that Geodon is an effective and generally well-tolerated adjunctive treatment for long-term symptom control in patients with bipolar disorder. Bipolar disorder, which affects approximately 5.7 milli

FDA Approves Intravenous Formulation Of Pfizer’s Revatio® (Sildenafil) For The Treatment Of Pulmonary Arterial Hypertension

Fri, 20 Nov 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations. Revatio is indicated for the treatment of adult patients with pulmonary arterial hypertension (WHO Group I) to improve exercise ability and delay clinical worsening. The delay in clinica

FDA Advisory Committee Finds Data Support the Claim That SPIRIVA® HandiHaler® Reduces COPD Exacerbations

Thu, 19 Nov 2009 21:36:00 UT

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new drug application (sNDA) provide substantial and convincing evidence to support the claim that SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) reduces exacerbations (worsening of symptoms) in patients with chronic obstructive pulmonary disease (COPD). The advisory committee also v

Pfizer Encourages Families To Bring Their Dogs To This Year’s Holiday Celebration

Thu, 19 Nov 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health wants families to talk with one another about bringing the family dog along when they travel to their Thanksgiving-to-New Year’s celebrations. For most people, the holidays are a time of joy and celebration. But some people feel guilty or sad about leaving their dog behind because they consider their dog part of the family. “In addition, this year, many families are experiencing tough economic times,” said Amy Trettien, DVM, Veter

FDA Advisory Committee Finds Data Support the Safety and Effectiveness of Prevnar 13™ Vaccine for the Prevention of Invasive Pneumococcal Disease in Infants and Young Children

Thu, 19 Nov 2009 00:09:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children. The Company

Pfizer and DNDi Advancing International Research Efforts In The Fight Against Neglected Tropical Diseases

Wed, 18 Nov 2009 13:30:00 UT

NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be devel

Pfizer Submits New Pediatric Data For Lipitor® (Atorvastatin) To The European Medicines Agency (EMEA)

Wed, 18 Nov 2009 09:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. Approximately one in 500 people suffer from an inherited disorder, called Familial Hypercholesterolemia (FH), which causes high levels of LDL-cholesterol (“bad” cholesterol) and an incre

Pfizer Announces Global Research Network

Mon, 9 Nov 2009 17:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its global research and development network, marking an important step in implementing a new R&D model as part of the integration of Pfizer and Wyeth. This global network brings together scientific strengths from both companies, continues efforts to increase research productivity, focuses disease-area research in single locations and more efficiently uses the company’s real estate. Pfizer will have five main research sites that will

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX® (Varenicline) Compared With Placebo

Wed, 4 Nov 2009 21:33:00 UT

SAN DIEGO--(BUSINESS WIRE)--New study results showed that 42.3 percent of smokers with mild-to-moderate chronic obstructive pulmonary disease (COPD) who took CHANTIX/CHAMPIX® (varenicline) were able to quit smoking and remain abstinent during the last four weeks of treatment (weeks 9-12) compared with 8.8 percent of those given placebo (p<0.0001). These findings were presented by investigators at CHEST 2009, the 75th annual international scientific assembly of the American College of Che

Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer’s Disease

Tue, 3 Nov 2009 13:00:00 UT

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of CONTACT and CONSTELLATION, two Phase 3 trials of the investigational drug dimebon (latrepirdine)* in patients with moderate-to-severe Alzheimer’s disease (AD). The CONTACT study will assess as primary endpoints the potential benefits of adding dimebon to ongoing treatment with donepezil HCI tablets, the leading AD medication worldwide, on neuropsychiatric

Pfizer Completes Consent Solicitation

Fri, 30 Oct 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that it has received the requisite consents to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary: Debt Security Description CUSIP No. Aggregate PrincipalAmount 6.700% Notes due 2011 026609AM

Pfizer’s Board Of Directors Approves Shareholder Advisory Vote On Executive Compensation

Thu, 29 Oct 2009 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced that its Board of Directors has approved giving shareholders an advisory vote on executive compensation. The vote will first occur at Pfizer’s Annual Meeting of Shareholders in 2010 and will take place on a biennial basis thereafter. “The Board’s action continues Pfizer’s long tradition of seeking and responding to shareholder input on compensation and other corporate governance topics,” said Matthew Lepor

Pfizer Declares a 16-Cent Fourth-Quarter 2009 Dividend

Thu, 22 Oct 2009 20:16:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent fourth-quarter 2009 dividend on the company’s common stock, payable December 1, 2009, to shareholders of record at the close of business on November 6, 2009. The fourth-quarter 2009 cash dividend will be the 284th consecutive quarterly dividend paid by Pfizer.

Pfizer Reports Third-Quarter 2009 Results

Tue, 20 Oct 2009 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts) Third-Quarter Year-to-Date 2009 2008 Change 2009 2008 Change Reported Revenues $ 11,621 $ 11,973 (3 %) $ 33,472 $ 35,950 (7 %) Reported Net Income(1) 2,878 2,278 26 % 7,868 7,838 -- Reported Diluted EPS(1) 0.43 0.34 26 % 1.16 1.16 -- Adjusted Income(2) 3,461 4

New Pfizer Animal Health is Unveiled with Acquisition of Wyeth

Mon, 19 Oct 2009 18:14:00 UT

NEW YORK--(BUSINESS WIRE)--A new Pfizer Animal Health was unveiled last week as Pfizer's acquisition of Wyeth, including its subsidiary Fort Dodge Animal Health, was completed. Pfizer Animal Health is now the world’s leader in the discovery, development, manufacture and sales of veterinary vaccines and medicines for livestock and companion animals. The acquisition of many of Fort Dodge’s U.S. products allows Pfizer Animal Health to greatly diversify its U.S. portfolio, as well as bro

CP-690,550, Pfizer’s Oral JAK Inhibitor, Demonstrates Response Both Alone And In Combination With Methotrexate At 24 Weeks In Patients With Active Rheumatoid Arthritis

Sat, 17 Oct 2009 21:00:00 UT

PHILADELPHIA--(BUSINESS WIRE)--Pfizer Inc announced today that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week at the 2009 ACR/ARHP Annual Scientific Meeting in Philadelphia, represent the final analyses from t

Pfizer Commences Consent Solicitation for Amendments to Wyeth Indenture

Fri, 16 Oct 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that it has commenced a consent solicitation to amend certain provisions of the indenture governing the following outstanding debt securities (the Securities) of Wyeth, its wholly owned subsidiary: Aggregate Debt Security Principal Description CUSIP No. Amount 6.700% Notes due 2011 026609AM $1,497,580,000 6.700% Notes due 2011 026609AJ $2,420,000 5.250% Notes due 2013 983024AA $1,500,000,000 5.500% Notes due 2014 983024AE $1,

Pfizer And Wyeth Become One: Working Together For A Healthier World™

Fri, 16 Oct 2009 04:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that it has combined operations with Wyeth following the closing of the acquisition yesterday. Pfizer is now a more diversified health care company, with product offerings in human, animal, and consumer health, including vaccines, biologics, small molecules and nutrition across the developed and emerging markets. It has medicines in numerous growing therapeutic areas, a robust pipeline, premier scientific and manufacturing capabil

Pfizer Completes Acquisition Of Wyeth

Thu, 15 Oct 2009 15:49:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) announced today that Pfizer has completed its acquisition of Wyeth following the receipt of regulatory approval from all government authorities required by the merger agreement and approval by Wyeth shareholders. Under the terms of the transaction, each outstanding share of Wyeth common stock has been converted into the right to receive $33 in cash (without interest) and 0.985 of a share of Pfizer common stock. Effective as of t

Pfizer Receives Clearance From The U.S. Federal Trade Commission And The Canadian Competition Bureau For Wyeth Acquisition

Wed, 14 Oct 2009 16:50:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the U.S. Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, with respect to Pfizer’s pending acquisition of Wyeth. In addition, Pfizer has received approval from the Canadian Competition Bureau for the pending acquisition. With the receipt of these clearances, Pfizer has now satisfied the regulatory approval requirements under the merger agre

Pfizer Announces Settlement And License Agreement With Mylan Related To Vfend®

Wed, 14 Oct 2009 11:49:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement with two subsidiaries of Mylan Inc. relating to a generic version of Vfend® (voriconazole), an antifungal agent. The agreement is limited to the tablet form of Vfend and does not cover Pfizer’s Vfend products for intravenous use or oral suspension. Pursuant to the agreement, Mylan will have the right to market voriconazole tablets in the United States in the first quarter of 2011. Additional de

FDA Advisory Committee Recommends Approval of Pfizer’s Selzentry for Use in Patients Starting HIV Therapy for the First Time

Thu, 8 Oct 2009 20:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted (10 to 4) to recommend the approval of Selzentry® (maraviroc) tablets for use in treatment-naïve adult patients with CCR5-tropic HIV-1 virus as part of combination therapy. “Pfizer is pleased that the Committee has recognized the effectiveness and safety profile of maraviroc in patients who are starting HIV therapy,&#

Pfizer Receives Approval From Australian Competition And Consumer Commission (ACCC) For Pending Acquisition Of Wyeth

Wed, 30 Sep 2009 08:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the Australian Competition and Consumer Commission (ACCC) has approved the company’s pending acquisition of Wyeth. The ACCC’s decision includes Pfizer’s commitment to divest certain animal health assets in Australia. “We are pleased to have achieved another significant milestone this week with the ACCC’s approval of the pending acquisition,” said Jeff Kindler, chairman and chief executive of

Pfizer Receives Approval from China’s Ministry of Commerce for Pending Wyeth Acquisition

Tue, 29 Sep 2009 12:54:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that China’s Ministry of Commerce has approved the company’s pending acquisition of Wyeth. The Ministry’s decision includes Pfizer’s commitment to divest certain animal health assets in China. “We are pleased to have achieved another significant milestone with the Ministry’s approval of the pending transaction,” said Jeff Kindler, Chairman and Chief Executive, Pfizer. The transaction remain

Frances D. Fergusson And John P. Mascotte Elected To Pfizer’s Board Of Directors

Fri, 25 Sep 2009 12:40:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the election of Frances D. Fergusson, Ph.D. and John P. Mascotte to its Board of Directors. Dr. Fergusson and Mr. Mascotte, current members of the Board of Directors of Wyeth, will join the Pfizer Board upon the closing of Pfizer’s pending acquisition of Wyeth in accordance with the terms of the merger agreement. Dr. Fergusson is President Emeritus and professor of art at Vassar College, where she became the ninth president in 1986 and

Pfizer and Eisai Continue Aricept Collaboration

Fri, 25 Sep 2009 02:13:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that its agreement with Eisai to provide Aricept to patients suffering from Alzheimer’s disease will continue without interruption. Under this redefined alliance, which resolves a previously disclosed dispute, Pfizer and Eisai will continue to co-promote Aricept in the U.S., Japan and key markets in Europe, and Pfizer will continue to have an exclusive license to sell Aricept in the other countries where it has rights. Pfize

Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation

Thu, 24 Sep 2009 12:28:00 UT

BERLIN--(BUSINESS WIRE)--Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy. Updated data from an expansion cohort of a Phase 1 study with PF-02341066 in NSCLC pa

New Survey of People with Diabetic Nerve Pain Shows the Condition Significantly Impacts Daily Activities Such as Exercise and Sleep Yet Often Goes Untreated

Wed, 23 Sep 2009 18:18:00 UT

DEL MAR, Calif.--(BUSINESS WIRE)--In a new online survey, eighty-five percent of people who experience diabetic nerve pain said that their pain was one of the top three most bothersome complications of their diabetes. Despite the fact that people with diabetic nerve pain recognize the condition’s impact on their lives and eighty-four percent of those surveyed said they have discussed the condition with a healthcare provider, just slightly less than half of respondents (49 percent) were tre

For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking

Wed, 23 Sep 2009 14:21:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has earned a score of 100 — the highest possible — in the 2010 Corporate Equality Index, which evaluates U.S.-based businesses on their treatment of lesbian, gay, bisexual and transgender (LGBT) employees, investors and consumers. The Corporate Equality Index — published annually by the Human Rights Campaign Foundation (HRCF), the largest LGBT advocacy organization in the United States — rates businesses using

For Sixth Consecutive Year, Pfizer Earns Highest Score In Human Rights Campaign Foundation LGBT Ranking

Wed, 23 Sep 2009 14:00:00 UT

Pfizer Again Named To Working Mother 100 Best Companies List

Tue, 22 Sep 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been named among the 2009 Working Mother 100 Best Companies for its steadfast commitment to family-friendly benefits. Pfizer and the other winning companies are pioneering programs that support families, with 100 percent offering flextime, on-site lactation and telecommuting; and 98 percent offering job-sharing and wellness programs—numbers that dwarf those seen nationwide. In addition, financial programs available to the 100 Best employees are on

Survival Benefit Maintained in Long Term Follow-up of IES with Pfizer’s AROMASIN® (Exemestane Tablets)

Tue, 22 Sep 2009 11:00:00 UT

BERLIN--(BUSINESS WIRE)--Pfizer Inc today announced new, longer-term data from the Intergroup Exemestane Study (IES) showing that women who switched to AROMASIN® (exemestane tablets) after taking tamoxifen for two to three years experienced a significant reduction (18%) in the risk of disease-free survival (DFS) events (HR=0.82; 95% CI: 0.73-0.92; P=0.0009), compared to women who continued on tamoxifen for a full five years of treatment.1 In addition, IES showed that AROMASIN prolonged over

Pfizer and Wyeth to Divest Certain Animal Health Assets to Boehringer Ingelheim

Mon, 21 Sep 2009 21:05:00 UT

NEW YORK & MADISON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into an agreement with Boehringer Ingelheim to divest certain animal health assets in connection with the regulatory approval process associated with Pfizer’s pending acquisition of Wyeth. Under the terms of the agreement, Boehringer Ingelheim will acquire products, research and manufacturing facilities, located in Fort Dodge, Iowa, as well as related assets and in

Pfizer Commended For Leadership In Addressing Climate Change For Third Consecutive Year

Mon, 21 Sep 2009 18:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc has been commended by the Carbon Disclosure Project (CDP) for its approach to addressing climate change. CDP named Pfizer to its Climate Disclosure Leadership Index, which highlights the company’s climate change disclosure practices. This is the third consecutive year that Pfizer has been recognized by CDP. “As a health care company, Pfizer is very aware of the potential impact of climate change on global health,” said Steve Brooks, vice pr

Pfizer To Present Research On Established Therapies And New Approaches To Cancer Treatment Using Investigational Agents

Fri, 18 Sep 2009 17:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer,1 updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET),2 and early-stage research of investigational agents PF-023410663 and figitumumab (CP-751,871)4 in patients with non-small cell lung cancer (NSCLC). These data, and over a do

Pfizer Invites Public to View and Listen to Webcast of October 20 Conference Call with Analysts

Wed, 9 Sep 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 20, 2009. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2009 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com and click on the

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Tue, 8 Sep 2009 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a discussion with David Simmons, President and General Manager, Established Products, and Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Morgan Stanley Global Healthcare Conference on Tuesday, September 15, 2009 at 8:35 a.m. Eastern Daylight Saving Time. To listen to the webcast, visit our web site at www.pfizer.com and click on the “Morgan Stanley Global He

Pfizer Concludes Previously Disclosed Settlement Agreement With U.S. Department Of Justice Regarding Past Promotional Practices

Wed, 2 Sep 2009 14:29:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has finalized a previously reported agreement in principle with the U.S. Department of Justice (DOJ) to settle an investigation regarding past off-label promotional practices related to Bextra, which Pfizer voluntarily withdrew from the market in 2005. The final agreement also resolves other DOJ investigations involving alleged past off-label promotional practices concerning Zyvox, Geodon and Lyrica, allegations related to certain pay

Heading Back to School: Veterinarians Combine Stethoscopes with Microscopes

Tue, 1 Sep 2009 15:17:00 UT

DENVER--(BUSINESS WIRE)--Private practice isn’t for everyone, but for graduating veterinary students facing an average of $120,000 in debt, it often is the only logical choice. A new program—the Pfizer Animal Health–Morris Animal Foundation (MAF) Veterinary Fellowship for Advanced Study—gives current practitioners necessary financial support while they pursue a veterinary research career. The program commits a minimum of nearly $1.7 million over four years toward a soluti

Novel Biomarkers, Including CRP, Did Not Predict Risk Of Cardiovascular Events In Patients With Heart Disease Who Were Treated With A Statin

Tue, 1 Sep 2009 06:30:00 UT

BARCELONA, Spain--(BUSINESS WIRE)--For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. By contrast, traditional lipid risk factors were strong predictors of cardiovascular events. The findings are based on a new post h

Pfizer Inc Sponsors 7th Biennial U.S.–Africa Business Summit

Wed, 26 Aug 2009 14:30:00 UT

WASHINGTON--(BUSINESS WIRE)--The Corporate Council on Africa (CCA) announced today that Pfizer Inc will sponsor the 7th Biennial U.S. – Africa Business Summit: Realizing the Investment Power of Africa, to be held at the Walter E. Washington Convention Center in Washington, D.C., September 29 – October 1, 2009. At a Pfizer-sponsored workshop titled Mobilizing Resources for Strengthening African Health Systems: A Case Study of Pfizer’s Global Health Fellows, Charles Shafran, form

Pfizer And Private Access Announce Plans To Develop Online Community To Accelerate Clinical Research

Wed, 19 Aug 2009 16:48:00 UT

NEW YORK--(BUSINESS WIRE)--Recognizing that patient participation in clinical trials is the key to progress in medical research, Pfizer Inc announced today that it has entered into a collaboration with Private Access,

President Clinton, Pfizer, and Mylan Announce New Agreements to Lower Prices of Medicines for Patients with Drug-Resistant HIV in Developing Countries

Thu, 6 Aug 2009 16:30:00 UT

NEW YORK--(BUSINESS WIRE)--President Bill Clinton announced two important and complementary agreements today to enable better, more affordable treatments for patients on second-line antiretroviral (ARV) therapy for

Pfizer, Kano State Reach Settlement Of Trovan Cases

Thu, 30 Jul 2009 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced it has reached agreement with the Kano State government in Nigeria to settle Kano State’s claims arising from the 1996 Trovan clinical study, which was

Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease

Thu, 30 Jul 2009 12:30:00 UT

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) today announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine)* in patients

Pfizer and Fudan University Announce Joint Graduate Program in Clinical Research

Wed, 29 Jul 2009 15:00:00 UT

SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a partnership with Fudan University to establish a graduate program in Clinical Data Management and Statistical Programming. This three year Masters Degree

Pfizer Announces Partnership With Shanghai Institutes For Biological Sciences For Drug Discovery Activities

Wed, 29 Jul 2009 14:00:00 UT

SHANGHAI, China--(BUSINESS WIRE)--Pfizer today announced a joint initiative with the Shanghai Institutes for Biological Sciences (SIBS) to support fundamental research in China. As part of the initiative, Pfizer China

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Wed, 29 Jul 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Chief Financial Officer, at the BMO Capital Markets 9th Annual Focus On

Pfizer Reports Second-Quarter 2009 Results; Increases Full-Year 2009 Adjusted Diluted EPS(1) Guidance

Wed, 22 Jul 2009 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):

96-Week MERIT ES Analysis Shows Efficacy Of Pfizer’s HIV/AIDS Treatment Celsentri/Selzentry (Maraviroc) In Treatment-Naïve HIV Patients; Results Consistent With 48-Week Analysis

Tue, 21 Jul 2009 09:30:00 UT

NEW YORK--(BUSINESS WIRE)--At 96-week follow up, data from the MERIT ES analysis show that treatment-naïve HIV patients taking Celsentri/Selzentry (maraviroc), in combination with Combivir®

Pfizer Receives Approval From European Commission For Pending Acquisition Of Wyeth

Fri, 17 Jul 2009 17:46:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) today announced that the European Commission (EC) has approved under the European Union (EU) Merger Regulation the company’s pending acquisition of Wyeth. The

Pfizer Announces New Phase 1 Data From Two Novel Compounds For Alzheimer’s Disease At ICAD Annual Meeting

Wed, 15 Jul 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today results from two Phase 1 safety studies, one of PF-04360365, a humanized anti-amyloid monoclonal antibody (mAb), and another of dimebon (latrepirdine*) in

Pfizer To Appeal Canadian Federal Court Decision On Company’s Norvasc® Patent

Thu, 9 Jul 2009 17:49:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it is disappointed by the Canadian Federal Court’s decision declaring invalid its patent covering amlodipine besylate, the active ingredient in Norvasc®,

Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer

Wed, 1 Jul 2009 21:08:00 UT

NEW YORK--(BUSINESS WIRE)--Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) today announced that they have entered into an Acquisition and License Agreement by

Pfizer Invites Public to Listen to Teleconference on Important Update Related to Chantix ® (varenicline)

Wed, 1 Jul 2009 16:49:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites media and investors to listen to a teleconference related to CHANTIX at 1:15 PM US/EST on Wednesday, July 1. In addition to providing an update on CHANTIX, Pfizer

Pfizer Updates CHANTIX ® (varenicline) Labeling in the United States

Wed, 1 Jul 2009 16:16:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it has updated the U.S. product labeling for CHANTIX® (varenicline), a prescription aid to smoking cessation treatment, to communicate important safety

Pfizer Launches Medicine Assistance Program for Newly Unemployed

Wed, 1 Jul 2009 15:30:00 UT

--(BUSINESS WIRE)--Pfizer: WHAT: An assistance program offered by Pfizer that can help unemployed Americans continue receiving their prescription medicines. The program is fully operational today, July 1.

Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer

Tue, 30 Jun 2009 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of the SUN 1122 Phase 3 trial that evaluated Sutent® (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and

Pfizer Declares a 16-Cent Third-Quarter 2009 Dividend

Thu, 25 Jun 2009 17:50:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 16-cent third-quarter 2009 dividend on the company’s common stock, payable September 2, 2009, to shareholders of record

Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors

Thu, 25 Jun 2009 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine

Pfizer Invites Public to View and Listen to Webcast of July 22 Conference Call with Analysts

Thu, 18 Jun 2009 15:31:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 11 a.m. EDT on Wednesday, July 22, 2009. The purpose of

Pfizer Registration Statement Relating To Pending Wyeth Acquisition Declared Effective By SEC

Thu, 18 Jun 2009 13:03:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective Pfizer’s Registration Statement on Form S-4. The Form S-4 registers with the SEC

Pfizer’s Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show

Thu, 11 Jun 2009 12:10:00 UT

COPENHAGEN--(BUSINESS WIRE)--Pfizer announced today that data from two new mid-stage clinical studies of the company’s oral JAK-3 inhibitor, CP-690,550, showed statistically significant response versus placebo

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Wed, 3 Jun 2009 14:00:00 UT

FDA Approves First Canine Cancer Therapy

Wed, 3 Jun 2009 13:36:00 UT

MONTREAL--(BUSINESS WIRE)--Pfizer Animal Health today announced that the U.S. Food and Drug Administration (FDA) has approved the first canine cancer therapy in the U.S. – PALLADIATM (toceranib phosphate) –

Pfizer Announces Completion Of European Debt Offering

Wed, 3 Jun 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the successful completion of its offering of €5.85 billion and £1.50 billion of senior unsecured notes (totaling approximately $10.5 billion). The notes

Pfizer Introduces New Treatment And Support Plan For Patients With Overactive Bladder

Tue, 2 Jun 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Toviaz™ (fesoterodine fumarate) extended release tablets and the YourWay™ plan (www.ToviazYourWay.com), a comprehensive, customizable support plan

Pfizer Discontinues SUN 1094 Trial of Sunitinib plus Paclitaxel in Advanced Breast Cancer

Mon, 1 Jun 2009 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of the SUN 1094 Phase 3 study that evaluated SUTENT® (sunitinib malate) plus paclitaxel versus bevacizumab plus paclitaxel for the first

Pfizer Data Identify Certain Lung Cancer Patients Who May Benefit from Treatment with Figitumumab

Sat, 30 May 2009 16:01:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from studies evaluating the company’s investigational anti-insulin growth factor- type 1 receptor (IGF-1R) antibody, figitumumab (CP-751,871), in

Pfizer Presents Data With Novel Investigational Agents In Select Patient Groups With Non-Small Cell Lung Cancer

Sat, 30 May 2009 12:24:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today results from four studies highlighting clinical data with targeted treatment approaches in patients with non-small cell lung cancer (NSCLC). Data on the

New Pfizer Data Helps to Identify Kidney Cancer Patients Who May Be Most Likely to Benefit from Treatment

Fri, 29 May 2009 16:13:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today, at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting, the results of several clinical studies that may help identify patients who are more

Pfizer Invites Public to View and Listen to Webcast of June 12 Conference Call with Analysts at EULAR

Fri, 29 May 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a conference call with investment analysts at 1:00 p.m. EDT on Friday, June 12, 2009. The purpose

Pfizer’s Sutent is Recommended for Reimbursement for Gastrointestinal Stromal Tumor Patients by British Health Agency

Thu, 28 May 2009 00:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the United Kingdom’s National Institute for Health and Clinical Excellence (NICE) has issued its final appraisal document (FAD) recommending reimbursement for

Pfizer Expands Its Generics Portfolio Through Innovative Licensing Deals, Increasing Access To Medicines For Billions Worldwide

Wed, 20 May 2009 12:39:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into licensing agreements with two pharmaceutical companies based in India, strengthening its position in emerging markets and significantly

Addition of Lyrica Significantly Improved Generalized Anxiety Disorder Symptoms in Patients Who Responded Only Partially to Previous GAD Treatments

Tue, 19 May 2009 19:00:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--The addition of Pfizer’s Lyrica® (pregabalin) capsules CV to other generalized anxiety disorder (GAD) treatments significantly improved the symptoms of the condition in

EU Commission Approves Pfizer Animal Health’s Vaccine Against Boar Taint

Tue, 19 May 2009 14:54:00 UT

PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that The European Commission has given Pfizer the go-ahead to market its innovative swine vaccine, Improvac®, across the European Union (EU).

Pfizer Launches Free Medicines Program For Newly Unemployed Americans

Thu, 14 May 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it will launch an innovative program to help eligible unemployed Americans and their families who have lost their health insurance maintain access to their

Pfizer to Present New Clinical Data Highlighting Customized Treatment Approaches For Difficult-To-Treat Cancers

Wed, 13 May 2009 16:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer will present new data highlighting the company’s commitment to a personalized approach to oncology clinical research, which includes the use of targeted agents in specific

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Tue, 12 May 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Frank D’Amelio, Chief Financial Officer, at the 34th Annual Deutsche Bank

Greg Simon, Noted Leader In Health And Science Policy, Joins Pfizer

Tue, 12 May 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Greg Simon has joined the company as Senior Vice President, Worldwide Policy. He comes to Pfizer from the presidency of FasterCures, where he led efforts to

Pfizer And Wisconsin Alumni Research Foundation (WARF) Sign License Agreement For Human Embryonic Stem Cells

Tue, 5 May 2009 18:32:00 UT

MADISON, Wis.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE), the world's premier biopharmaceutical company, and the Wisconsin Alumni Research Foundation (WARF), the private, non-profit patenting and licensing organization

Dr. Freda Lewis-Hall Joins Pfizer As Chief Medical Officer

Mon, 4 May 2009 20:16:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Freda Lewis-Hall, M.D., has been appointed as Chief Medical Officer and Senior Vice President, Pfizer Inc. Dr. Lewis-Hall will be the senior physician in the

Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show

Wed, 29 Apr 2009 19:30:00 UT

SEATTLE--(BUSINESS WIRE)--Patients suffering from post-traumatic peripheral nerve pain treated with Lyrica® (pregabalin) capsules CV experienced significantly reduced pain compared to those taking placebo,

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Wed, 29 Apr 2009 15:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jean-Michel Halfon, President and General Manager, Emerging Markets, at the Bernstein

Pfizer Reports First-Quarter 2009 Results; Reaffirms Full-Year 2009 Financial Guidance for Revenues and Adjusted Results(1)

Tue, 28 Apr 2009 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Pfizer Supports The Global Fight Against Malaria And Commemorates World Malaria Day – “Counting Malaria Out”

Fri, 24 Apr 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--According to the World Health Organization (WHO) malaria infects approximately 250 million people per year throughout the developing world and results in a grave loss of life of at least

Pfizer And University College London Announce Collaboration To Advance Development Of Stem Cell-Based Therapies

Fri, 24 Apr 2009 07:00:00 UT

CAMBRIDGE, England--(BUSINESS WIRE)--Pfizer Regenerative Medicine today announced that it has entered into a collaboration and license agreement with University College London focused on gaining better understanding

Pfizer Hosts Annual Meeting Of Shareholders; Declares A 16-Cent Second-Quarter 2009 Dividend

Thu, 23 Apr 2009 14:36:00 UT

ATLANTA--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 16-cent second-quarter 2009 dividend on the company’s common stock, payable June 2, 2009, to shareholders of record at the close of

Pfizer and Medicines for Malaria Venture Advancing International Research Efforts in the Fight against Malaria

Wed, 22 Apr 2009 15:00:00 UT

NEW YORK & GENEVA--(BUSINESS WIRE)--Pfizer Inc and Medicines for Malaria Venture (MVV) have signed an agreement that is designed to facilitate advancements in the battle against malaria, a disease that afflicts

New Findings from Global Survey of Women Living with Metastatic Breast Cancer Highlight Strategies to Improve Patient Enrollment in Clinical Trials

Wed, 22 Apr 2009 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Newly released findings from the BRIDGE survey (Bridging Gaps, Expanding Outreach – Metastatic Breast Cancer Patient Survey) found that most (78 percent) women living with metastatic

Pfizer Invites Public to Listen to Webcast of April 23 Annual Meeting of Shareholders

Mon, 20 Apr 2009 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday, April 23. To access the

Pfizer To Make A Tender Offer To Increase Stake In Pfizer Limited

Mon, 13 Apr 2009 02:00:00 UT

MUMBAI, India--(BUSINESS WIRE)--Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced today that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from

Pfizer’s Oncology Business Unit Appoints Vice President of Medical Affairs

Fri, 10 Apr 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Martine J. George, M.D., M.Sc, to Vice President of Medical Affairs for its Oncology Business Unit. Dr. George will be responsible for managing

Pfizer Announces Operating Structure and Select Senior Leadership Posts to Be Effective Immediately Upon Close of Wyeth Acquisition

Tue, 7 Apr 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes.

Pfizer Receives Request for Additional Information from FTC Regarding Proposed Acquisition of Wyeth

Fri, 3 Apr 2009 18:23:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced that it has received a request for additional information from the U.S. Federal Trade Commission (“FTC”) with respect to its previously

Pfizer Becomes The First Pharmaceutical Company To Be Accredited For Protection Of Human Rights In Clinical Research

Fri, 3 Apr 2009 16:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has become the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for

Pfizer Development Pipeline Shows Advances In High-Priority Disease Areas

Thu, 2 Apr 2009 16:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials

Pfizer Discontinues One Sunitinib Phase 3 Trial in Advanced Breast Cancer; Other Advanced Breast Cancer Trials Continue

Thu, 2 Apr 2009 12:29:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of one of its Phase 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in

Significantly More Patients With Cardiovascular Disease Quit Smoking Using Chantix/Champix(®) (Varenicline) Compared With Placebo

Tue, 31 Mar 2009 13:00:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer Inc today announced the results of a study that found that 47 percent of smokers with a history of cardiovascular disease who took CHANTIX/CHAMPIX® (varenicline) were able to

Intensive Lipitor Therapy Provided Sustained Risk Reduction Of Cardiovascular Events In Older Patients With Heart Disease

Mon, 30 Mar 2009 19:30:00 UT

NEW YORK--(BUSINESS WIRE)--Among patients aged 65 and older with established coronary heart disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the relative risk of a first cardiovascular event by

Pfizer Invites Public to View and Listen to Webcast of April 28 Conference Call with Analysts

Mon, 30 Mar 2009 14:00:00 UT

Pfizer Announces Completion of $13.5 Billion Debt Offering

Wed, 25 Mar 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced the successful completion of its offering of $13.5 billion of senior unsecured notes. The notes consist of:

Pfizer’s Oncology Business Unit Appoints Senior Executive to Head U.S. Region

Mon, 23 Mar 2009 14:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the appointment of Elizabeth Barrett to Regional President, U.S. for its Oncology Business Unit where she will lead sales, field operations, and marketing. Ms.

Pfizer, PlaNet Finance Partner to Study Options for Expanding Access to Healthcare in China

Fri, 20 Mar 2009 09:00:00 UT

NEW YORK & PARIS--(BUSINESS WIRE)--Pfizer Inc and PlaNet Finance announced today that they will team up to conduct an in-depth research project on the healthcare needs of the working poor in China. The study will

Pfizer-Sponsored Prescription Savings Program - Together Rx Access® - Expands Eligibility Criteria in Response to Challenging Economic Times

Thu, 19 Mar 2009 11:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Together Rx Access®, a prescription savings program sponsored by Pfizer along with several other leading pharmaceutical companies, has expanded the

U.S. Patent & Trademark Office Grants Reissue Patent Relating to Lipitor

Tue, 17 Mar 2009 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has granted reissue patent RE40667, relating to Lipitor. The company had applied for the reissue patent in January 2007,

Wide-Reaching Global Survey Reveals Majority of Women Living with Metastatic Breast Cancer Desire Increased Public Attention

Fri, 13 Mar 2009 07:00:00 UT

NEW YORK--(BUSINESS WIRE)--A new global survey of 950 women living with metastatic breast cancer (MBC) in nine countries (the United Kingdom, France, Spain, Belgium, Poland, the United States, Argentina, Egypt and

Pfizer Invites Public to View and Listen to Webcast of Investor Breakfast at Healthcare Conference

Tue, 10 Mar 2009 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a discussion with members of Pfizer’s leadership team at an investor breakfast at the Cowen and

Pfizer and Bausch & Lomb to Co-Promote Products for the Treatment of Ophthalmic Conditions

Tue, 3 Mar 2009 13:25:00 UT

NEW YORK & ROCHESTER, N.Y.--(BUSINESS WIRE)--Pfizer Inc and Bausch & Lomb announced today a co-promotion agreement involving both companies’ prescription ophthalmic pharmaceuticals in the United States. The

Pfizer Expands Portfolio of Generic Medicines in the U.S. and Europe Through Licensing Agreements with Aurobindo

Tue, 3 Mar 2009 08:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that it has entered into a series of agreements with Aurobindo Pharma Ltd., a pharmaceutical company based in India, to commercialize medicines that are

Pfizer Discontinues Development of Two Phase 3 Compounds

Tue, 24 Feb 2009 13:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that, following a review of the development and commercial portfolios in the Primary Care Business Unit, it is terminating Phase 3 development programs for the

Pfizer to Publicly Disclose Payments to U.S. Physicians, Healthcare Professionals and Clinical Investigators

Mon, 9 Feb 2009 21:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced its plans to make publicly available its compensation of U.S. healthcare professionals for consulting, speaking engagements and clinical trials. The disclosure will

Pfizer and The Pfizer Foundation Recognize “World Cancer Day” Award $7 Million in Grants to Support Global Cancer Control Efforts

Wed, 4 Feb 2009 17:08:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc and The Pfizer Foundation announced today, on “World Cancer Day”, that they have awarded $7 million in 2009 to help 13 non-governmental organizations (NGOs) focus on

Pfizer’s Sutent is Recommended as First-Line Treatment for Kidney Cancer Patients by British Health Agency

Wed, 4 Feb 2009 00:29:00 UT

Lipitor Significantly Reduced hsCRP Levels in Patients with Stable Coronary Artery Disease, According to New Study

Mon, 2 Feb 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Patients treated with Lipitor® (atorvastatin calcium) 80 mg had a significant 55 percent reduction in levels of high-sensitivity C-reactive protein (hsCRP), while those taking Lipitor 10

Pfizer Discontinues Global Phase III Trial of Axitinib for Futility in Advanced Pancreatic Cancer

Fri, 30 Jan 2009 22:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III study of its investigational agent axitinib for the treatment of advanced pancreatic cancer. Based on an interim analysis, an

Pfizer Invites Public to Listen to Audio-Only Webcast of January 27 Investor Luncheon

Tue, 27 Jan 2009 16:35:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to an audio-only webcast of a discussion with the Pfizer leadership team at an investor luncheon on Tuesday, January 27, 2009 at

MEDIA ADVISORY: Pfizer and Wyeth to Host Live Press Conference in New York

Mon, 26 Jan 2009 11:35:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they will be holding a live press conference to discuss today’s announcement that Pfizer will acquire Wyeth. The executives

Pfizer Reports Fourth-Quarter and Full-Year 2008 Results and 2009 Financial Guidance

Mon, 26 Jan 2009 11:29:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company

Mon, 26 Jan 2009 11:27:00 UT

NEW YORK & MADISON, N.J.--(BUSINESS WIRE)--Pfizer (NYSE: PFE) and Wyeth (NYSE: WYE) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock

Pfizer Receives FDA Complete Response Letter for Lasofoxifene

Fri, 16 Jan 2009 22:05:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today it has received a complete response letter from the U.S. Food and Drug Administration (FDA) asking for additional information on the company’s application for

Stephen W. Sanger Elected to Pfizer’s Board of Directors

Wed, 14 Jan 2009 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the election of Stephen W. Sanger to its Board of Directors, effective February 1, 2009.

U.S. Patent and Trademark Office Accepts Pfizer’s Reissue Application on Lipitor Enantiomer Patent

Tue, 6 Jan 2009 18:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” accepting the company’s application to correct the technical defect

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Mon, 22 Dec 2008 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research & Development, at the 27th Annual

Bradley E. Lerman Joins Pfizer as Senior Vice President of Litigation

Mon, 22 Dec 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that Bradley E. Lerman will join the company as Senior Vice President, Litigation. Mr. Lerman, who will be responsible for leading the company’s

Pfizer Declares a 32-Cent First-Quarter 2009 Dividend

Mon, 15 Dec 2008 20:45:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent first-quarter 2009 dividend on the company’s common stock, payable March 3, 2009, to shareholders of record at

Pfizer Invites Public to View and Listen to Webcast of January 28 Conference Call with Analysts

Mon, 15 Dec 2008 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Wednesday, January 28, 2009. The purpose of

Pfizer Announces Results from Trial of AROMASIN in Postmenopausal Women with Hormone Sensitive Early Breast Cancer

Thu, 11 Dec 2008 20:00:00 UT

SAN ANTONIO--(BUSINESS WIRE)--Pfizer today announced results from a first planned analysis of the TEAM (Tamoxifen, Exemestane, Adjuvant, Multicenter) trial. TEAM was originally designed in 2001 as a comparison of

Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria in Africa

Tue, 9 Dec 2008 13:30:00 UT

NEW YORK & ROME, Italy--(BUSINESS WIRE)--Pfizer Inc (Pfizer) and Sigma-Tau Industrie Farmaceutiche Riunite S.p.A (Sigma-Tau), a privately owned Italian pharmaceutical company, announced today that they have entered

Patients Taking Lipitor Had a Significantly Reduced Risk of Cardiovascular Events Compared with Patients Taking Simvastatin, New Observational Study Shows

Wed, 3 Dec 2008 13:18:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced the results of an observational study that showed patients taking Lipitor® (atorvastatin calcium) had a significant 13 percent reduction in the relative risk of

Pfizer’s Novel HIV/AIDS Treatment SELZENTRY™ Becomes the Latest Fully Approved Antiretrovial for Treatment-Experienced HIV Patients

Tue, 25 Nov 2008 22:45:00 UT

NEW YORK--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted SELZENTRY™ (maraviroc) full (traditional) approval for use in treatment-experienced adults with CCR5-tropic HIV-1 in combination

Pfizer Withdraws Application to Switch Viagra to Non-Prescription Status in Europe

Thu, 20 Nov 2008 10:28:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has withdrawn its application to switch the legal status of the 50 mg tablet strength of Viagra from ‘prescription only’ to

Pfizer Launches Global Regenerative Medicine Research Unit

Fri, 14 Nov 2008 11:00:00 UT

LONDON--(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific

Pfizer Launches Global Regenerative Medicine Research Unit

Fri, 14 Nov 2008 11:00:00 UT

LONDON--(BUSINESS WIRE)--Pfizer today announced the launch of a new research unit known as Pfizer Regenerative Medicine. This independent research unit will build on recent scientific

New Analysis Suggests That Improvements in Kidney Function in Patients Treated with Lipitor Strongly Correlate with a Reduced Risk of Major Cardiovascular Events

Wed, 12 Nov 2008 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Improvements in kidney function in patients treated with Lipitor® (atorvastatin calcium) were shown to strongly

Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference

Thu, 6 Nov 2008 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Jeff Kindler, Chairman and CEO, at the 2008 Credit Suisse

Pfizer Discontinues Development Program for Its Phase 3 Obesity Compound (CP-945,598)

Wed, 5 Nov 2008 21:35:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer, Inc announced today that it is terminating the phase 3 development program for its investigational compound (CP-945,598) for weight management. CP-945,598

Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder

Fri, 31 Oct 2008 17:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) approved TOVIAZ™ (fesoterodine

Pfizer's Novel HIV/AIDS Treatment Selzentry(TM) (Maraviroc) Demonstrates Increased Efficacy Rate In Treatment-Naive HIV Patients

Sun, 26 Oct 2008 15:16:00 UT

NEW YORK--(BUSINESS WIRE)--Patients taking Selzentry, in combination with Combivir® (zidovudine/lamivudine) and selected by an enhanced sensitivity tropism

Pfizer to Present Data on New Approaches to Pain and Inflammation Treatment at ACR Meeting

Sun, 26 Oct 2008 00:00:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Pfizer will present data on three investigational compounds that represent potential new mechanisms for targeting pain and inflammation. These data will

Pfizer Declares a 32-Cent Fourth-Quarter 2008 Dividend

Thu, 23 Oct 2008 17:40:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc (NYSE: PFE) today declared a 32-cent fourth-quarter 2008 dividend on the company’s common

Pfizer Completes Settlement Agreements with State Attorneys General Regarding its NSAID Pain Medications

Wed, 22 Oct 2008 16:46:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has finalized agreements with 33 states and the District of Columbia to resolve claims primarily related to alleged promotional

Pfizer Names New Head of Clinical Development and Medical Affairs for Its Oncology Business Unit

Wed, 22 Oct 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has named Mace L. Rothenberg, M.D. as Senior Vice President, Clinical Development and Medical Affairs for its Oncology Business

Pfizer Reports Third-Quarter 2008 Results

Tue, 21 Oct 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Pfizer and UCB Announce Formation of New Company 'Cyclofluidic' to Accelerate Drug Discovery Process

Mon, 20 Oct 2008 12:00:00 UT

LONDON--(BUSINESS WIRE)--Pfizer Ltd (NYSE:PFE) (LSE:PFZ) and UCB today announced the formation of Cyclofluidic, a breakthrough technology company established with the aim of significantly

Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications

Fri, 17 Oct 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state

New Data across Pfizer's Pain and Inflammation Portfolio to Be Presented at Upcoming ACR Meeting

Tue, 14 Oct 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer will highlight several presentations and posters across a spectrum of pain and inflammatory conditions at the American College of Rheumatology (ACR) annual

Landmark COPD Trial UPLIFT(R) Shows SPIRIVA(R) HandiHaler(R) Sustained Lung Function Improvements over Four Years

Thu, 9 Oct 2008 18:21:00 UT

RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--Results of the UPLIFT® (Understanding Potential Long-term Impacts on Function with Tiotropium)

Aetna and Pfizer Present ''State of Motion'' Health Fair in Hartford to Encourage Families to Adopt Healthy Lifestyles

Thu, 9 Oct 2008 15:33:00 UT

HARTFORD, Conn.--(BUSINESS WIRE)--Aetna and Pfizer Inc are co-sponsoring a recreational health fair for Hartford families on October 18 to raise awareness of the importance of

EPA Honors Pfizer for Reducing Greenhouse Gas Emissions

Wed, 8 Oct 2008 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--The U.S. Environmental Protection Agency (EPA) honored Pfizer Inc today in recognition of the company’s award-winning Energy and

Pfizer Invites Public to View and Listen to Webcast of October 28 Analyst and Investor Meeting at ACR

Fri, 3 Oct 2008 20:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media and the general public to view and listen to a webcast of a presentation by Pfizer’s pain and

Pfizer Invites Public to View and Listen to Webcast of October 21 Conference Call with Analysts

Wed, 1 Oct 2008 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday,

Pfizer Shows Accelerating Pipeline with Significant Growth in Late-Stage Clinical Development

Tue, 30 Sep 2008 13:34:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s

Established Safety Profile of Spiriva(R) Confirmed by 30 Rigorously Controlled Clinical Trials

Wed, 24 Sep 2008 16:08:00 UT

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim and Pfizer have released a new analysis of 30 rigorously controlled clinical trials confirming the long term safety profile of

Grameen Health and Pfizer Announce Novel Partnership to Explore Sustainable Healthcare Delivery Models for the Developing World

Wed, 24 Sep 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc and Grameen Health, an affiliate of Grameen Bank, the pioneering micro-financing organization in Bangladesh that shared the Nobel Peace Prize in 2006

Pfizer Recognized as Leader in Improving Climate Change for Second Consecutive Year

Mon, 22 Sep 2008 14:56:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that for the second consecutive year it was recognized for its approach to improving the environment by being named to the Climate

MannKind and Pfizer Announce Collaboration for Certain Exubera Patients to Transition to MannKind's Inhaled Insulin Therapy

Tue, 16 Sep 2008 12:06:00 UT

VALENCIA, Calif. & NEW YORK--(BUSINESS WIRE)--MannKind Corporation (Nasdaq: MNKD) and Pfizer Inc (NYSE: PFE) announced today that MannKind will transition certain Exubera patients with a

Pfizer Launches New Medicine Safety Website to Help Healthcare Professionals and Patients Make Better Informed Decisions about Treatment Options

Mon, 15 Sep 2008 16:21:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the launch of a new interactive online educational resource designed to give healthcare professionals, medical students, patients,

Pfizer Oncology Presents Safety and Efficacy Results Of CP-751,871 Study At ESMO 2008

Mon, 15 Sep 2008 12:56:00 UT

STOCKHOLM, Sweden--(BUSINESS WIRE)--Pfizer announced today updated safety and efficacy results surrounding its investigational compound, CP-751,871, in patients with non-small cell lung

Pfizer Animal Health Adds Former Schering-Plough Products to European Portfolio

Wed, 10 Sep 2008 22:27:00 UT

PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that its acquisition of multiple product franchises in Europe from the Schering-Plough Corporation has been completed and

Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial

Tue, 9 Sep 2008 12:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced it will globally withdraw all dalbavancin marketing applications for the treatment of complicated skin and skin structure infections in

Data to Be Presented At ESMO 2008 Highlight Pfizer Commitment to Cancer Care and Research

Mon, 8 Sep 2008 20:11:00 UT

STOCKHOLM, Sweden--(BUSINESS WIRE)--Pfizer announced today that important study results involving the company’s leading anticancer agent, SUTENT

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Mon, 8 Sep 2008 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, President, Worldwide Pharmaceutical Operations,

Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases

Wed, 3 Sep 2008 11:00:00 UT

NEW YORK & SAN FRANCISCO--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Medivation, Inc.(NASDAQ: MDVN) announced today that they have entered into an agreement to develop and commercialize

Lipitor 80 mg Provided Sustained Risk Reduction of Cardiovascular Events in Patients with Heart Disease During the Five-Year TNT Trial

Tue, 2 Sep 2008 12:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced that in patients with established heart disease, Lipitor® (atorvastatin calcium) 80 mg not only

New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients

Tue, 2 Sep 2008 09:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) announced today the results of a Phase 2 dose-ranging study (APPRAISE-1)

Court in Denmark Upholds Two Lipitor Patents, Prevents Launch of Ranbaxy Generic Product before November 2011

Fri, 29 Aug 2008 13:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Eastern Division of the High Court in Copenhagen, Denmark has ruled in the company’s favor in

Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program

Tue, 26 Aug 2008 20:15:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) provided an update on the apixaban clinical development program today. The

Pfizer Says Vacation with Your Dog before the Summer Ends

Thu, 14 Aug 2008 15:09:00 UT

NEW YORK--(BUSINESS WIRE)--With canine motion sickness the leading reason pet owners are not able to take their dogs on day trips or vacation, Pfizer is encouraging more people to talk with

IAFF Launches Smoking Cessation Campaign with Pfizer

Mon, 11 Aug 2008 15:03:00 UT

LAS VEGAS--(BUSINESS WIRE)--The International Association of Fire Fighters has announced the launch of a new initiative to help fire fighters, family members and friends to quit smoking

Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke in Patients with Heart Disease, Type 2 Diabetes and Chronic Kidney Disease

Wed, 6 Aug 2008 18:43:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that, in patients with heart disease, type 2 diabetes and chronic kidney disease, Lipitor

Pfizer Reports Second-Quarter 2008 Results

Wed, 23 Jul 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Pfizer to Showcase Alzheimer's Research and Pipeline at Upcoming Alzheimer's Disease Medical Meeting

Mon, 14 Jul 2008 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer, Inc announced today that it will present nine abstracts from its Alzheimer’s disease (AD) research and development program,

Pfizer Fully Supports Updated PhRMA Code

Thu, 10 Jul 2008 16:28:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer endorses the updates to the PhRMA Code on Interactions with Healthcare Professionals and will fully comply with all aspects of the Code.

Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows

Mon, 7 Jul 2008 16:20:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new statin users who took Lipitor® (atorvastatin calcium) were significantly more

Pfizer Changes Its Funding of Continuing Medical Education in the U.S.

Wed, 2 Jul 2008 16:09:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced changes in the way it supports continuing medical education (CME) initiatives for U.S. healthcare professionals.

FDA Approves First and Only Single-Dose Antibiotic for Dogs and Cats

Mon, 30 Jun 2008 12:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health has announced the Food and Drug Administration (FDA) has approved Convenia® (cefovecin sodium), the first and

Pfizer Declares a 32-Cent Third Quarter 2008 Dividend

Thu, 26 Jun 2008 16:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent third–quarter, 2008, dividend on the company

Pfizer Invites Public to View and Listen to Webcast of July 23 Conference Call with Analysts

Wed, 25 Jun 2008 16:04:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 11 a.m. Eastern Daylight

Pfizer Invites Public to View and Listen to Webcast of July 28 Pfizer Analyst and Investor Meeting at ICAD

Mon, 23 Jun 2008 16:55:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors, media, and the general public to view and listen to a webcast of a presentation by Pfizer’s

EyeCyte, Inc. Secures Series A Funding from Pfizer

Mon, 23 Jun 2008 13:00:00 UT

SAN DIEGO--(BUSINESS WIRE)--EyeCyte, Inc., an early stage stem/progenitor cell-based ophthalmology research and development company based in La Jolla, California, today announced that it has

Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide

Wed, 18 Jun 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that it has entered into an agreement with generics manufacturer Ranbaxy Laboratories Ltd. of India and certain of its affiliates to

Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions

Thu, 12 Jun 2008 15:49:00 UT

NEW YORK--(BUSINESS WIRE)--This summer, Maria Machado, a supply chain expert from Brazil, will make an extended visit to Africa – unlike any trip she

Pfizer Inc. and the University of Pennsylvania Announce $15 Million Partnership

Thu, 12 Jun 2008 15:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) announced today that it has entered into a $15-million dollar collaboration with the University of Pennsylvania School of Medicine. The

Bristol-Myers Squibb and Pfizer Initiate New Study in the Apixaban Phase 3 Clinical Trial Program

Tue, 10 Jun 2008 20:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today the start of a new Phase 3 clinical trial to assess the effect of

Pfizer and UCSF Form Alliance to Advance a Broad Range of Research

Tue, 10 Jun 2008 14:06:00 UT

NEW YORK--(BUSINESS WIRE)--In a novel experiment to advance new drug discovery and development, as well as stimulate basic research, Pfizer, Inc. and UCSF have launched a collaboration that

Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc.

Tue, 10 Jun 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that it has completed the acquisition of all remaining outstanding shares of common stock of Encysive Pharmaceuticals Inc.

Charles E. Triano Joins Pfizer as Head of Investor Relations

Thu, 5 Jun 2008 20:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that Charles E. Triano will join the company as Senior Vice President, Investor Relations, effective June 23. Mr. Triano, who will be

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Wed, 4 Jun 2008 16:40:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research &

Pfizer Reviews Progress of Oncology Pipeline and New Commercial Business Unit Structure with Analysts

Mon, 2 Jun 2008 23:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today as part of its commitment to oncology that it expects to start a total of seven Phase 3 studies in 2008; two are open and enrolling, and

New Pfizer Data Presented on CP-751,871 across Non-Small Cell Lung Cancer and Ewing's Sarcoma

Mon, 2 Jun 2008 20:02:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer announced today results from several clinical trials further describing the activity of its investigational compound CP-751,871 in non-small cell lung cancer

Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting

Mon, 2 Jun 2008 15:34:00 UT

CHICAGO--(BUSINESS WIRE)--AVANT Immunotherapeutics (Nasdaq: AVAN) and Pfizer, Inc. (NYSE: PFE) today announced the presentation of new data from two Phase 2 studies at the 44th Annual

Pfizer Oncology ASCO 2008 Media Briefing to Discuss Study Results in Broad Range of Cancers

Fri, 30 May 2008 16:14:00 UT

--(BUSINESS WIRE)--

Pfizer Names Amy W. Schulman as Senior Vice President and General Counsel

Wed, 28 May 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Amy W. Schulman as Senior Vice President and General Counsel, effective June 23. In her new role, Ms. Schulman will be responsible for

Australian Full Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product

Wed, 28 May 2008 00:21:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Australian Full Federal Court in Victoria has upheld on appeal the exclusivity of its basic patent covering atorvastatin, the active

Pfizer Invites Public to View and Listen to Webcast of June 2 Pfizer Analyst and Investor Meeting at ASCO

Thu, 22 May 2008 13:52:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts and institutional investors to be held on

New Analysis Showed That High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients

Wed, 21 May 2008 20:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg significantly reduced the risk of major

FivePrime and Pfizer Enter Oncology and Diabetes Collaboration

Tue, 20 May 2008 16:00:00 UT

SAN FRANCISCO--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. and Pfizer Inc. (NYSE:PFE) today announced the initiation of a worldwide collaborative research and license agreement. The

New Pfizer Data in Lung Cancer, Ewing's Sarcoma, Prostate Cancer and Other Difficult-to-Treat Tumor Types to Be Presented at ASCO

Fri, 16 May 2008 14:05:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that study results across several difficult-to-treat cancers will be presented at the 44th American Society of

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Thu, 15 May 2008 16:04:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc Chief Financial Officer, Frank D

Pfizer Names Garry Nicholson to Head New Oncology Business Unit

Wed, 14 May 2008 22:12:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Garry A. Nicholson as Senior Vice President, General Manager of the company’s newly created Oncology

As Part of New Transparency Initiative Pfizer Releases List of Grants and Charitable Contributions Made in the First Quarter of 2008

Wed, 14 May 2008 19:41:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has posted a list of U.S. medical, scientific and patient organization grants and charitable contributions made in the first quarter

Pfizer Extends 10 Million Yuan to Earthquake Victims and Relief Efforts in China

Tue, 13 May 2008 14:57:00 UT

BEIJING, China--(BUSINESS WIRE)--BEIJING, CHINA, MAY 13 – Today Pfizer China announced it is providing up to RMB 10 million (approximately $1.4 million U.S.D)

Esperion Therapeutics Completes $22.75 M Series A Financing

Thu, 1 May 2008 12:30:00 UT

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--Esperion Therapeutics, Inc. a biopharmaceutical company formed to focus on the discovery and development of compounds to treat cardiovascular

U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent

Wed, 30 Apr 2008 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Mon, 28 Apr 2008 19:23:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer, Jeffrey

Pfizer Enters into Research Consortium to Expand Understanding of Diabetes and Obesity Pathobiology

Fri, 25 Apr 2008 19:06:00 UT

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Pfizer has entered into a collaboration agreement with four major research universities – University of California,

Pfizer Declares a 32-Cent Second Quarter, 2008, Dividend

Thu, 24 Apr 2008 18:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent second–quarter, 2008, dividend on the company

Pfizer on Track to Deliver Greater Shareholder Value, CEO Kindler Tells Shareholders

Thu, 24 Apr 2008 14:30:00 UT

MEMPHIS, Tenn.--(BUSINESS WIRE)--Today at Pfizer’s annual shareholder meeting, Chairman and Chief Executive Officer Jeffrey B. Kindler detailed his plan to

Pfizer Animal Health Enters into Agreement to Acquire Animal Health Products from Schering-Plough

Wed, 23 Apr 2008 21:00:00 UT

PARIS--(BUSINESS WIRE)--Pfizer Animal Health today announced that it has entered into an agreement to acquire multiple product franchises from Schering-Plough Corporation covering all major

Pfizer Japan to Launch Champix(R) the First Prescription Oral Smoking Cessation Aid in Japan

Tue, 22 Apr 2008 04:45:00 UT

TOKYO--(BUSINESS WIRE)--Pfizer Inc announced today that on May 8, 2008, it will launch Champix® Tablet 0.5mg/1mg (varenicline tartrate), a novel smoking cessation aid

Pfizer Invites Public to Listen to Webcast of April 24 Annual Meeting of Shareholders

Mon, 21 Apr 2008 18:17:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Central Daylight Time) on Thursday,

High-Dose Lipitor Reduced the Risk of Heart Attack and Stroke in Patients with Chronic Kidney Disease

Mon, 21 Apr 2008 14:52:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that Lipitor® (atorvastatin calcium) 80 mg reduced the risk of

Pfizer Japan Receives Manufacturing and Marketing Authorization for SUTENT

Mon, 21 Apr 2008 14:30:00 UT

TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc announced that on April 16, the company received an approval for the manufacturing and marketing authorization of the anti-tumor drug/kinase

Pfizer Opens New Development Centre

Fri, 18 Apr 2008 14:36:00 UT

BRUSSELS, Belgium--(BUSINESS WIRE)--A new development centre for veterinary vaccines which will accelerate the development of new animal health products has been opened by Pfizer as part of

Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010

Thu, 17 Apr 2008 20:24:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued

Pfizer Reports First-Quarter 2008 Results; Reaffirms Full-Year 2008 Financial Guidance

Thu, 17 Apr 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Results from Largest Statin Study of Patients with Alzheimer's Disease Show Lipitor(R) Has No Significant Impact on Disease

Wed, 16 Apr 2008 23:33:00 UT

NEW YORK--(BUSINESS WIRE)--In a study in patients with mild-to-moderate Alzheimer’s disease (AD), the addition of Lipitor (atorvastatin calcium tablets) 80 mg

Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer

Wed, 16 Apr 2008 20:37:00 UT

NEW YORK & NEEDHAM, Mass.--(BUSINESS WIRE)--Pfizer, Inc (NYSE: PFE) and AVANT Immunotherapeutics (Nasdaq: AVAN), acting through its wholly-owned subsidiary Celldex Therapeutics, Inc. today

Lyrica Reduced Pain of Fibromyalgia in Patients Regardless of Symptoms of Anxiety or Depression

Wed, 16 Apr 2008 12:00:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer’s Lyrica reduced pain of fibromyalgia in patients regardless of whether they experienced symptoms of anxiety or depression at

Pfizer Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc.

Tue, 15 Apr 2008 12:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced that the subsequent offering period of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to

Pfizer Statement on Exubera Labeling Update in the United States

Wed, 9 Apr 2008 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it updated the US product labeling for EXUBERA® (insulin human [rDNA original

Pfizer Extends Subsequent Offering Period of Tender Offer for Shares of Encysive Pharmaceuticals

Tue, 8 Apr 2008 12:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has extended the subsequent offering period of its

Pfizer Reports Shares of Encysive Pharmaceuticals Inc. Tendered Pursuant to Guaranteed Delivery Procedures

Mon, 7 Apr 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--On April 1, 2008, Pfizer Inc (NYSE: PFE) announced results of its tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., to purchase all of the

Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma

Tue, 1 Apr 2008 21:48:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the discontinuation of a Phase III clinical trial (A3671009), of single-agent tremelimumab (CP-675,206) in patients with advanced

Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study

Tue, 1 Apr 2008 16:18:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in

Pfizer Invites Public to View and Listen to Webcast of April 17 Conference Call with Analysts

Tue, 1 Apr 2008 14:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10am EDT on Thursday, April

Pfizer Successfully Completes Tender Offer for Shares of Encysive Pharmaceuticals Inc. and Announces Subsequent Offer Period

Tue, 1 Apr 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that Explorer Acquisition Corp., a wholly-owned subsidiary of Pfizer, has purchased all of the shares validly tendered and

Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent

Mon, 31 Mar 2008 17:02:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active

Pfizer Obtains Clearance from Federal Cartel Office of Germany for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.; ``Regulatory Condition'' Now Satisfied

Thu, 27 Mar 2008 21:05:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that it has obtained clearance from the Federal Cartel Office of Germany (FCO) in connection with the tender offer by its

Pfizer Clears U.S. Antitrust Review for Acquisition of All Outstanding Shares of Encysive Pharmaceuticals Inc.

Thu, 27 Mar 2008 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired in connection

Federal Court of Appeal in Canada Upholds Lipitor Enantiomer Patent, Decision Prevents Launch of Generic Product by Ranbaxy until 2010

Thu, 20 Mar 2008 23:27:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Federal Court of Appeal of Canada has reversed a lower court ruling that held that Pfizer’s

Pfizer Animal Health to Acquire Catapult Genetics and Bovigen

Tue, 18 Mar 2008 21:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health today announced it will acquire two market-leading livestock genomics companies:

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Wed, 12 Mar 2008 15:43:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, President, Pfizer Global Research &

Pfizer's Waxman to Leave

Tue, 11 Mar 2008 20:16:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that Senior Vice President and General Counsel Allen Waxman is leaving the company for personal reasons. Mr. Waxman will remain outside counsel

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Mon, 10 Mar 2008 18:17:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chief Medical Officer, Joseph Feczko, at the

Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex by Generic Manufacturer Teva

Fri, 7 Mar 2008 18:34:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company

Pfizer Presents New Opportunities for Global Growth

Wed, 5 Mar 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today reviewed strategies to accelerate and refocus Pfizer’s pipeline and capture new opportunities for global growth at a

Pfizer Announces Commencement of Tender Offer for All Outstanding Shares of Encysive Pharmaceuticals Inc.

Tue, 4 Mar 2008 21:56:00 UT

NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of the tender offer by its wholly-owned subsidiary, Explorer Acquisition Corp., for all

Pfizer Names William Ringo Senior Vice President of Strategy and Business Development

Mon, 3 Mar 2008 15:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named William Ringo as the company’s new Senior Vice President of Strategy and Business Development with

Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform

Mon, 3 Mar 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Serenex, Inc., a privately-held biotechnology company with a Phase I clinical candidate

Pfizer to Seek to Appeal Lipitor Enantiomer Patent Ruling in the Netherlands, Company Notes That Ruling Has No Commercial Impact

Thu, 28 Feb 2008 15:11:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it will seek to appeal a ruling of the Court of Appeal of The Hague in the Netherlands that Pfizer

Pfizer Voluntarily Withdraws Lipitor Advertising Featuring Dr. Robert Jarvik

Mon, 25 Feb 2008 19:21:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that it is voluntarily withdrawing Lipitor advertising and promotion featuring Dr. Robert Jarvik and committing to ensuring greater clarity in

Appellate Court in the Netherlands Upholds Basic Lipitor Patent, Prevents Launch of Ranbaxy Product before November 2011

Thu, 21 Feb 2008 13:42:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of The Hague in the Netherlands has ruled that the basic patent covering atorvastatin - the active ingredient in

Pfizer to Acquire Encysive Pharmaceuticals

Wed, 20 Feb 2008 14:14:00 UT

NEW YORK & HOUSTON--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire Encysive Pharmaceuticals Inc. (NASDAQ: ENCY), a publicly held

Pfizer and The Pfizer Foundation Award Multi-Year Grants to Support Cancer and Tobacco Control around the World

Tue, 19 Feb 2008 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation announced today a groundbreaking $33 million multi-year program to address the emerging challenges in cancer and tobacco control. The first

Pan-African Conference Focuses on Keeping the Medicine Supply in Africa Safe

Wed, 13 Feb 2008 06:00:00 UT

JOHANNESBURG, South Africa--(BUSINESS WIRE)--An international conference to discuss the issue of counterfeit medicines in Africa started this week in Johannesburg. The aim of the conference,

Pfizer Presents New Data from HIV/AIDS Portfolio at Conference on Retroviruses and Opportunistic Infections

Wed, 6 Feb 2008 23:00:00 UT

BOSTON--(BUSINESS WIRE)--At this week’s major HIV/AIDS research meeting, Pfizer presented new data on two investigational second generation HIV compounds

Pfizer Japan Receives Manufacturing and Marketing Authorization for Champix(R)

Tue, 29 Jan 2008 01:10:00 UT

TOKYO--(BUSINESS WIRE)--Pfizer Japan Inc (headquarter in Shibuya-ku, Tokyo; headed by President & Chief Executive Officer, Hiromitsu Iwasaki; and capitalized at Yen 64.8 billion)

Pfizer Reports Fourth-Quarter and Full-Year 2007 Results and 2008 Financial Guidance

Wed, 23 Jan 2008 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE):

Make a New Year's Resolution to Lose Weight - For Your Dog

Tue, 22 Jan 2008 11:00:00 UT

NEW YORK--(BUSINESS WIRE)--As millions of Americans vow to get healthier and stave off illness by making a New Year’s resolution to lose weight, it

Pfizer Invites Public to View and Listen to Webcast of March 5 Meeting with Analysts

Fri, 18 Jan 2008 16:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on Wednesday, March 5, at

Pfizer Statement on CHANTIX (varenicline) Labeling Update in the United States

Fri, 18 Jan 2008 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Cigarette smoking is associated with significant morbidity and mortality. Smoking is the leading preventable cause of disease and premature death in the United

Pfizer Reaffirms Leadership in International Corporate Volunteerism by Deploying the Largest Round of Global Health Fellows

Wed, 16 Jan 2008 17:04:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced the eighth class of Global Health Fellows, a group of 28 Pfizer colleagues from North America, Europe and Asia, who

Adding Lipitor Early to Effective Blood Pressure Treatment Provided a Significant Reduction in Heart Attacks or Deaths from Heart Attacks over Five Years

Wed, 16 Jan 2008 16:38:00 UT

NEW YORK--(BUSINESS WIRE)--The early addition of Lipitor® (atorvastatin calcium) Tablets to effective blood pressure lowering

Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor

Wed, 16 Jan 2008 09:00:00 UT

NEW YORK & MARTINSRIED, Germany--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Scil Technology GmbH (Scil) have signed a licensing agreement for worldwide collaboration on Scil

Overweight Dogs in Europe to Benefit from Pfizer U.S. Experience

Tue, 15 Jan 2008 14:00:00 UT

NEW YORK--(BUSINESS WIRE)--European vets are about to be given the same powerful medical tool which has helped U.S. vets manage obese dogs who don’t respond

Patients Treated with Lipitor Were Significantly Less Likely to Have a Cardiovascular Event Than Those Treated with Simvastatin, New Observational Study Shows

Mon, 14 Jan 2008 15:40:00 UT

NEW YORK--(BUSINESS WIRE)--Results of an observational study of a large U.S. managed care claims database showed that new statin users without cardiovascular disease who

Pfizer Receives Initial Communication from U.S. Patent and Trademark Office Regarding Lipitor Basic Patent

Mon, 14 Jan 2008 12:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893

Pfizer Wins Key New York State Court Ruling on Celebrex

Wed, 9 Jan 2008 23:23:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer

Pfizer Invites Public to View and Listen to Webcast of January 23 Conference Call with Analysts

Wed, 9 Jan 2008 19:44:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EST on Wednesday,

ADDING MULTIMEDIA Pfizer Names Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer

Tue, 8 Jan 2008 17:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer with overall responsibility for Pfizer

Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate

Mon, 7 Jan 2008 06:00:00 UT

NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) and Taisho

Pfizer to Appeal Canadian Federal Court Ruling on Lipitor Patent; Court's Decision Will Have No Immediate Commercial Impact

Thu, 3 Jan 2008 17:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today it will appeal a Canadian Federal Court decision in favor of generic manufacturer Apotex in its challenge to a Pfizer patent covering

Talking to a Doctor about Smoking Makes Quitting Easier - New Survey Reveals

Thu, 3 Jan 2008 12:14:00 UT

LONDON--(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would

Pfizer Inc Announces Completion of the Tender Offer Relating to Outstanding Shares of Coley Pharmaceutical Group, Inc.

Mon, 31 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that it has completed the cash tender offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical

Pfizer Receives Approvable Letter from FDA for Dalbavancin

Fri, 21 Dec 2007 19:05:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer

Pfizer Statement on Results of Comparative Analysis of Tropism Assays

Fri, 21 Dec 2007 15:13:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc recently conducted a comparative analysis of the tropism assays TrofileTM, provided by Monogram Biosciences, and SensiTrop

Pfizer Inc Clears Antitrust Review for Acquisition of All Outstanding Shares of Coley Pharmaceutical Group, Inc.

Tue, 18 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has expired, and that it has

Pfizer to Acquire CovX to Extend Biotherapeutics Investment

Tue, 18 Dec 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today it has entered into an agreement to acquire CovX, a privately-held biotherapeutics company specializing in preclinical oncology and

Pfizer Declares a 32-Cent First Quarter, 2008, Dividend

Mon, 17 Dec 2007 20:26:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 32-cent first–quarter, 2008, dividend on the company

Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds

Wed, 5 Dec 2007 12:00:00 UT

NEW YORK & EXTON, Pa.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Adolor Corporation (Nasdaq: ADLR) announced today an exclusive worldwide collaboration to develop and commercialize novel

Pfizer Inc Commences Tender Offer for All Outstanding Shares of Coley Pharmaceutical Group, Inc.

Fri, 30 Nov 2007 13:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) today announced the commencement of its cash tender offer for all outstanding shares of common stock of Coley Pharmaceutical Group, Inc.

Pfizer Invites Public to View and Listen to Webcast of November 30 Analyst Meeting in Hong Kong

Fri, 16 Nov 2007 18:22:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Friday, November 30, at

Pfizer to Acquire Coley Pharmaceutical Group

Fri, 16 Nov 2007 13:31:00 UT

NEW YORK & WELLESLEY, Mass.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today it has entered into an agreement to acquire Coley Pharmaceutical Group, Inc. (NASDAQ: COLY), a

Pfizer and Nektar Reach Agreement on Exubera(R)

Tue, 13 Nov 2007 13:30:00 UT

NEW YORK & SAN CARLOS, Calif.--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) and Nektar Therapeutics (NASDAQ: NKTR) announced today that the two companies have resolved all outstanding contractual

Lipitor Provides Greater Benefit Compared to simvastatin in Patients with a History of Heart Attacks Who Have Had Subsequent Cardiovascular Events

Tue, 6 Nov 2007 16:30:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) was more effective than

Post-Stroke Patients Treated with Lipitor Demonstrated Significant Improvement or Stabilization of Kidney Function

Mon, 5 Nov 2007 14:30:00 UT

ORLANDO, Fla.--(BUSINESS WIRE)--Pfizer announced today that post-stroke or mini-stroke patients treated with Lipitor® (atorvastatin

New Lipitor Data Analyses from Landmark Ideal and SPARCL Trials to Be Presented at Upcoming Annual Scientific Sessions of the American Heart Association

Sun, 4 Nov 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the cardiovascular and kidney function effects of Lipitor® (atorvastatin calcium)

Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate

Tue, 30 Oct 2007 07:00:00 UT

TOKYO & NEW YORK--(BUSINESS WIRE)--Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara]

Pfizer to Appeal German Court Decision in Lipitor Patent Case; Company Notes That Ruling Has No Immediate Commercial Impact

Mon, 29 Oct 2007 19:17:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Federal Patent Court in Munich, Germany has revoked the company’s patent covering atorvastatin

Pfizer Announces Retirement of Vice Chairman David L. Shedlarz

Thu, 25 Oct 2007 20:45:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that after a 31-year career Vice Chairman David L. Shedlarz will retire from the company at the end of this year.

Pfizer Declares a 29-Cent Fourth-Quarter, 2007, Dividend

Thu, 25 Oct 2007 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent fourth-quarter, 2007, dividend on the company's common stock, payable December 4, 2007, to

Spanish Appellate Court Rules in Pfizer's Favor, Upholds Lipitor Patent

Tue, 23 Oct 2007 13:51:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeal of Barcelona has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active

Pfizer Reports Third-Quarter 2007 Results; Reconfirms 2007 and 2008 Revenue and Adjusted Diluted EPS(1) Guidance

Thu, 18 Oct 2007 10:30:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer:

Pfizer Engages with Nation's Physicians Through Sermo to Improve Patient Care

Mon, 15 Oct 2007 04:01:00 UT

NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc (www.pfizer.com) and Sermo (

Research Reveals New Trends and Best Practices among Multinational Corporations Engaging in International Corporate Volunteering Programs

Thu, 11 Oct 2007 15:00:00 UT

WASHINGTON--(BUSINESS WIRE)--The Brookings Institution’s Initiative on International Volunteering and Service, FSG Social Impact Advisors and Pfizer Inc,

Pfizer Invites Public to View and Listen to Webcast of October 18 Conference Call with Analysts

Fri, 5 Oct 2007 15:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Thursday,

Dr. Martin Mackay Named President of Pfizer Global Research and Development

Thu, 4 Oct 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today named Dr. Martin Mackay as President of Pfizer Global Research and Development (PGRD); launched an independent, stand-alone biotherapeutics and

Pfizer Hires New Vice President and Chief Talent Officer

Wed, 3 Oct 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that Dr. Tanya Clemons, a senior executive with extensive experience in leadership and organization change at Microsoft and IBM, will join

Canadian Federal Court Upholds Viagra Patent

Fri, 28 Sep 2007 16:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s second medical use patent covering Viagra

Pfizer Recognized as Leader in Addressing Climate Change

Fri, 28 Sep 2007 15:59:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that in recognition for its approach to improving the environment, the company was named to the Climate Disclosure Leadership Index

Two New Directors Elected to Pfizer Board

Thu, 27 Sep 2007 16:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today the election of Suzanne Nora Johnson and James M. Kilts to the Pfizer Board of Directors effective September 27, 2007.

New Preliminary Phase II Data Show Anti-Tumor Activity of Single-Agent Sunitinib Malate in Advanced Gastric Cancer

Wed, 26 Sep 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Preliminary results from a new Phase II study provide data on the anti-tumor activity and tolerability of sunitinib malate in patients with

Pfizer's Celsentri(R) Approved in the European Union, Providing a Novel Treatment Option for Treatment-Experienced HIV Patients

Mon, 24 Sep 2007 07:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the European Commission (EC) has approved Celsentri® (maraviroc).

Court Rules for Pfizer in Patent Infringement Case on Neurontin

Fri, 21 Sep 2007 18:08:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that an appeals court has overturned a lower court ruling that several generic manufacturers did not infringe the company

Pfizer and the European Foundation for the Study of Diabetes Announce a New Research Program Focused on Cardiovascular Risk in Patients with Diabetes

Fri, 21 Sep 2007 07:00:00 UT

AMSTERDAM, Netherlands--(BUSINESS WIRE)--Pfizer and the European Foundation for the Study of Diabetes (EFSD) announced today, at the European Association for the Study of Diabetes (EASD)

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Wed, 19 Sep 2007 16:46:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Martin Mackay, Vice President, Pfizer Global Research

Long-Term Data Reinforce Safety and Efficacy Profile of Pfizer's New HIV Drug Selzentry(TM) (Maraviroc)

Tue, 18 Sep 2007 15:00:00 UT

CHICAGO--(BUSINESS WIRE)--Nearly three times as many patients receiving Selzentry, in addition to an optimized background regimen, achieved undetectable levels of HIV virus compared with

New Data Support Long-Term Efficacy and Safety in Patients Who Took Exubera for Eight Years

Tue, 18 Sep 2007 07:00:00 UT

AMSTERDAM, Netherlands--(BUSINESS WIRE)--Two new studies presented today at the European Association for the Study of Diabetes (EASD) meeting reinforce the efficacy and safety of Exubera

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Thu, 13 Sep 2007 19:38:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Ian Read, Senior Vice President, Pfizer Inc., President,

Pfizer to Share New Data and Portfolio Update on Infectious Disease Portfolio at ICAAC Meeting; Invites Public to View and Listen to Webcast of September 18 Analyst Meeting

Thu, 13 Sep 2007 15:44:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the company plans to present key data on in-line medicines and pipeline research at the Annual Meeting of Interscience Conference on

Canadian Court Finds Infringement of Lipitor Crystal Form Patent

Wed, 12 Sep 2007 21:02:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Canadian Federal Court in Toronto has ruled that Pfizer’s patent covering a crystalline form of

Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer

Thu, 6 Sep 2007 03:30:00 UT

SEOUL, Korea--(BUSINESS WIRE)--Pfizer announced today the initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with

Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education - Mobilize Against Malaria

Wed, 5 Sep 2007 15:28:00 UT

NAIROBI--(BUSINESS WIRE)--To help address critical gaps in malaria treatment and education, Pfizer today announced the launch of Mobilize Against Malaria. This three-country

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

Wed, 5 Sep 2007 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey

Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows

Wed, 5 Sep 2007 06:03:00 UT

VIENNA, Austria--(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s

Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program

Mon, 27 Aug 2007 11:30:00 UT

NEW YORK & PRINCETON, N.J.--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today

Pfizer Names Frank A. D'Amelio Chief Financial Officer

Wed, 22 Aug 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial

Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling Phase III Portfolio by 2009

Mon, 6 Aug 2007 20:33:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that it now has a total of 47 programs in its Phase II Research and Development pipeline, which is the largest Phase II cohort in

Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA

Mon, 6 Aug 2007 17:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a

Breast Cancer Guidelines Confirm Central Role of 'Switch Strategy'; Recommendations of St Gallen Panel Support Exemestane Indication

Thu, 2 Aug 2007 23:01:00 UT

PARIS--(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (

First Medication to Prevent and Treat Vomiting in Dogs Now Available by Prescription

Mon, 30 Jul 2007 16:01:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant

Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent

Wed, 25 Jul 2007 11:04:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor.

Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show

Wed, 25 Jul 2007 04:01:00 UT

NEW YORK--(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6%

Pfizer Receives Positive Opinion from CHMP for Celsentri(R) (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1

Thu, 19 Jul 2007 21:26:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion

Pfizer Announces First Occupant in its Science Incubator

Wed, 18 Jul 2007 18:34:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced its first occupant for the company’s Incubator – a new

Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year 2007 and 2008 Financial Guidance and Updates Progress on Immediate Business Priorities

Wed, 18 Jul 2007 10:45:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer:

High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011

Tue, 10 Jul 2007 10:45:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be

Pfizer Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation

Mon, 9 Jul 2007 16:44:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation

Pfizer Invites Public to Listen to Webcast of July 18 Conference Call with Analysts

Tue, 3 Jul 2007 17:50:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Wednesday, July 18. The

Crystal Trial Confirms Central Role of Irinotecan in Metastatic Colorectal Cancer

Sat, 30 Jun 2007 09:00:00 UT

BARCELONA--(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with

Pfizer Declares a 29-cent Third-Quarter, 2007, Dividend

Thu, 28 Jun 2007 13:18:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders

Pfizer Board of Directors to Initiate Face-to-Face Meetings with Company's Institutional Investors on Corporate Governance Policies and Practices

Thu, 28 Jun 2007 13:10:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that members of its Board of Directors will invite its largest institutional shareholders to a meeting where they will have an opportunity to

Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer

Thu, 28 Jun 2007 07:00:00 UT

BARCELONA, Spain--(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard

Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

Mon, 25 Jun 2007 14:06:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type

Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses

Sat, 23 Jun 2007 15:00:00 UT

CHICAGO--(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took

Pfizer's Lyrica Receives FDA Approval for Fibromyalgia Based on Expedited Review

Thu, 21 Jun 2007 20:03:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Food and Drug Administration (FDA) approved Lyrica® (pregabalin) capsules

Pfizer Receives Approvable Letter From FDA For Maraviroc

Wed, 20 Jun 2007 21:33:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today the U.S. Food and Drug Administration (FDA) issued an approvable letter for maraviroc, which is under review as a therapy for

Pfizer Discontinues Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer

Wed, 20 Jun 2007 17:50:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) announced today the discontinuation of a development program in lung cancer for PF-3512676, an investigational compound, in combination with

Slentrol, First Medication to Combat Canine Obesity, Now Available by Prescription

Tue, 12 Jun 2007 13:09:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health (NYSE: PFE) today announced that SLENTROL™ (dirlotapide), the first

Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at June 14 Healthcare Conference

Thu, 7 Jun 2007 19:14:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, Senior Vice President of Pfizer

Pfizer to Advance Three Key Oncology Compounds into Phase 3 Trials in 2007, Company Tells Financial Analysts

Tue, 5 Jun 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced that it is advancing key compounds through clinical development at a meeting with financial analysts yesterday in connection with the American

New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy

Mon, 4 Jun 2007 13:05:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer announced today that axitinib (AG-013736), an investigational oral, selective inhibitor of VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2,

Single-Agent SUTENT Prolonged Progression-Free Survival across All Advanced Kidney Cancer Patient Risk Groups, Including Those with Poorest Prognoses, Data Show

Sun, 3 Jun 2007 19:00:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer announced today that single-agent, oral SUTENT® (sunitinib malate) prolonged progression-free survival (PFS)

Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says

Sun, 3 Jun 2007 12:30:00 UT

CHICAGO--(BUSINESS WIRE)--Data on Pfizer’s investigational compound CP-675,206, which works by a novel mechanism of action and represents a new

New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer

Sat, 2 Jun 2007 22:00:00 UT

CHICAGO--(BUSINESS WIRE)--Pfizer said today that clinical trials examining its different cancer-fighting approaches showed activity in patients with non-small cell lung cancer (NSCLC). Data

Pfizer and Express Scripts Sign Agreement

Wed, 30 May 2007 13:04:00 UT

ST. LOUIS & NEW YORK--(BUSINESS WIRE)--Express Scripts, Inc. (NASDAQ: ESRX), and Pfizer Inc (NYSE: PFE), today announced an agreement providing for Pfizer’s

UK Body Recommends Pfizer's Champix (varenicline) for Smokers

Wed, 30 May 2007 08:47:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom has recommended Champix (varenicline) for

Pfizer Invites Public to View and Listen to Webcast of June 4 Pfizer Analyst Meeting at ASCO

Tue, 29 May 2007 15:42:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts to be held on Monday, June 4, at 6:00

Pfizer's Growing Strength in Oncology

Tue, 29 May 2007 15:41:00 UT

--(BUSINESS WIRE)--At next week’s American Society of Clinical Oncology Meeting, Pfizer will present new information that underscores the depth and breadth of

New Pfizer Oncology Data Across Numerous Cancer Types to be Presented at ASCO

Tue, 29 May 2007 15:39:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that results showing potential across numerous types of cancer, such as melanoma, thyroid, liver, non-small cell lung (NSCLC), colorectal (CRC)

Pfizer Will Immediately Seek to Appeal Lipitor Patent Ruling in Norway

Tue, 29 May 2007 14:19:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. said today that it will immediately seek to appeal a ruling by the Borgarting Court of Appeal in Oslo, Norway that four of Pfizer

Pfizer Animal Health Medicine Used to Treat Whales

Sun, 27 May 2007 02:11:00 UT

RIO VISTA, Calif.--(BUSINESS WIRE)--Responding to a request from the Marine Mammal Center, Pfizer Animal Health (PAH) has donated an antibiotic which was used today to treat the two humpback

Pfizer Supports Complete Smoking Ban in Public Areas and Improved Access to Smoking Cessation Treatments across Europe

Thu, 24 May 2007 08:00:00 UT

BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) (LSE:PFZ) welcomes the European Commission’s Green Paper on smoke free environments

Pfizer Says Research and Development Head John LaMattina Will Retire This Year

Mon, 21 May 2007 01:25:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that the President of Pfizer Global Research and Development, Dr. John LaMattina, who made many important contributions to the Company

Pharmacia and Upjohn Will Appeal Verdict in Simon Case, 'Ruling is Not Supported by the Evidence'

Tue, 15 May 2007 23:06:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said its subsidiary, Pharmacia and Upjohn, will appeal today’s jury verdict linking its product, Provera, with plaintiff Merle

Counterfeit Drugs Put Lives at Risk

Mon, 14 May 2007 10:27:00 UT

BRUSSELS, Belgium--(BUSINESS WIRE)--Pfizer welcomes the 1st European Parliamentary symposium on pharmaceuticals “Putting an end to

Pfizer Launches Online Initiative Disclosing Its U.S. Post-Marketing Commitments

Wed, 2 May 2007 13:35:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that it has launched an online site to provide up-to-date, user-friendly information on the status of its U.S. post-marketing commitments.

Lyrica Significantly Reduced Pain and Helped Patients Manage the Symptoms of Fibromyalgia, Data Show

Tue, 1 May 2007 20:15:00 UT

BOSTON--(BUSINESS WIRE)--Significantly more patients treated with Pfizer’s Lyrica reduced their pain by 50 percent or more compared with placebo, according to

Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014

Mon, 30 Apr 2007 20:24:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc reported today that the Federal Court of Appeal of Canada has reversed a lower court ruling that would have permitted generic manufacturer Novopharm to

Pfizer Foundation's ConnectHIV Initiative Provides $7.5 Million in Grants to Community-Based AIDS Service Organizations Across 10 States

Mon, 30 Apr 2007 10:00:00 UT

NEW YORK--(BUSINESS WIRE)--The Pfizer Foundation today announced the names of 20 U.S. community-based AIDS service organizations (ASOs) chosen to participate in ConnectHIV, the

Pfizer Invites Public to View and/or Listen to Webcasts of Pfizer Participation at Healthcare Conferences

Fri, 27 Apr 2007 16:32:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Vice Chairman David Shedlarz at the 32nd

Pfizer Declares a 29-cent Second-Quarter, 2007, Dividend

Thu, 26 Apr 2007 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 29-cent second-quarter, 2007, dividend on the company's common stock, payable June 5, 2007, to shareholders

Pfizer Focused on Delivering the Value Customers Expect and Shareholders Deserve, CEO Kindler Tells Shareholders

Thu, 26 Apr 2007 14:48:00 UT

SOUTH BEND, Ind.--(BUSINESS WIRE)--In remarks at the annual shareholders meeting, Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler said, “We

Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds

Thu, 26 Apr 2007 11:00:00 UT

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc (NYSE: PFE) today announced a worldwide collaboration to develop and commercialize

FDA Advisory Committee Recommends Accelerated Approval of Pfizer's Maraviroc for Treatment-Experienced Patients Infected with CCR5-tropic HIV-1

Tue, 24 Apr 2007 21:43:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Antiviral Drugs Advisory Committee voted unanimously (12-0)

Pfizer Delivers Solid First-Quarter 2007 Results, Updates Full-Year Expectations for 2007 and 2008

Fri, 20 Apr 2007 10:43:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer:

Pfizer Invites Public to Access Webcast of April 26 Annual Meeting of Shareholders

Thu, 19 Apr 2007 19:41:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a Webcast of the Annual Meeting of Shareholders at 8:30 a.m. (Eastern Daylight Time) on Thursday,

Pfizer Invites Public to Listen to Webcast of April 20 Conference Call with Analysts

Mon, 9 Apr 2007 13:58:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to listen to a webcast of a conference call with investment analysts at 12 Noon EDST on Friday, April 20. The

Pharmacia Subsidiaries Reach $34.7 Million Settlement with DOJ; Resolve Allegations of Improper Activities Prior to Acquisition by Pfizer

Mon, 2 Apr 2007 17:38:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that two subsidiaries of Pharmacia have reached separate settlements with the United States Department of Justice to address charges

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

Tue, 27 Mar 2007 17:20:00 UT

NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets (80 mg) lowered hospitalization costs by

Lipitor Provides Unprecedented Cardiovascular Risk Reductions in Diabetes Patients with Metabolic Syndrome and in Stroke Patients

Mon, 26 Mar 2007 20:30:00 UT

NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent

Two New Imaging Studies Show Higher Dose Lipitor Stopped the Progression of Atherosclerosis

Mon, 26 Mar 2007 15:27:00 UT

NEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary

Pfizer Announces Launch of Generic Amlodipine Besylate Product by Greenstone

Fri, 23 Mar 2007 21:01:00 UT

NEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic

Pfizer to Present New Lipitor Data, Including Results from Three Large Atherosclerosis Imaging Trials, at the American College of Cardiology Meeting

Fri, 23 Mar 2007 14:14:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and

Pfizer Statement in Response to Appeals Court Decision in Norvasc Patent Case

Thu, 22 Mar 2007 17:59:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the

Exubera: A Highly Effective Needle-Free Alternative to Diabetes Pills and Insulin Injections

Wed, 21 Mar 2007 15:00:00 UT

NEW YORK--(BUSINESS WIRE)--In response to recent news coverage of Exubera, Pfizer believes people with diabetes and their families should have the following information

Pfizer Wins Celebrex Patent Challenge by Generic Manufacturer Teva

Tue, 20 Mar 2007 19:36:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company

Pfizer Honored as a Top American Corporation for Women Business Enterprises

Tue, 20 Mar 2007 18:40:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer today announced that the Women’s Business Enterprise National Council (WBENC), the nation

Pfizer Invites Public to View and Listen to Webcasts of Pfizer Presentations at Healthcare Conferences

Mon, 12 Mar 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) invites investors and the general public to view and listen to webcasts of presentations by Vice Chairman David Shedlarz at

Lipitor Receives FDA Approval for Five New Indications in Patients With Heart Disease

Wed, 7 Mar 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the U.S. Food and Drug Administration (FDA) has approved Lipitor® (atorvastatin calcium)

Lipitor Significantly Reduced the Risk of Serious Cardiovascular Events Compared With Simvastatin in an 80,000-Patient Analysis of a Real-World Managed Care Database

Fri, 2 Mar 2007 13:00:00 UT

BUENA VISTA, Fla.--(BUSINESS WIRE)--A retrospective analysis of a large U.S. managed care database showed that patients who took Pfizer's cholesterol-lowering medicine

Pfizer's Maraviroc, Novel Medicine For HIV, Significantly Reduces Viral Load, in Combination Therapy Across Range of Treatment-Experienced Patients

Thu, 1 Mar 2007 13:00:00 UT

LOS ANGELES--(BUSINESS WIRE)--At this week's major HIV/AIDS research meeting, Pfizer presented pivotal data of its experimental medicine, maraviroc, which tackles HIV in an

Pfizer Wins Challenge to Norvasc Patent by Mylan

Tue, 27 Feb 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a federal court in the Western District of Pennsylvania (Pittsburgh) has upheld the company's U.S. patent covering the

Pfizer Board of Directors Elects Constance J. Horner to Serve as Lead Director

Fri, 23 Feb 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer said today that Constance J. Horner, a member of the company's Board of Directors since 1993, has been elected lead director effective

Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product

Fri, 23 Feb 2007 13:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in

Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe

Tue, 13 Feb 2007 13:14:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States

Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label

Thu, 8 Feb 2007 13:23:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the U.S. Food and Drug Administration (FDA) has approved new labeling of Sutent®

New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Coronary Heart Disease

Wed, 7 Feb 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Patients with coronary heart disease who took Lipitor® (atorvastatin calcium) 80 mg tablets reduced their risk of

Pfizer to Acquire BioRexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline

Thu, 1 Feb 2007 13:47:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has entered into an agreement to acquire BioRexis Pharmaceutical Corporation, a privately-held

Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct

Wed, 31 Jan 2007 14:07:00 UT

NEW YORK--(BUSINESS WIRE)--The federal district court in the Eastern District of Virginia (Alexandria) has ruled that Synthon IP obtained, by inequitable conduct, two

Pfizer Gains Favorable Ruling From Canadian Court on Lipitor Basic Patent, Will Appeal Ruling on Calcium Salt Patent

Thu, 25 Jan 2007 14:18:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that it will appeal a decision by the Canadian Federal Court in Toronto denying its application to block approval of

Pfizer Achieves Key 2006 Financial Targets

Mon, 22 Jan 2007 16:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc:

Pfizer Announces Priorities to Drive Improved Performance, Position Company for Future Success and Enhance Total Shareholder Return

Mon, 22 Jan 2007 14:54:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Chairman and Chief Executive Officer Jeffrey B. Kindler today announced the company's immediate priorities to drive improved

Pfizer Animal Health Completes Acquisition of Embrex, Inc.

Fri, 19 Jan 2007 15:07:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Animal Health, a division of Pfizer Inc (NYSE: PFE) today announced the completion of its acquisition of Embrex, Inc. (NASDAQ:

Pfizer's Sutent(R) is Granted Full Marketing Authorization for First-Line Use in Advanced Kidney Cancer in the European Union

Thu, 18 Jan 2007 15:15:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that Sutent® (sunitinib malate) has received the European Commission’s

Pfizer Invites Public to View and Listen to Webcast of January 22 Meeting with Analysts

Tue, 16 Jan 2007 12:00:00 UT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a meeting with investment analysts being held on